{"8ef81fee8eb8b394eb6d6530ad81144a46a1af32": [["IntroductionInfectious diseases remain one of the greatest threats to human health and commerce, and the analysis of epidemic data is one of the most important applications of statistics in public health.", [["IntroductionInfectious diseases", "DISEASE", 0, 31], ["human", "ORGANISM", 70, 75], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["IntroductionInfectious diseases", "PROBLEM", 0, 31]]], ["If person i infects person j with a given disease, the generation interval is the time between the infection of i and the infection of j.", [["infection", "DISEASE", 99, 108], ["infection", "DISEASE", 122, 131], ["person", "SPECIES", 3, 9], ["person", "SPECIES", 20, 26], ["disease", "PROBLEM", 42, 49], ["the infection", "PROBLEM", 95, 108], ["infection", "OBSERVATION", 99, 108], ["infection", "OBSERVATION", 122, 131]]], ["The serial interval, which is often used as a proxy for the generation interval, is the time between the onset of symptoms in i and the onset of symptoms in j.", [["symptoms", "PROBLEM", 114, 122], ["symptoms", "PROBLEM", 145, 153]]], ["Data from several recent and historical epidemics have been analyzed using methods based on generation or serial interval distributions, including the 1918 influenza (Mills et al., 2004) , severe acute respiratory syndrome (SARS) (Lipsitch et al., 2003; Wallinga and Teunis, 2004) , pandemic influenza A(H1N1) McBryde et al., 2009; Yang et al., 2009) , and avian influenza (Ferguson et al., 2005 (Ferguson et al., , 2006 .IntroductionThough the generation and serial interval distributions are often considered invariant features of an infectious disease (Fine, 2003) , these distributions can change systematically over the course of an epidemic (Svensson, 2007; Kenah et al., 2008) .", [["influenza", "DISEASE", 156, 165], ["acute respiratory syndrome", "DISEASE", 196, 222], ["SARS", "DISEASE", 224, 228], ["pandemic influenza A", "DISEASE", 283, 303], ["avian influenza", "DISEASE", 357, 372], ["infectious disease", "DISEASE", 536, 554], ["avian influenza", "ORGANISM", 357, 372], ["avian influenza", "SPECIES", 357, 372], ["methods", "TREATMENT", 75, 82], ["serial interval distributions", "PROBLEM", 106, 135], ["severe acute respiratory syndrome", "PROBLEM", 189, 222], ["SARS", "PROBLEM", 224, 228], ["pandemic influenza A", "PROBLEM", 283, 303], ["the generation and serial interval distributions", "PROBLEM", 441, 489], ["an infectious disease", "PROBLEM", 533, 554], ["severe", "OBSERVATION_MODIFIER", 189, 195], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["respiratory syndrome", "OBSERVATION", 202, 222], ["infectious", "OBSERVATION", 536, 546]]], ["When a susceptible person is exposed to multiple infectious people, his or her infector must be the first person to make infectious contact.", [["person", "ORGANISM", 19, 25], ["people", "ORGANISM", 60, 66], ["person", "SPECIES", 19, 25], ["people", "SPECIES", 60, 66], ["person", "SPECIES", 106, 112], ["multiple", "OBSERVATION_MODIFIER", 40, 48], ["infectious", "OBSERVATION", 49, 59]]], ["Thus, the mean generation and serial intervals contract as the prevalence of infection increases.", [["infection", "DISEASE", 77, 86], ["the mean generation", "TREATMENT", 6, 25], ["infection", "PROBLEM", 77, 86], ["infection", "OBSERVATION", 77, 86]]], ["When transmission is rapid within groups of close contacts such as households or schools, this can occur even when the global prevalence of infection remains low (Kenah et al., 2008) .IntroductionStatistical methods for infectious disease data that use generation or serial interval distributions are based on the Lotka-Euler equation (Wallinga and Lipsitch, 2007; Roberts and Heesterbeek, 2007) or a branching-process approximation to the early spread of disease (Wallinga and Teunis, 2004; White and Pagano, 2008) .", [["infection", "DISEASE", 140, 149], ["infection", "PROBLEM", 140, 149], ["infectious disease data", "PROBLEM", 220, 243], ["serial interval distributions", "PROBLEM", 267, 296], ["a branching-process approximation", "TREATMENT", 399, 432], ["disease", "PROBLEM", 456, 463], ["infection", "OBSERVATION", 140, 149], ["early", "OBSERVATION_MODIFIER", 440, 445], ["spread", "OBSERVATION_MODIFIER", 446, 452], ["disease", "OBSERVATION", 456, 463]]], ["In both of these approaches, epidemic spread is modeled as a process that creates a population rather than a process of percolation through an existing population.", [["epidemic spread", "PROBLEM", 29, 44], ["epidemic", "OBSERVATION_MODIFIER", 29, 37], ["spread", "OBSERVATION_MODIFIER", 38, 44]]], ["Thus, these methods fail to account for the effects of exposure to multiple infectors and ignore information contributed by uninfected person-time.", [["person", "SPECIES", 135, 141], ["these methods", "TEST", 6, 19], ["multiple infectors", "PROBLEM", 67, 85]]], ["Since they assume generation intervals are independent and identically distributed, they implicitly assume a constant latent period (infection to onset of infectiousness) and a constant infectious period.", [["infection", "DISEASE", 133, 142], ["infection", "PROBLEM", 133, 142], ["infectiousness", "PROBLEM", 155, 169], ["infectious", "OBSERVATION_MODIFIER", 186, 196]]], ["When serial intervals are used as a proxy for generation intervals, they implicitly assume that the incubation period (infection to onset of symptoms) is also constant.", [["infection", "DISEASE", 119, 128], ["infection", "PROBLEM", 119, 128], ["symptoms", "PROBLEM", 141, 149], ["constant", "OBSERVATION_MODIFIER", 159, 167]]], ["Kenah (2010) outlined an alternative analysis of epidemic data based on contact intervals.", [["epidemic data", "TEST", 49, 62]]], ["Informally, the contact interval from an infectious person i to a susceptible person j is the time between the onset of infectiousness in i and the first infectious contact from i to j, where we define infectious contact to be a contact sufficient to infect a susceptible individual.", [["person", "SPECIES", 52, 58], ["person", "SPECIES", 78, 84], ["infectiousness", "PROBLEM", 120, 134], ["infectious", "OBSERVATION", 202, 212]]], ["The contact interval is similar to the generation interval, but it is defined for all possible infector-infectee pairs, not just those in which infection is actually transmitted, and it begins with the onset of infectiousness, not infection.", [["infection", "DISEASE", 144, 153], ["infectiousness", "DISEASE", 211, 225], ["infection", "DISEASE", 231, 240], ["infector", "PROBLEM", 95, 103], ["infectee pairs", "PROBLEM", 104, 118], ["infection", "PROBLEM", 144, 153], ["infectiousness", "PROBLEM", 211, 225], ["infection", "PROBLEM", 231, 240], ["infection", "OBSERVATION", 144, 153], ["infectiousness", "OBSERVATION", 211, 225], ["infection", "OBSERVATION", 231, 240]]], ["The contact interval from i to j will be right-censored if j is infected by k = i prior to infectious contact from i or if i recovers before making infectious contact with j.", [["right", "ANATOMY_MODIFIER", 41, 46]]], ["This censoring is accounted for using methods from survival analysis.", [["survival analysis", "TEST", 51, 68]]], ["Statistical methods based on contact intervals avoid many of the problems with methods based on generation and serial intervals.", [["the problems", "PROBLEM", 61, 73], ["methods", "TREATMENT", 79, 86]]], ["They can incorporate a greater variety of transmission models, they use information contributed by uninfected person-time, and they allow clearer expression of analytical assumptions.IntroductionIn epidemic modeling, it is common to specify infectious contact within an underlying contact process between individuals in the population.", [["person", "SPECIES", 110, 116], ["infectious", "OBSERVATION", 241, 251], ["contact process", "OBSERVATION", 281, 296]]], ["While a person i is infectious, he or she has some probability of transmitting infection to a susceptible person j each time a contact from i to j is made (e.g., Rhodes et al., 1996) .", [["infection", "DISEASE", 79, 88], ["person", "SPECIES", 8, 14], ["person", "SPECIES", 106, 112], ["transmitting infection", "PROBLEM", 66, 88], ["infectious", "OBSERVATION", 20, 30], ["infection", "OBSERVATION", 79, 88]]], ["Models based on contact intervals define an infectious contact as a contact sufficient to infect a susceptible individual, ignore all contacts made by person i outside his or her infectious period, and ignore all infectious contacts from i to j after the first.", [["person", "SPECIES", 151, 157], ["infectious", "OBSERVATION", 44, 54]]], ["This relaxes the assumption that the contact process is unaffected by infection and limits our attention to those contacts relevant to disease transmission.", [["infection", "DISEASE", 70, 79], ["the contact process", "PROBLEM", 33, 52], ["infection", "PROBLEM", 70, 79], ["infection", "OBSERVATION", 70, 79]]], ["Any model specified in terms of an underlying contact process can be specified equivalently in terms of contact intervals.", [["an underlying contact process", "PROBLEM", 32, 61], ["contact", "OBSERVATION", 46, 53]]], ["This paper outlines the nonparametric survival analysis of epidemic data based on contact intervals.", [["epidemic data", "TEST", 59, 72]]], ["The rest of Section 1 defines the general stochastic Susceptible-Exposed-Infectious-Removed (SEIR) model, describes our observed data, and reviews the parametric survival analysis of epidemic data.", [["the parametric survival analysis", "TEST", 147, 179], ["epidemic data", "TEST", 183, 196], ["Infectious", "OBSERVATION", 73, 83]]], ["Section 4 uses them to analyze household surveillance data from the 2009 influenza A(H1N1) pandemic.", [["influenza A(H1N1) pandemic", "DISEASE", 73, 99], ["2009 influenza A(H1N1)", "ORGANISM", 68, 90], ["influenza A(H1N1", "SPECIES", 73, 89], ["2009 influenza A(H1N1)", "SPECIES", 68, 90], ["surveillance data", "TEST", 41, 58], ["pandemic", "PROBLEM", 91, 99]]], ["Section 5 discusses the limitations, advantages, and future development of these methods.", [["these methods", "TREATMENT", 75, 88]]], ["Appendix A shows how our methods can be used when who-infected-whom is partially observed, and Appendix B shows how our methods generalize chain-binomial models to continuous time.Stochastic SEIR model and observed dataConsider a closed population of n individuals assigned indices 1 . . . n.", [["Appendix", "ANATOMY", 95, 103]]], ["Each individual is in one of four possible states: susceptible (S), exposed (E), infectious (I), or removed (R).", [["infectious", "OBSERVATION", 81, 91]]], ["Person i moves from S to E at his or her infection time t i , with t i = \u221e if i is never infected.", [["infection", "DISEASE", 41, 50], ["infected", "PROBLEM", 89, 97], ["infected", "OBSERVATION", 89, 97]]], ["After infection i has a latent period of length \u03b5 i , during which he or she is infected but not infectious.", [["infection", "DISEASE", 6, 15], ["infection", "PROBLEM", 6, 15], ["infected", "PROBLEM", 80, 88], ["infectious", "PROBLEM", 97, 107], ["infection", "OBSERVATION", 6, 15], ["latent", "OBSERVATION_MODIFIER", 24, 30], ["infected", "OBSERVATION", 80, 88], ["not", "UNCERTAINTY", 93, 96], ["infectious", "OBSERVATION", 97, 107]]], ["At time t i + \u03b5 i , i moves from E to I, beginning an infectious period of length \u03b9 i .", [["infectious", "OBSERVATION", 54, 64]]], ["At time t i + r i , where r i = \u03b5 i + \u03b9 i is the recovery period, i moves from I to R. Once in R, i can no longer infect others or be infected.", [["R", "GENE_OR_GENE_PRODUCT", 95, 96], ["no longer", "UNCERTAINTY", 104, 113], ["infected", "OBSERVATION", 134, 142]]], ["The latent period is a nonnegative random variable, the infectious and recovery periods are strictly positive random variables, and the recovery period is finite with probability one.Stochastic SEIR model and observed dataAn epidemic begins with one or more persons infected from outside the population, which we call imported infections.", [["infections", "DISEASE", 327, 337], ["persons", "ORGANISM", 258, 265], ["persons", "SPECIES", 258, 265], ["latent", "OBSERVATION_MODIFIER", 4, 10], ["period", "OBSERVATION_MODIFIER", 11, 17], ["infectious", "OBSERVATION_MODIFIER", 56, 66], ["infections", "OBSERVATION", 327, 337]]], ["For simplicity, we assume that epidemics begin with one or more imported infections at time 0 and there are no other imported infections.Stochastic SEIR model and observed dataAfter becoming infectious at time t i + \u03b5 i , person i makes infectious contact with j = i at time t ij = t i + \u03b5 i + \u03c4 * ij , where the infectious contact interval \u03c4 * ij is a strictly positive random variable with \u03c4 * ij = \u221e if infectious contact never occurs.", [["infections", "DISEASE", 73, 83], ["infections", "DISEASE", 126, 136], ["person", "SPECIES", 222, 228], ["epidemics", "PROBLEM", 31, 40], ["other imported infections", "PROBLEM", 111, 136], ["ij", "TREATMENT", 298, 300], ["ij", "TREATMENT", 345, 347], ["ij", "TREATMENT", 396, 398], ["infections", "OBSERVATION", 73, 83], ["no other", "UNCERTAINTY", 108, 116], ["infections", "OBSERVATION", 126, 136], ["infectious", "OBSERVATION", 191, 201], ["ij", "ANATOMY", 277, 279], ["ij", "ANATOMY", 298, 300], ["infectious", "OBSERVATION", 313, 323], ["ij", "ANATOMY", 345, 347], ["ij", "ANATOMY", 396, 398], ["infectious", "OBSERVATION", 406, 416]]], ["Since infectious contact must occur while i is infectious or never, \u03c4 * ij \u2208 (0, \u03b9 j ] or \u03c4 * ij = \u221e.", [["ij", "TEST", 72, 74], ["ij", "TEST", 94, 96], ["infectious", "OBSERVATION", 47, 57], ["ij", "ANATOMY", 94, 96]]], ["We define infectious contact to be sufficient to cause infection in a susceptible person, so t j \u2264 t ij .Stochastic SEIR model and observed dataFor each ordered pair ij, let C ij = 1 if infectious contact from i to j is possible and C ij = 0 otherwise.", [["infection", "DISEASE", 55, 64], ["person", "SPECIES", 82, 88], ["infection", "PROBLEM", 55, 64], ["t j \u2264 t ij", "TREATMENT", 93, 103], ["each ordered pair ij", "TREATMENT", 148, 168], ["let C ij", "TREATMENT", 170, 178], ["infectious", "OBSERVATION", 10, 20], ["infection", "OBSERVATION", 55, 64], ["ij", "ANATOMY", 101, 103], ["ij", "ANATOMY", 166, 168], ["ij", "ANATOMY", 176, 178], ["ij", "ANATOMY", 235, 237]]], ["We assume that the infectious contact interval \u03c4 * ij is generated in the following way: A contact interval \u03c4 ij is drawn from a distribution with hazard function \u03bb ij (\u03c4 ).", [["ij", "TREATMENT", 51, 53], ["ij", "TREATMENT", 110, 112], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["ij", "ANATOMY", 110, 112], ["ij", "ANATOMY", 165, 167]]], ["If \u03c4 ij \u2264 \u03b9 i and C ij = 1, then \u03c4 * ij = \u03c4 ij .", [["ij \u2264 \u03b9 i and C ij", "TREATMENT", 5, 22], ["ij", "TREATMENT", 37, 39], ["ij", "TREATMENT", 44, 46], ["ij", "ANATOMY", 5, 7], ["ij", "ANATOMY", 20, 22], ["ij", "ANATOMY", 37, 39], ["ij", "ANATOMY", 44, 46]]], ["Otherwise, \u03c4 * ij = \u221e.", [["ij", "ANATOMY", 15, 17]]], ["In this paper, we assume that all contact intervals have a continuous distribution and, for a fixed i or a fixed j, the contact intervals \u03c4 ij , j = i, are independent.Stochastic SEIR model and observed dataThe parametric methods in Kenah (2010) are derived using counting processes and martingales, which are described in Kalbfleisch and Prentice (2002) and Aalen et al. (2009) .", [["ij", "ANATOMY", 140, 142]]], ["Let S i (t) = 1 t\u2264ti and I i (t) = 1 t\u2208(ti+\u03b5i,ti+ri] be the susceptibility and infectiousness processes for person i, where 1 X = 1 if X is true and zero otherwise.", [["person", "SPECIES", 108, 114], ["t\u2208", "TEST", 37, 39], ["ti", "TEST", 40, 42], ["the susceptibility and infectiousness processes", "PROBLEM", 56, 103]]], ["These processes are left-continuous and infectious contact from i to j is possible at time t only if C ij I i (t)S j (t) = 1.", [["left", "ANATOMY_MODIFIER", 20, 24], ["infectious", "OBSERVATION", 40, 50], ["ij", "ANATOMY", 103, 105]]], ["Following Wallinga and Teunis (2004) , let v j denote the index of the person who infected person j, with v j = 0 for imported infections and v j = \u221e for persons not infected at or before time T .", [["infections", "DISEASE", 127, 137], ["let v j", "GENE_OR_GENE_PRODUCT", 39, 46], ["persons", "ORGANISM", 154, 161], ["person", "SPECIES", 71, 77], ["person", "SPECIES", 91, 97], ["persons", "SPECIES", 154, 161], ["infections", "OBSERVATION", 127, 137]]], ["Let V j = {i : C ij I i (t j ) = 1} denote the set of persons who could have infected person j, which we call this the infectious set of person j.", [["persons", "ORGANISM", 54, 61], ["persons", "SPECIES", 54, 61], ["person", "SPECIES", 86, 92], ["person", "SPECIES", 137, 143], ["ij", "ANATOMY", 17, 19]]], ["Let V denote the set of all possible v consistent with the observed data.Stochastic SEIR model and observed dataOur population has size n, and we observe the times of all S \u2192 E (infection), E \u2192 I (onset of infectiousness), and I \u2192 R (removal) transitions in the population between time 0 and time T .", [["infection", "DISEASE", 178, 187], ["Let V", "GENE_OR_GENE_PRODUCT", 0, 5], ["I \u2192 R", "GENE_OR_GENE_PRODUCT", 227, 232], ["Let V", "DNA", 0, 5], ["infection", "PROBLEM", 178, 187], ["infectiousness", "PROBLEM", 206, 220], ["removal", "TREATMENT", 234, 241], ["size", "OBSERVATION_MODIFIER", 131, 135]]], ["For all ordered pairs ij such that i is infected, we observe C ij .", [["all ordered pairs ij", "TREATMENT", 4, 24], ["C ij", "TREATMENT", 61, 65], ["ij", "ANATOMY", 63, 65]]], ["Let m denote the total number of infections we observe.", [["infections", "DISEASE", 33, 43], ["Let m", "GENE_OR_GENE_PRODUCT", 0, 5], ["infections", "PROBLEM", 33, 43], ["total", "OBSERVATION_MODIFIER", 17, 22], ["number", "OBSERVATION_MODIFIER", 23, 29], ["infections", "OBSERVATION", 33, 43]]], ["Our goal is to estimate the contact interval distribution via its cumulative hazard function.Parametric survival analysis of epidemic dataWe begin by reviewing the parametric survival analysis of epidemic data (Kenah, 2010) , where we assume that \u03bb ij (\u03c4 ) comes from a family of hazard functions indexed by a parameter vector \u03b8 with a unique \u03b8 0 such that \u03bb ij (\u03c4 ) = \u03bb(\u03c4 ; \u03b8 0 ) for all ij.", [["\u03b8 0", "PROTEIN", 343, 346], ["a parameter vector", "TREATMENT", 308, 326], ["all ij", "TREATMENT", 385, 391], ["ij", "ANATOMY", 249, 251], ["ij", "ANATOMY", 359, 361], ["ij", "ANATOMY", 389, 391]]], ["To guarantee that the maximum likelihood estimates are consistent and asymptotically normal, we assume that, for all \u03c4 , \u03bb(\u03c4 ; \u03b8) and ln \u03bb(\u03c4 ; \u03b8) have continuous third derivatives with respect to \u03b8 in an open neighborhood of \u03b8 0 .Parametric survival analysis of epidemic data1.2.1.", [["\u03b8", "PROTEIN", 143, 144], ["\u03b8", "PROTEIN", 196, 197], ["continuous third derivatives", "TREATMENT", 151, 179], ["Parametric survival analysis", "TEST", 230, 258]]], ["Likelihood when who-infects-whom is observed Let N ij (t) = 1 t\u2265tij count the first infectious contact from i to j.", [["ij", "ANATOMY", 51, 53], ["infectious", "OBSERVATION", 84, 94]]], ["By definition, N ij (t) is right-continuous with left-hand limits (cadlag).", [["left-hand", "ANATOMY", 49, 58], ["ij", "ANATOMY", 17, 19], ["right", "ANATOMY_MODIFIER", 27, 32], ["left", "ANATOMY_MODIFIER", 49, 53], ["hand", "ANATOMY", 54, 58], ["limits", "OBSERVATION", 59, 65]]], ["We count only the first infectious contact because j is infected at or before t ij .", [["infected", "OBSERVATION", 56, 64], ["ij", "ANATOMY", 80, 82]]], ["Since \u03bb ij (\u03c4 ) = \u03bb(\u03c4 ; \u03b8 0 ) and N ij (0) = 0, the processParametric survival analysis of epidemic datais a zero-mean martingale when \u03b8 = \u03b8 0 .", [["ij", "TEST", 8, 10], ["the processParametric survival analysis", "TEST", 48, 87], ["epidemic datais", "TEST", 91, 106], ["ij", "ANATOMY", 8, 10], ["ij", "ANATOMY", 36, 38]]], ["Since S j (u)1 u\u2264T is predictable, the stochastic integralParametric survival analysis of epidemic datais a zero-mean martingale when \u03b8 = \u03b8 0 .", [["S j (u)1", "GENE_OR_GENE_PRODUCT", 6, 14], ["epidemic datais", "TEST", 90, 105]]], ["The corresponding log likelihood isParametric survival analysis of epidemic datawhich has the score processParametric survival analysis of epidemic dataSince it is the integral of a predictable process with respect to a zero-mean martingale, U ij (t; \u03b8 0 ) is a zero-mean martingale.", [["the score process", "PROBLEM", 90, 107], ["Parametric survival analysis", "TEST", 107, 135], ["epidemic dataSince", "PROBLEM", 139, 157], ["a zero-mean martingale", "PROBLEM", 260, 282], ["ij", "ANATOMY", 244, 246], ["zero-mean martingale", "OBSERVATION", 262, 282]]], ["If we observe infectious contacts in all ordered pairs ij from time 0 until time T , the log likelihood isParametric survival analysis of epidemic datawith the score processParametric survival analysis of epidemic dataU \u00b7j (t; \u03b8 0 ) is a zero-mean martingale because it is a sum of zero-mean martingales.", [["zero-mean martingales", "SPECIES", 282, 303], ["Parametric survival analysis", "TEST", 173, 201], ["epidemic dataU", "TEST", 205, 219], ["a zero-mean martingale", "PROBLEM", 236, 258], ["zero-mean martingales", "PROBLEM", 282, 303], ["zero-mean martingales", "OBSERVATION", 282, 303]]], ["If t j \u2264 T , the likelihood in equation (6) requires that we observe which counting process N ij jumped at t j , which is equivalent to observing which i infected j.", [["ij", "ANATOMY", 94, 96]]], ["The complete-data log likelihood when we observe who-infects-whom is \u2113(\u03b8) = n j=1 \u2113 \u00b7j (\u03b8) with the score process U (t; \u03b8) = n j=1 U \u00b7j (t; \u03b8).", [["\u00b7j", "TEST", 84, 86], ["the score process", "TEST", 96, 113], ["U", "TEST", 114, 115], ["t", "TEST", 117, 118], ["\u03b8)", "TEST", 120, 122], ["j", "TEST", 127, 128], ["U \u00b7j", "TEST", 131, 135], ["\u03b8", "TEST", 140, 141]]], ["Clearly, U (t; \u03b8 0 ) is a zero-mean martingale.Likelihood when who-infects-whom is not observedNow assume that we do not observe who infected person j.", [["person", "SPECIES", 142, 148], ["a zero-mean martingale", "PROBLEM", 24, 46]]], ["The corresponding counting process isLikelihood when who-infects-whom is not observedand the process M \u00b7j (t; \u03b8) = i =j M ij (t; \u03b8) is a zero-mean martinale when \u03b8 = \u03b8 0 .", [["\u03b8)", "TEST", 110, 112], ["\u03b8", "TEST", 129, 130], ["a zero", "TEST", 135, 141], ["mean martinale", "TEST", 142, 156], ["\u03b8", "TEST", 162, 163], ["ij", "ANATOMY", 122, 124]]], ["Expanding M \u00b7j (t; \u03b8), we getLikelihood when who-infects-whom is not observedwhereLikelihood when who-infects-whom is not observedis the total hazard of infectious contact with j at time t given \u03b8.", [["infectious", "OBSERVATION", 153, 163]]], ["When person j is observed from time 0 to time T , the log likelihood isLikelihood when who-infects-whom is not observedwith the score processLikelihood when who-infects-whom is not observedU \u00b7j (t; \u03b8 0 ) is a zero-mean martingale because it is the integral of a predictable process with respect to M \u00b7j (t; \u03b8 0 ).", [["person", "SPECIES", 5, 11]]], ["The log likelihood for the complete observed data when we do not observe who-infected-whom is \u2113(\u03b8) = n j=1 \u2113 \u00b7j (\u03b8) with score process U (t; \u03b8) = n j=1 U \u00b7j (t; \u03b8), which is a zero-mean martingale when \u03b8 = \u03b8 0 .MethodsIn this section, we extend the Nelson-Aalen estimator (Altshuler, 1970; Nelson, 1972; Aalen, 1978) to derive a nonparametric estimators of the cumulative hazard function of the contact interval distribution.", [["\u00b7j", "TEST", 109, 111], ["score", "TEST", 121, 126], ["U", "TEST", 135, 136], ["t", "TEST", 138, 139], ["\u03b8)", "TEST", 141, 143], ["j", "TEST", 148, 149], ["\u00b7j", "TEST", 154, 156], ["\u03b8", "TEST", 161, 162], ["a zero", "TEST", 174, 180], ["martingale", "TEST", 186, 196], ["\u03b8", "TEST", 202, 203], ["Methods", "TEST", 211, 218]]], ["LetMethodsdenote the cumulative hazard function.", [["LetMethodsdenote", "CHEMICAL", 0, 16], ["cumulative", "OBSERVATION_MODIFIER", 21, 31], ["hazard function", "OBSERVATION", 32, 47]]], ["Whereas absolute time processes are defined for all ordered pairs ij, infectiousness age processes are defined only for those ij in which t i < \u221e.", [["all ordered pairs ij", "TREATMENT", 48, 68], ["infectiousness age processes", "PROBLEM", 70, 98], ["those ij", "TREATMENT", 120, 128]]], ["In our notation, we use the argument t for absolute time and \u03c4 for infectiousness age.", [["infectiousness", "PROBLEM", 67, 81]]], ["When who-infects-whom is not observed, we average the Nelson-Aalen estimates from all v \u2208 V to get a marginal Nelson-Aalen estimator.", [["v \u2208 V", "GENE_OR_GENE_PRODUCT", 86, 91]]], ["Since the probability of each v \u2208 V is unknown, we use an EM algorithm (Dempster et al., 1977) to iteratively reweight each possible v, obtaining a sequence of marginal Nelson-Aalen estimates that converges to a nonparametric MLE of \u039b(\u03c4 ).", [["v \u2208 V", "GENE_OR_GENE_PRODUCT", 30, 35], ["an EM algorithm", "TEST", 55, 70]]], ["Finally, we show how these estimates can be approximated in mass-action SEIR models using only data about infected persons.", [["persons", "ORGANISM", 115, 122], ["persons", "SPECIES", 115, 122]]], ["In Appendix A, we show how these methods adapt to a situation where the transmission network is partially observed.Nonparametric estimation when who-infects-whom is observedFirst, we assume that we observe who infected whom.", [["Appendix", "ANATOMY", 3, 11]]], ["For each person i such that t i +\u03b5 i \u2264 T , let N * ij (\u03c4 ) = 1 \u03c4 \u2265\u03c4ij count the first infectious contact from i to j at or before infectiousness age \u03c4 in person i, and let I * i (\u03c4 ) = 1 \u03c4 \u2208(0,\u03b9i] indicate whether i remains infectious at infectiousness age \u03c4 .", [["person", "SPECIES", 9, 15], ["person", "SPECIES", 154, 160], ["ij", "ANATOMY", 51, 53], ["infectious", "OBSERVATION", 86, 96], ["infectious", "OBSERVATION", 224, 234]]], ["By definition, N * ij (\u03c4 ) is cadlag andNonparametric estimation when who-infects-whom is observedis a zero-mean martingale.", [["ij", "ANATOMY", 19, 21]]], ["Now let S * ij (\u03c4 ) = S j (t i + \u03b5 i + \u03c4 ) indicate the susceptibility of person j at infectiousness age \u03c4 of person i and let T i = T \u2212 t i \u2212 \u03b5 i denote the time between the onset of infectiousness in i and the end of observation.", [["person", "SPECIES", 74, 80], ["person", "SPECIES", 110, 116], ["infectiousness", "PROBLEM", 184, 198], ["infectiousness", "OBSERVATION", 184, 198]]], ["Since S * ij (\u03c4 )1 \u03c4 \u2264Ti is predictable,Nonparametric estimation when who-infects-whom is observedis a zero-mean martingale corresponding to the counting processNonparametric estimation when who-infects-whom is observedwhich counts infectious contacts from i to j prior to time T while j remains susceptible.", [["Ti", "CHEMICAL", 22, 24], ["a zero-mean martingale", "PROBLEM", 101, 123], ["ij", "ANATOMY", 10, 12]]], ["Since it is a sum of zero-mean martingales,Nonparametric estimation when who-infects-whom is observedis a zero-mean martingale, whereNonparametric estimation when who-infects-whom is observedis a counting process that jumps at the infectiousness age at which v j (the infector of j) makes infectious contact with j andNonparametric estimation when who-infects-whom is observeddenotes the number of persons who could have infected j at infectiousness age \u03c4 .", [["persons", "ORGANISM", 398, 405], ["persons", "SPECIES", 398, 405]]], ["Note that Y \u00b7j (\u03c4 ) is left-continuous and decreasing in \u03c4 .Nonparametric estimation when who-infects-whom is observedFinally, consider the combined observations of all j.", [["\u03c4", "PROTEIN", 57, 58], ["Nonparametric estimation", "TEST", 60, 84], ["left", "ANATOMY_MODIFIER", 23, 27], ["decreasing", "OBSERVATION_MODIFIER", 43, 53]]], ["Since it is a sum of zero-mean martingales,Nonparametric estimation when who-infects-whom is observedis a zero-mean martingale, whereNonparametric estimation when who-infects-whom is observedcounts the number of observed infectious contacts with susceptible individuals occuring at infectiousness age \u2264 \u03c4 andNonparametric estimation when who-infects-whom is observeddenotes the number of contact intervals of length \u2265 \u03c4 that were observed.", [["infectious", "OBSERVATION", 221, 231]]], ["Like each Y \u00b7j (\u03c4 ), Y (\u03c4 ) is left-continuous and decreasing in \u03c4 .Nonparametric estimation when who-infects-whom is observedWe are now ready to show that the standard Nelson-Aalen estimator will produce an unbiased estimate of \u039b(\u03c4 ).", [["\u03c4", "PROTEIN", 65, 66], ["Nonparametric estimation", "TEST", 68, 92], ["left", "ANATOMY_MODIFIER", 31, 35], ["decreasing", "OBSERVATION_MODIFIER", 51, 61]]], ["Therefore,\u039b(\u03c4 ) is an unbiased estimate of \u039b(\u03c4 ) for all \u03c4 \u2208 [0, T ].", [["\u039b(\u03c4 )", "GENE_OR_GENE_PRODUCT", 10, 15], ["\u039b(\u03c4 )", "PROTEIN", 10, 15]]], ["For these \u03c4 , a variance estimate for\u039b(\u03c4 ) \u2212 \u039b(\u03c4 ) is given by its optional variation proces\u015dNonparametric estimation when who-infects-whom is observedUsing the martingale central limit theorem and a log transformation, we get the approximate pointwise 1 \u2212 \u03b1 confidence limit\u015dNonparametric estimation when who-infects-whom is observedwhere \u03a6 is the cumulative distribution function of the standard normal distribution.", [["\u03c4", "DNA", 10, 11], ["a variance estimate", "TEST", 14, 33], ["Nonparametric estimation", "TEST", 93, 117], ["Nonparametric estimation", "TEST", 276, 300], ["normal", "OBSERVATION", 398, 404], ["distribution", "OBSERVATION_MODIFIER", 405, 417]]], ["Note that the point estimate\u039b(\u03c4 ) in equation (23) is valid for an arbitrary contact interval distribution but the variance estimate\u03c3 2 (\u03c4 ) in equation (25) and the approximate confidence interval in equation (26) assume a continuous contact interval distribution.Nonparametric estimation when who-infects-whom is not observedNow assume that we do not observe who-infected-whom.", [["the variance estimate\u03c3", "TEST", 111, 133], ["a continuous contact interval distribution", "PROBLEM", 222, 264], ["distribution", "OBSERVATION_MODIFIER", 252, 264], ["infected", "OBSERVATION", 365, 373]]], ["However,Nonparametric estimation when who-infects-whom is not observedby the law of iterated expectation, so we can still obtain an unbiased estimate of \u039b(\u03c4 ).Nonparametric estimation when who-infects-whom is not observedLet\u039b v (\u03c4 ) denote the value of\u039b(\u03c4 ) that we would have calculated had we observed the transmission network v. ThenNonparametric estimation when who-infects-whom is not observedis an unbiased estimate of \u039b(\u03c4 ) for each \u03c4 \u2208 [0, T ].", [["Let\u039b v", "GENE_OR_GENE_PRODUCT", 221, 227], ["Nonparametric estimation", "TEST", 159, 183]]], ["For each v \u2208 V, Pr(v|observed data) can be calculated if we know \u03bb(\u03c4 ) (Kenah et al., 2008) .", [["Pr(v|observed data", "TEST", 16, 34]]], ["For each person j with t j < \u221e, the probability that j was infected by person i \u2208 V j isNonparametric estimation when who-infects-whom is not observedand the probability of a given transmission networkNonparametric estimation when who-infects-whom is not observedNote that equations (29) and (30) assume a continuous contact interval distribution, which ensures that simultaneous infectious contacts have probability zero.", [["person", "SPECIES", 9, 15], ["person", "SPECIES", 71, 77], ["Nonparametric estimation", "TEST", 201, 225], ["simultaneous", "OBSERVATION_MODIFIER", 367, 379], ["infectious", "OBSERVATION", 380, 390]]], ["We outline this calculation and then use it as the basis of an EM algorithm that converges to a nonparametric MLE of \u039b(\u03c4 ).", [["an EM algorithm", "TEST", 60, 75]]], ["First, letNonparametric estimation when who-infects-whom is not observedwhich is a cadlag step function with a jump of sizeNonparametric estimation when who-infects-whom is not observedBy equations (28) through (30), the marginal Nelson-Aalen estimate given \u03bb(\u03c4 ) isNonparametric estimation when who-infects-whom is not observedIf \u03bb(\u03c4 ) is the true contact interval hazard function, this is an unbiased estimate of \u039b(\u03c4 ) for each \u03c4 \u2208 [0, T ].", [["\u03bb(\u03c4 )", "PROTEIN", 331, 336], ["\u03c4", "PROTEIN", 430, 431], ["not observed", "UNCERTAINTY", 316, 328]]], ["The whole point of calculating \u039b(\u03c4 ) is that \u03bb(\u03c4 ) is unknown, but equation (33) can be used in the following EM algorithm:Nonparametric estimation when who-infects-whom is not observed(a) Begin with an initial \u03bb (0) (\u03c4 ).", [["Nonparametric estimation", "TEST", 123, 147]]], ["This could be a parametric estimate or a constant.", [["constant", "OBSERVATION_MODIFIER", 41, 49]]], ["Use this to calculate an initial marginal Nelson-Aalen estimate \u039b(\u03c4 |\u03bb (0) ). (b) Use \u039b(\u03c4 |\u03bb (k) ) to calculate a new hazard function estimate \u03bb (k+1) (\u03c4 ). (c) Update the probabilities in equation (29) using \u03bb (k+1) (\u03c4 ). (d) Use the updated probabilities to calculate \u039b(\u03c4 |\u03bb (k+1) ) using equation (33). (e) Repeat the smoothing step (b), the E-step (c) and the M-step (d) until the sequence \u039b(\u03c4 |\u03bb (k) ) converges.Nonparametric estimation when who-infects-whom is not observedThe limit of this sequence is the marginal Nelson-Aalen estimate, which we denote \u039b(\u03c4 ).Nonparametric estimation when who-infects-whom is not observedTo show that this is truly an EM algorithm, we must prove that \u039b(\u03c4 |\u03bb (k) ) maximizes the expected log likelihood given \u03bb (k) (\u03c4 ).", [["the sequence", "TEST", 381, 393], ["Nonparametric estimation", "TEST", 417, 441], ["Nonparametric estimation", "TEST", 567, 591], ["not observed", "UNCERTAINTY", 467, 479], ["not observed", "UNCERTAINTY", 617, 629]]], ["Let \u03c4 1 , . . . , \u03c4 M denote the distinct infectiousness ages at which infectious contacts might have been made, and let S(\u03c4 ) denote an arbitrary survival function for the contact interval distribution.", [["Let \u03c4 1", "GENE_OR_GENE_PRODUCT", 0, 7], ["the distinct infectiousness ages", "PROBLEM", 29, 61], ["an arbitrary survival function", "PROBLEM", 134, 164], ["distinct", "OBSERVATION_MODIFIER", 33, 41], ["infectiousness", "OBSERVATION", 42, 56]]], ["The conditional probability of failure (i.e., infectious contact) at infectiousness age \u03c4 j given survival (i.e., no infectious contact) until \u03c4 j isNonparametric estimation when who-infects-whom is not observedThe j th term of G(S) is maximized byNonparametric estimation when who-infects-whom is not observedso the survival function that maximizes G(S) isNonparametric estimation when who-infects-whom is not observedwhere \u03c0 represents the product integral described in Kalbfleisch and Prentice (2002) and Aalen et al. (2009) .", [["failure", "PROBLEM", 31, 38], ["The j th term of G(S)", "TREATMENT", 211, 232], ["failure", "OBSERVATION", 31, 38], ["not observed", "UNCERTAINTY", 199, 211], ["j th", "OBSERVATION_MODIFIER", 215, 219]]], ["The corresponding marginal Kaplan-Meier estimator is a nonparametric MLE of S(\u03c4 ).", [["marginal", "OBSERVATION_MODIFIER", 18, 26]]], ["The variance \u03c3 2 (\u03c4 ) of \u039b(\u03c4 ) can be estimated using the conditional variance formula.", [["The variance", "TEST", 0, 12]]], ["The first term of equation (40) reduces toNonparametric estimation when who-infects-whom is not observedand the second term reduces toNonparametric estimation when who-infects-whom is not observedwhere N * \u00b7j (\u03c4 ) = N * \u00b7j \u03c4 \u03bb .", [["Nonparametric estimation", "TEST", 134, 158]]], ["Therefore,Nonparametric estimation when who-infects-whom is not observedUsing the martingale central limit theorem and a log transformation, we get the approximate pointwise 1 \u2212 \u03b1 confidence limitsEstimating the hazard functionObtaining \u03bb (k+1) (\u03c4 ) from \u039b(\u03c4 |\u03bb (k) ) in step (b) of the EM algorithm is nontrivial.", [["the hazard function", "TEST", 208, 227], ["the EM algorithm", "TEST", 283, 299], ["not observed", "UNCERTAINTY", 60, 72]]], ["To see this, consider a person j with t j \u2264 T .", [["person", "SPECIES", 24, 30]]], ["For each person i \u2208 V j , let p (k)Estimating the hazard functionij denote the estimated probability that i infected j in the k th iteration of the EM algorithm, with p (0) ij denoting the initial estimate.", [["person", "SPECIES", 9, 15], ["the hazard functionij", "PROBLEM", 46, 67], ["ij", "TREATMENT", 173, 175]]], ["In the first iteration, we get pEstimating the hazard functionSince Y (\u03c4 ) is decreasing in \u03c4 , the EM algorithm would converge to a marginal Nelson-Aalen estimate where the i \u2208 V j with the longest \u03c4 ij is assigned probability one of being v j .", [["the longest \u03c4 ij", "TREATMENT", 187, 203], ["decreasing", "OBSERVATION_MODIFIER", 78, 88]]], ["This problem arises because equation (29) assumes a continuous contact interval distribution, which ensures that simultaneous infectious contacts have zero probability.", [["simultaneous infectious contacts", "PROBLEM", 113, 145], ["simultaneous", "OBSERVATION_MODIFIER", 113, 125], ["infectious", "OBSERVATION", 126, 136]]], ["Since the contact interval distribution is continuous, the intervals between the increments of \u039b(\u03c4 |\u03bb (k) ) contain information about \u03bb(\u03c4 ) that is ignored if these increments are used directly as an estimate of \u03bb(\u03c4 ).", [["distribution", "OBSERVATION_MODIFIER", 27, 39]]], ["Thus, obtaining \u03bb (k+1) (\u03c4 ) from \u039b(\u03c4 |\u03bb (k) ) requires some form of smoothing.", [["k", "TEST", 19, 20]]], ["The algorithm depends on the smoothed estimate of \u03bb(\u03c4 ) only to calculate the probabilities p ij in equation (29).", [["ij", "ANATOMY", 94, 96]]], ["In our experience, cubic smoothing splines and kernel smoothers produce nearly identical results, so the algorithm seems insensitive to reasonable choices among smoothers.Approximate Nelson-Aalen estimates for mass-action SEIR modelsIn a mass-action model, C ij = 1 for all ordered pairs ij but the hazard of infectious contact is inversely proportional to the population size n.", [["cubic smoothing splines", "TREATMENT", 19, 42], ["mass", "PROBLEM", 210, 214], ["a mass", "PROBLEM", 236, 242], ["C ij", "TREATMENT", 257, 261], ["all ordered pairs ij", "TREATMENT", 270, 290], ["mass", "OBSERVATION", 210, 214], ["mass", "OBSERVATION", 238, 242], ["ij", "ANATOMY", 259, 261], ["ij", "ANATOMY", 288, 290], ["infectious", "OBSERVATION", 309, 319]]], ["More specifically, if \u039b n (\u03c4 ) is the cumulative hazard function of the contact interval distribution in a population of size n, thenApproximate Nelson-Aalen estimates for mass-action SEIR modelswhere we call \u039b * (\u03c4 ) the normalized cumulative hazard function of the contact interval distribution.", [["mass", "PROBLEM", 172, 176], ["size", "OBSERVATION_MODIFIER", 121, 125]]], ["With knowledge of n, the methods of the previous two sections could be used to estimate \u039b n (\u03c4 ) and \u039b * (\u03c4 ).", [["the previous two sections", "TREATMENT", 36, 61]]], ["In Kenah (2010) , it was shown that the full parametric likelihoods for mass-action SEIR models can be approximated by likelihoods that depend only on data about infected individuals.", [["the full parametric likelihoods", "PROBLEM", 36, 67], ["mass", "PROBLEM", 72, 76], ["action SEIR models", "PROBLEM", 77, 95], ["infected individuals", "PROBLEM", 162, 182], ["mass", "OBSERVATION", 72, 76]]], ["Here, we derive approximate nonparametric estimates of \u039b * (\u03c4 ) that depend only on data about infected individuals.", [["infected individuals", "PROBLEM", 95, 115]]], ["For a fixed number m of infections, these approximations become exact in the limit as n \u2192 \u221e.", [["infections", "DISEASE", 24, 34], ["infections", "PROBLEM", 24, 34], ["infections", "OBSERVATION", 24, 34]]], ["Thus, they can be used to analyze data from the early stages of an epidemic, when m \u226a n.Approximate Nelson-Aalen estimates for mass-action SEIR modelsLet Y * (\u03c4 ) = i I * i (\u03c4 )1 \u03c4 \u2264Ti denote the number of infected persons who remain infectious and under observation at infectiousness age \u03c4 .", [["persons", "ORGANISM", 215, 222], ["persons", "SPECIES", 215, 222], ["mass", "PROBLEM", 127, 131], ["infectious", "PROBLEM", 234, 244], ["infected", "OBSERVATION", 206, 214], ["infectious", "OBSERVATION", 234, 244]]], ["By equations (19) and (22),Approximate Nelson-Aalen estimates for mass-action SEIR modelsSinceApproximate Nelson-Aalen estimates for mass-action SEIR modelsLet\u039b n (\u03c4 ) be the Nelson-Aalen estimate of \u039b(\u03c4 ) obtained in a population of size n when who-infects-whom is observed, and letApproximate Nelson-Aalen estimates for mass-action SEIR modelsSince n \u226b m, Y (u) > 0 if and only if Y * (u) > 0.", [["mass", "PROBLEM", 66, 70], ["mass", "PROBLEM", 133, 137], ["mass", "PROBLEM", 322, 326]]], ["Therefore,\u039b * (\u03c4 ) \u2192 (n\u22121)\u039b n (\u03c4 ) for a fixed m as n \u2192 \u221e.", [["a fixed m", "TEST", 39, 48]]], ["Sinc\u00ea \u039b(\u03c4 ) is a consistent estimator of \u039b n (\u03c4 ), this implies that\u039b * (\u03c4 ) is a consistent estimator of \u039b * (\u03c4 ) if we take limits first as n \u2192 \u221e and then as m \u2192 \u221e.", [["\u039b(\u03c4 )", "PROTEIN", 6, 11]]], ["Similarly,Approximate Nelson-Aalen estimates for mass-action SEIR modelsis a consistent estimate of the variance of\u039b * (\u03c4 ).", [["mass-action", "TEST", 49, 60]]], ["Using the martingale central limit theorem and a log transformation, we get the asymptotic 1 \u2212 \u03b1 confidence limit\u015dApproximate Nelson-Aalen estimates for mass-action SEIR modelswhere we take limits first as n \u2192 \u221e and then as m \u2192 \u221e.Approximate Nelson-Aalen estimates for mass-action SEIR modelsWhen who-infects-whom is not observed, we have the approximate marginal Nelson-Aalen estimateApproximate Nelson-Aalen estimates for mass-action SEIR modelsSince the probabilities p ij in equation (29) depend on \u03bb (k+1) (\u03c4 ) only up to a multiplicative constant, they can be estimated by smoothing the normalized cumulative hazard function \u039b * (\u03c4 |\u03bb (k) * ).", [["mass", "PROBLEM", 153, 157], ["mass", "PROBLEM", 269, 273], ["mass", "PROBLEM", 424, 428], ["ij in equation", "TEST", 473, 487], ["mass", "OBSERVATION", 269, 273], ["ij", "ANATOMY", 473, 475]]], ["Thus, \u039b * (\u03c4 |\u03bb * ) can replace \u039b(\u03c4 |\u03bb) in the EM algorithm from Section 2.2.", [["\u039b", "PROTEIN", 32, 33], ["the EM algorithm", "TEST", 43, 59], ["Section", "TEST", 65, 72]]], ["Let \u039b * (\u03c4 ) denote the marginal Nelson-Aalen estimate to which this algorithm converges, let \u03bb * (\u03c4 ) denote the corresponding normalized hazard function, and let N * (\u03c4 ) = N * \u03c4 \u03bb * .", [["hazard function", "TEST", 139, 154]]], ["The variance of \u039b * (\u03c4 ) isApproximate Nelson-Aalen estimates for mass-action SEIR modelswhere N * \u00b7j (\u03c4 ) = N * \u00b7j \u03c4 \u03bb * .", [["mass", "TEST", 66, 70], ["action", "TEST", 71, 77], ["SEIR", "TEST", 78, 82], ["modelswhere", "TEST", 83, 94]]], ["In each simulation, we used data on the first 1,000 infections from an epidemic in a population of 100,000 to calculate the Nelson-Aalen and marginal Nelson-Aalen estimates of \u039b(\u03c4 ) and the Kaplan-Meier and marginal Kaplan-Meier estimates of the corresponding survival function.", [["infections", "DISEASE", 52, 62]]], ["All models had a latent period of zero and an exponential infectious period with mean one.", [["latent", "OBSERVATION_MODIFIER", 17, 23], ["exponential", "OBSERVATION_MODIFIER", 46, 57], ["infectious", "OBSERVATION", 58, 68]]], ["The smoothing step of the EM algorithm was done via an inverse-variance weighted cubic smoothing spline with a smoothing parameter chosen by generalized cross-validation (Wegman and Wright, 1983) .", [["the EM algorithm", "TEST", 22, 38], ["an inverse-variance weighted cubic smoothing spline", "TREATMENT", 52, 103], ["a smoothing parameter", "TEST", 109, 130]]], ["Convergence of the EM algorithm was monitored by calculating the mean of the absolute values of the differences between the current and previous marginal Nelson-Aalen estimates at the 5 th , 10 th , 15 th ,. . . , 85 th , 90 th , and 95 th percentiles of the possible contact intervals.", [["the EM algorithm", "TEST", 15, 31]]], ["All EM algorithms began by assuming that all possible transmission networks were equally likely, which is equivalent to assuming an exponential contact interval distribution.", [["All EM algorithms", "TEST", 0, 17], ["distribution", "OBSERVATION_MODIFIER", 161, 173]]], ["We ran the algorithm for a minimum of 5 iterations, and it was continued until an L1 difference less than a specified tolerance was achieved or the 50 th iteration was completed.SimulationsAll epidemic models were written in Python (www.python.org) using the NumPy and SciPy packages (www.scipy.org).", [["the NumPy and SciPy packages", "TREATMENT", 255, 283]]], ["For network-based models, our contact networks were generated using the NetworkX package (networkx.lanl.gov).", [["contact networks", "MULTI-TISSUE_STRUCTURE", 30, 46], ["the NetworkX package", "TREATMENT", 68, 88]]], ["Statistical analysis was conducted in R (www.r-project.org) via the RPy2 package (rpy.sourceforge.net).", [["Statistical analysis", "TEST", 0, 20], ["the RPy2 package", "TREATMENT", 64, 80]]], ["The code for the models and estimators is available as Online Supplementary Information.Network-based simulationsIn all network-based simulations, the contact network was a Watts-Strogatz small-world network (Watts and Strogatz, 1998) , which mimics the high clustering and low diameter of real human contact networks.", [["human", "ORGANISM", 295, 300], ["contact networks", "MULTI-TISSUE_STRUCTURE", 301, 317], ["human", "SPECIES", 295, 300], ["human", "SPECIES", 295, 300], ["low diameter", "OBSERVATION_MODIFIER", 274, 286]]], ["Starting with a ring of 100,000 nodes, each node was connected to its 10 nearest neighbors.", [["node", "ANATOMY", 44, 48], ["nodes", "OBSERVATION", 32, 37], ["node", "OBSERVATION", 44, 48]]], ["Each edge was then rewired to a randomly chosen node with probability .1.", [["node", "ANATOMY", 48, 52], ["node", "MULTI-TISSUE_STRUCTURE", 48, 52], ["node", "OBSERVATION", 48, 52]]], ["Thus, 34.9% of nodes are connected only to their ten nearest neighbors, 38.7% are have one long-distance edge, 19.4% have two long-distance edges, 5.7% have three long-distance edges, and 1.3% have four or more long-distance edges.", [["nodes", "ANATOMY", 15, 20], ["nodes", "MULTI-TISSUE_STRUCTURE", 15, 20], ["long-distance edges", "DNA", 211, 230], ["nodes", "OBSERVATION", 15, 20], ["long", "OBSERVATION_MODIFIER", 126, 130], ["1.3%", "OBSERVATION_MODIFIER", 188, 192], ["more", "OBSERVATION_MODIFIER", 206, 210], ["long", "OBSERVATION_MODIFIER", 211, 215]]], ["This network structure gave us high clustering, so infected nodes typically had several possible infectors.", [["nodes", "ANATOMY", 60, 65], ["nodes", "MULTI-TISSUE_STRUCTURE", 60, 65], ["high clustering", "PROBLEM", 31, 46], ["infected nodes", "PROBLEM", 51, 65], ["infectors", "PROBLEM", 97, 106], ["high", "OBSERVATION_MODIFIER", 31, 35], ["infected", "OBSERVATION_MODIFIER", 51, 59], ["nodes", "OBSERVATION", 60, 65]]], ["A new contact network was built for each simulation, so the results do not reflect the idiosyncrasies of any particular realization of the network.Network-based simulationsWe used Weibull(.5, 1), exponential(1), and Weibull(2, 1) contact interval distributions, where Weibull(s, r) denotes a Weibull distribution with shape parameter s and rate parameter r.", [["shape parameter s", "TEST", 318, 335], ["new", "OBSERVATION_MODIFIER", 2, 5]]], ["The corresponding cumulative hazard functions are:Network-based simulations\u039b(\u03c4 ) = \u03c4 for the exponential(1) distribution, and (57) \u039b(\u03c4 ) = \u03c4 2 for the Weibull(2, 1) distribution.Network-based simulationsNote that the exponential(1) distribution is the same as a Weibull(1, 1) distribution.", [["cumulative", "OBSERVATION_MODIFIER", 18, 28], ["exponential", "OBSERVATION_MODIFIER", 217, 228]]], ["The hazard of infectious contact decreases throughout the infectious period in the Weibull(.5, 1) case, remains constant in the exponential(1) case, and increases throughout the infectious period in the Weibull(2, 1) case.Network-based simulationsThe L1 tolerance for the EM algorithm was set to .0005.", [["infectious contact", "PROBLEM", 14, 32], ["the EM algorithm", "TEST", 268, 284], ["infectious", "OBSERVATION", 14, 24], ["decreases", "OBSERVATION_MODIFIER", 33, 42], ["infectious", "OBSERVATION_MODIFIER", 58, 68], ["constant", "OBSERVATION_MODIFIER", 112, 120], ["infectious", "OBSERVATION", 178, 188], ["L1", "ANATOMY", 251, 253]]], ["This was approximately the minimum tolerance consistently achieved by the EM algorithm before the L1 differences became a chaotic sequence of small numbers.ResultsThe EM algorithm for the marginal Nelson-Aalen estimate converged easily in all simulations.", [["the EM algorithm", "TEST", 70, 86], ["a chaotic sequence of small numbers", "PROBLEM", 120, 155], ["The EM algorithm", "TEST", 163, 179], ["L1", "ANATOMY", 98, 100], ["small", "OBSERVATION_MODIFIER", 142, 147]]], ["Coverage probabilities for the marginal Nelson-Aalen and Kaplan-Meier estimators was slightly lower but above .90 in all cases.", [["Meier estimators", "TEST", 64, 80]]], ["Coverage probabilities for the model with exponential contact intervals were above .93 for all estimators and data quantiles (not shown).", [["data quantiles", "TEST", 110, 124]]], ["Figures 1 and 2 show good agreement between the estimated and true cumulative hazard and survival functions for the contact interval distribution across the range of available data.", [["Figures", "TEST", 0, 7]]], ["The true cumulative hazard function (top) and survival function (bottom) are indicated by dashed lines.", [["lines", "CELL", 97, 102], ["dashed lines", "CELL_LINE", 90, 102], ["dashed lines", "OBSERVATION", 90, 102]]], ["The marginal Nelson-Aalen and Kaplan-Meier estimates (right) do not use this information.", [["marginal", "OBSERVATION_MODIFIER", 4, 12]]], ["The point clouds are the point estimates at the 5 th , 10 th , 25 th , 50 th , 75 th , 90 th , and 95 th percentiles of the possible contact intervals in each of 1,000 simulations.", [["possible", "UNCERTAINTY", 124, 132], ["contact intervals", "OBSERVATION", 133, 150]]], ["The clouds for the 5 th and 10 th and the 90 th and 95 th percentiles often run together, leaving five separate clouds of points.Mass-action simulationsFor mass-action models, we used Weibull(.5, 5), exponential(2), and Weibull(2, 1) normalized contact interval distributions.", [["mass-action models", "PROBLEM", 156, 174], ["clouds", "OBSERVATION", 4, 10], ["mass", "OBSERVATION", 156, 160]]], ["The corresponding cumulative hazard functions are: \u039b * (\u03c4 ) = \u221a 5\u03c4 for the Weibull(.5, 5) distribution (59) \u039b * (\u03c4 ) = \u03c4 for the exponential(1) distribution, andMass-action simulations\u039b * (\u03c4 ) = \u03c4 2 for the Weibull(2, 1) distribution.Mass-action simulationsIn a mass-action model, a Weibull(.5, 1) distribution for the normalized contact interval distribution produces R 0 = .89, so no epidemics occur.", [["the Weibull", "TEST", 71, 82], ["the exponential(1) distribution", "PROBLEM", 125, 156], ["Mass", "TEST", 161, 165], ["the Weibull", "TEST", 203, 214], ["epidemics", "PROBLEM", 386, 395], ["Mass", "OBSERVATION", 161, 165], ["mass", "OBSERVATION", 262, 266]]], ["Changing the rate parameter to 5 produces R 0 = 1.98, which is very close to the R 0 = 2 of the other two models.", [["Changing the rate parameter", "TREATMENT", 0, 27]]], ["These are R 0 estimates assuming a network with no clustering (Kenah, 2010) , which places an upper bound on the true R 0 in networks with clustering.", [["an upper bound", "PROBLEM", 91, 105], ["upper", "ANATOMY_MODIFIER", 94, 99]]], ["The hazard of infectious contact decreases throughout the infectious period in the Weibull(.5, 5) case, remains constant in the exponential(1) case, and increases throughout the infectious period in the Weibull(2, 1) case.", [["infectious contact", "PROBLEM", 14, 32], ["infectious", "OBSERVATION_MODIFIER", 14, 24], ["contact", "OBSERVATION_MODIFIER", 25, 32], ["decreases", "OBSERVATION_MODIFIER", 33, 42], ["infectious", "OBSERVATION_MODIFIER", 58, 68], ["constant", "OBSERVATION_MODIFIER", 112, 120], ["infectious", "OBSERVATION", 178, 188]]], ["The L1 tolerance for the EM algorithm was set to .005.", [["the EM algorithm", "TEST", 21, 37], ["L1", "ANATOMY", 4, 6]]], ["This was approximately the minimum tolerance consistently achieved by the EM algorithm before the L1 differences became a chaotic sequence of small numbers.ResultsThe EM algorithm for the marginal Nelson-Aalen estimate took longer to converge for mass-action models than for network-based models, despite the greater tolerance.", [["the EM algorithm", "TEST", 70, 86], ["a chaotic sequence of small numbers", "PROBLEM", 120, 155], ["The EM algorithm", "TEST", 163, 179], ["mass", "PROBLEM", 247, 251], ["L1", "ANATOMY", 98, 100], ["small", "OBSERVATION_MODIFIER", 142, 147]]], ["For models with exponential contact intervals, the maximum number of iterations required was 19.", [["exponential", "OBSERVATION_MODIFIER", 16, 27]]], ["In contrast, the marginal Nelson-Aalen and Kaplan-Meier estimators were spectacular failures.", [["spectacular failures", "PROBLEM", 72, 92], ["spectacular failures", "OBSERVATION", 72, 92]]], ["In the model with exponential normalized contact interval distributions, coverage probabilities for Nelson-Aalen and Kaplan-Meier estimators were all above .93 and coverage probabilities for the marginal Nelson-Aalen and Kaplan-Meier estimators were all above .99.", [["Meier estimators", "TEST", 124, 140], ["Meier estimators", "TEST", 228, 244]]], ["Figures 3 and 4 show good agreement between the estimated and true survival and cumulative hazard functions when who-infected-whom is observed (left) but poor agreement when who-infected-whom is not observed (right).", [["left", "ANATOMY_MODIFIER", 144, 148], ["right", "ANATOMY_MODIFIER", 209, 214]]], ["The dashed lines and clouds of points have the same interpretation as in Figures 1 and 2 .ResultsThe number of possible infectors for each infection is much, much larger in a massaction model than in a network-based model.", [["infection", "DISEASE", 139, 148], ["lines", "CELL", 11, 16], ["dashed lines", "CELL_LINE", 4, 16], ["The dashed lines", "TREATMENT", 0, 16], ["infectors", "PROBLEM", 120, 129], ["each infection", "PROBLEM", 134, 148], ["dashed lines", "OBSERVATION", 4, 16], ["possible", "UNCERTAINTY", 111, 119], ["infectors", "OBSERVATION", 120, 129], ["infection", "OBSERVATION", 139, 148], ["larger", "OBSERVATION_MODIFIER", 163, 169]]], ["It seems likely that the EM algorithm cannot usefully assign probabilities to the possible infectors of each infected person because the asymptotic approximation to the marginal Nelson-Aalen estimate is not sufficiently precise and because of limited numerical precision.", [["person", "SPECIES", 118, 124], ["the EM algorithm", "PROBLEM", 21, 37], ["seems likely", "UNCERTAINTY", 3, 15]]], ["In the case of exponential contact intervals, the initial step of the EM algorithm correctly guesses that all possible infectors are equally likely to have been the source of infection, so the EM algorithm converges.", [["infection", "DISEASE", 175, 184], ["infection", "PROBLEM", 175, 184], ["infection", "OBSERVATION", 175, 184]]], ["The large coverage probabilities suggest that the variance approximation from equation (54) overestimates the true variance.Data analysis: Pandemic influenza A(H1N1) in Los Angeles County, 2009In this section, we use the marginal Nelson-Aalen estimator to analyze pandemic influenza A(H1N1) (pH1N1) surveillance data collected by the Los Angeles County Department of Public Health between April 22 and May 19, 2009.", [["Pandemic influenza A", "DISEASE", 139, 159], ["influenza", "DISEASE", 273, 282], ["Pandemic influenza A", "ORGANISM", 139, 159], ["influenza A(H1N1) (pH1N1", "ORGANISM", 273, 297], ["influenza A(H1N1", "SPECIES", 273, 289], ["The large coverage probabilities", "PROBLEM", 0, 32], ["the true variance", "PROBLEM", 106, 123], ["Data analysis", "TEST", 124, 137], ["Pandemic influenza A", "PROBLEM", 139, 159], ["surveillance data", "TEST", 299, 316], ["large", "OBSERVATION_MODIFIER", 4, 9], ["coverage", "OBSERVATION_MODIFIER", 10, 18], ["true variance", "OBSERVATION", 110, 123]]], ["The data was collected according to the following protocol :Data analysis: Pandemic influenza A(H1N1) in Los Angeles County, 2009(a) Individuals who presented to healthcare providers or the county health department with acute febrile respiratory illness (AFRI, defined as fever \u2265 100 \u2022 F plus cough, sore throat, or runny nose) had nasopharyngeal swabs and aspirates tested for pandemic influenza A(H1N1).", [["respiratory", "ANATOMY", 234, 245], ["nasopharyngeal swabs", "ANATOMY", 332, 352], ["aspirates", "ANATOMY", 357, 366], ["Pandemic influenza A", "DISEASE", 75, 95], ["febrile respiratory illness", "DISEASE", 226, 253], ["AFRI", "DISEASE", 255, 259], ["fever", "DISEASE", 272, 277], ["cough", "DISEASE", 293, 298], ["sore throat", "DISEASE", 300, 311], ["pandemic influenza A", "DISEASE", 378, 398], ["Pandemic influenza A", "ORGANISM", 75, 95], ["nose", "ORGANISM_SUBDIVISION", 322, 326], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 332, 352], ["influenza A", "ORGANISM", 387, 398], ["acute febrile respiratory illness", "PROBLEM", 220, 253], ["fever", "PROBLEM", 272, 277], ["cough", "PROBLEM", 293, 298], ["sore throat", "PROBLEM", 300, 311], ["runny nose", "PROBLEM", 316, 326], ["nasopharyngeal swabs", "PROBLEM", 332, 352], ["aspirates", "TEST", 357, 366], ["pandemic influenza A", "PROBLEM", 378, 398], ["acute", "OBSERVATION_MODIFIER", 220, 225], ["febrile", "OBSERVATION_MODIFIER", 226, 233], ["respiratory illness", "OBSERVATION", 234, 253], ["nasopharyngeal", "ANATOMY", 332, 346]]], ["Those who tested positive are the index cases. (b) The index cases were interviewed by telephone and asked to report AFRI episodes among household contacts, including the dates of illness onset.", [["illness", "DISEASE", 180, 187]]], ["Additional AFRI episodes among household contacts were ascertained during follow-up interviews 14 days after the illness onset of the index case.", [["illness", "DISEASE", 113, 120]]], ["All cases of AFRI in the household after 10 days prior to symptom onset in the index case were assumed to be pH1N1 cases.Data analysis: Pandemic influenza A(H1N1) in Los Angeles County, 2009The earliest pH1N1 case in each household is the primary case; this is usually (but not always) the index case.Data analysis: Pandemic influenza A(H1N1) in Los Angeles County, 2009There were 58 households with a total of 299 members.", [["AFRI", "DISEASE", 13, 17], ["pH1N1", "DISEASE", 109, 114], ["Pandemic influenza A", "DISEASE", 136, 156], ["Pandemic influenza A", "DISEASE", 316, 336], ["AFRI", "CANCER", 13, 17], ["Pandemic influenza A", "ORGANISM", 136, 156], ["Pandemic influenza A", "ORGANISM", 316, 336], ["symptom onset", "PROBLEM", 58, 71], ["Data analysis", "TEST", 121, 134], ["Pandemic influenza", "PROBLEM", 136, 154], ["Data analysis", "TEST", 301, 314], ["Pandemic influenza", "PROBLEM", 316, 334]]], ["This is a good example of household surveillance data from the early stages of an epidemic.", [["surveillance data", "TEST", 36, 53], ["an epidemic", "PROBLEM", 79, 90], ["epidemic", "OBSERVATION", 82, 90]]], ["We use the corresponding marginal Kaplan-Meier estimate to estimate the probability that an infected person makes infectious contact with a given household member during his or her infectious period, which we call the household infectious contact probability.Data analysis: Pandemic influenza A(H1N1) in Los Angeles County, 2009Our natural history assumptions are adapted from Yang et al. (2009) .", [["Pandemic influenza A", "DISEASE", 274, 294], ["Pandemic influenza A", "ORGANISM", 274, 294], ["person", "SPECIES", 101, 107], ["Data analysis", "TEST", 259, 272], ["Pandemic influenza A", "PROBLEM", 274, 294], ["infected", "OBSERVATION", 92, 100]]], ["In the primary analysis, we assumed an incubation period of 2 days, a latent period of 0 days, and an infectious period of 6 days.", [["infectious", "OBSERVATION", 102, 112]]], ["This means that a person i with onset of symptoms on day t sym i is infected on day t i = t sym i \u2212 2, has onset of infectiousness on day t i , and recovers from infectiousness on day t i + 6.", [["person", "SPECIES", 18, 24], ["symptoms", "PROBLEM", 41, 49], ["infectiousness", "PROBLEM", 116, 130], ["infected", "OBSERVATION", 68, 76], ["infectiousness", "OBSERVATION", 116, 130]]], ["In discrete time, the first day on which i is able to infect other persons is the day after his or her onset of infectiousness, which is t i +1 = t sym i \u22121 under our assumptions.", [["persons", "ORGANISM", 67, 74], ["persons", "SPECIES", 67, 74], ["infectiousness", "PROBLEM", 112, 126], ["discrete", "OBSERVATION_MODIFIER", 3, 11]]], ["If day 0 is the infection time, then we have the first secondary transmissions on day 1, the onset of symptoms on day 2, and recovery on day 6.", [["infection", "DISEASE", 16, 25], ["symptoms", "PROBLEM", 102, 110], ["infection", "OBSERVATION", 16, 25]]], ["In a sensitivity analysis, we vary the incubation period from 1 day to 3 days, the infectious period from 5 days to 7 days, and the latent period from 0 days to 1 day.", [["a sensitivity analysis", "TEST", 3, 25], ["infectious", "OBSERVATION", 83, 93], ["latent", "OBSERVATION_MODIFIER", 132, 138]]], ["Figure 5 shows the marginal Nelson-Aalen estimate of the cumulative hazard function of the contact interval distribution, along with approximate 95% confidence limits and parametric estimates assuming exponential and Weibull contact interval distributions.", [["parametric estimates", "TEST", 171, 191], ["marginal", "OBSERVATION_MODIFIER", 19, 27], ["distribution", "OBSERVATION_MODIFIER", 108, 120]]], ["A cumulative hazard estimate assuming a gamma contact interval distribution (not shown) was almost exactly the same as that assuming a Weibull distribution.ResultsThe exponential, Weibull, and marginal Nelson-Aalen point estimates of the cumulative hazard at 6 days post-infection are .0687, .0692, and .0729, respectively.", [["a gamma contact interval distribution", "PROBLEM", 38, 75], ["exponential", "OBSERVATION_MODIFIER", 167, 178], ["marginal", "OBSERVATION_MODIFIER", 193, 201]]], ["The corresponding survival probabilities are .9334, .9331, and .9296.", [["survival", "OBSERVATION_MODIFIER", 18, 26]]], ["Thus, all three estimates indicate a household infectious contact probability of .07 over the course of the infectious period.", [["infectious", "OBSERVATION", 108, 118]]], ["Therefore, our nonparametric estimate of the household infectious contact probability is .07 (.05, .10).ResultsWhile the nonparametric and parametric estimates agree on the household infectious contact probability, they differ in their estimates of distribution of infectiousness over time.", [["infectiousness", "PROBLEM", 265, 279], ["infectiousness", "OBSERVATION", 265, 279]]], ["The exponential estimate inherently predicts a constant hazard of infectious contact over the entire infectious period.", [["infectious", "OBSERVATION", 66, 76], ["entire", "OBSERVATION_MODIFIER", 94, 100], ["infectious", "OBSERVATION", 101, 111]]], ["The Weibull estimate also predicts little variation in the hazard of infectious contact over the infectious period, with slightly lower infectiousness near the beginning and slightly higher infectiousness near the end.", [["slightly lower infectiousness", "PROBLEM", 121, 150], ["slightly higher infectiousness", "PROBLEM", 174, 204], ["little", "OBSERVATION_MODIFIER", 35, 41], ["variation", "OBSERVATION_MODIFIER", 42, 51], ["infectious", "OBSERVATION", 69, 79], ["infectious", "OBSERVATION_MODIFIER", 97, 107], ["slightly", "OBSERVATION_MODIFIER", 121, 129], ["lower", "OBSERVATION_MODIFIER", 130, 135], ["infectiousness", "OBSERVATION", 136, 150], ["slightly", "OBSERVATION_MODIFIER", 174, 182], ["higher", "OBSERVATION_MODIFIER", 183, 189], ["infectiousness", "OBSERVATION", 190, 204]]], ["The marginal Nelson-Aalen curve has much larger jumps on days 1, 2, and 3 following infection than on days 5 and 6, which places the highest infectiousness on the day prior to, the day of, and the day after the onset of symptoms.", [["infection", "DISEASE", 84, 93], ["infection", "PROBLEM", 84, 93], ["symptoms", "PROBLEM", 220, 228], ["marginal", "OBSERVATION_MODIFIER", 4, 12], ["Nelson", "OBSERVATION", 13, 19], ["infection", "OBSERVATION", 84, 93], ["highest", "OBSERVATION_MODIFIER", 133, 140], ["infectiousness", "OBSERVATION", 141, 155]]], ["According to this estimate, only 12% of infectious contacts occur > 2 days after the onset of symptoms and only 6% occur > 3 days after symptom onset.", [["symptoms", "PROBLEM", 94, 102], ["symptom onset", "PROBLEM", 136, 149], ["infectious", "OBSERVATION", 40, 50]]], ["Figure 6 shows the results of a sensitivity analysis in which we vary the assumed (a) incubation period, (b) latent period, and (c) infectious period.", [["a sensitivity analysis", "TEST", 30, 52], ["infectious", "OBSERVATION", 132, 142]]], ["In panel (d), we vary all three of these intervals simultaneously to generate the greatest possible variation.", [["greatest", "OBSERVATION_MODIFIER", 82, 90], ["possible variation", "OBSERVATION", 91, 109]]], ["The results are insensitive to the incubation period and infectious period but sensitive to the latent period.", [["infectious", "OBSERVATION", 57, 67], ["latent", "OBSERVATION_MODIFIER", 96, 102]]], ["However, there is good evidence that little or no transmission occurs two or more days prior to the onset of symptoms (Donnelly et al., 2011) .Previous pH1N1 household data analysesOur nonparametric estimate of .07 (.05, .10) for the household infectious contact probability is very similar to the .06 (.03, .11) estimated using data collected by Public Health-Seattle and King County during April-May, 2009 .", [["symptoms", "PROBLEM", 109, 117], ["nonparametric estimate", "TEST", 185, 207], ["good", "OBSERVATION_MODIFIER", 18, 22], ["little", "OBSERVATION_MODIFIER", 37, 43]]], ["This estimate was obtained using a chain-binomial model to estimate the probability of infectious contact with a given household member on each day of the infectious period and then calculating the probability that infectious contact occurs at least once, making it directly comparable with our estimate.", [["a chain-binomial model", "TREATMENT", 33, 55], ["infectious", "OBSERVATION", 87, 97], ["infectious", "OBSERVATION", 155, 165], ["infectious", "OBSERVATION", 215, 225]]], ["The relationship between contact intervals and chain binomial models is explained in Appendix B.Previous pH1N1 household data analysesIt is more difficult to compare our estimated household infectious contact probability with estimates of the household secondary attack rate (SAR), which are usually obtained by calculating the proportion of all susceptible members of study households who have the onset of a given set of symptoms within a given time period relative to symptom onset in the index case.", [["chain binomial models", "TEST", 47, 68], ["symptoms", "PROBLEM", 423, 431], ["symptom onset in the index case", "PROBLEM", 471, 502], ["Appendix", "ANATOMY", 85, 93]]], ["Among these estimates for pH1N1 are: .145 (.129, .164) for influenzalike illness (ILI) within 7 days after the index case symptom onset (Carcione et al., 2011) , .13 for acute respiratory infection (ARI) and .9 for ILI within 1-9 days after the index case symptom onset (Morgan et al., 2010) , .113 (.088, .137) for ILI up to 23 days after index case symptom onset (France et al., 2010) , and .13 for ARI and .10 for ILI 7 days before or after the index case symptom onset .", [["respiratory", "ANATOMY", 176, 187], ["influenzalike illness", "DISEASE", 59, 80], ["ILI", "DISEASE", 82, 85], ["acute respiratory infection", "DISEASE", 170, 197], ["ARI", "DISEASE", 199, 202], ["ILI", "DISEASE", 215, 218], ["ILI", "DISEASE", 316, 319], ["ARI", "DISEASE", 401, 404], ["ILI", "DISEASE", 417, 420], ["pH1N1", "SPECIES", 26, 31], ["pH1N1", "TEST", 26, 31], ["influenzalike illness", "PROBLEM", 59, 80], ["acute respiratory infection", "PROBLEM", 170, 197], ["ILI", "PROBLEM", 215, 218], ["ILI", "PROBLEM", 316, 319], ["ARI", "TEST", 401, 404], ["ILI", "PROBLEM", 417, 420], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["respiratory", "ANATOMY", 176, 187], ["infection", "OBSERVATION", 188, 197]]], ["We did the following simulations to see if our estimated household infectious contact probability of .07 is consistent with these estimates:Previous pH1N1 household data analyses(a) For each of the 58 households in the LA data, we simulated an epidemic using its observed number of index cases and an household infectious contact probability of .07. (b) After the epidemics in all households completed, we calculated the proportion of all household contacts who were infected.Previous pH1N1 household data analysesRepeating this 10, 000 times, we got a mean household SAR of .12 with a bootstrap percentile 95% confidence interval of (.06, .19), which places us solidly within the range of previous household SAR estimates.", [["a bootstrap percentile", "TEST", 584, 606], ["consistent with", "UNCERTAINTY", 108, 123]]], ["Our nonparametric estimate of the distribution of infectiousness over time is consistent with estimates of the serial interval distribution for pH1N1 by Donnelly et al. (2011) , who found high infectiousness on days 0, 1, and 2 following symptom onset with only 18% of transmission occurring > 2 days after the onset of symptoms and only 5% occurring > 3 days after symptom onset.", [["pH1N1", "DISEASE", 144, 149], ["infectiousness", "PROBLEM", 50, 64], ["the serial interval distribution", "PROBLEM", 107, 139], ["pH1N1", "PROBLEM", 144, 149], ["high infectiousness", "PROBLEM", 188, 207], ["symptom onset", "PROBLEM", 238, 251], ["symptoms", "PROBLEM", 320, 328], ["symptom onset", "PROBLEM", 366, 379], ["distribution", "OBSERVATION_MODIFIER", 34, 46], ["infectiousness", "OBSERVATION", 50, 64], ["consistent with", "UNCERTAINTY", 78, 93], ["high", "OBSERVATION_MODIFIER", 188, 192], ["infectiousness", "OBSERVATION", 193, 207]]], ["A similar pattern of high infectiousness early in the infectious period was found by Cauchemez et al. (2009) , who also used a serial interval distribution.", [["high infectiousness", "PROBLEM", 21, 40], ["a serial interval distribution", "TREATMENT", 125, 155], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["pattern", "OBSERVATION_MODIFIER", 10, 17], ["high", "OBSERVATION_MODIFIER", 21, 25], ["infectiousness", "OBSERVATION", 26, 40], ["infectious", "OBSERVATION_MODIFIER", 54, 64], ["distribution", "OBSERVATION_MODIFIER", 143, 155]]], ["Though theoretical and practical problems with the serial interval distribution were noted in Section 1, the similarity between our results and those of Donnelly et al. (2011) and Cauchemez et al. (2009) suggests that the marginal Nelson-Aalen estimate captured an important feature of pH1N1 transmission that was missed by the parametric contact interval distribution estimates.DiscussionThe marginal Nelson-Aalen estimator suffers many of the same limitations as the parametric estimators in Kenah (2010) and some of its own.", [["pH1N1", "ORGANISM", 286, 291], ["theoretical and practical problems", "PROBLEM", 7, 41], ["pH1N1 transmission", "PROBLEM", 286, 304], ["pH1N1", "OBSERVATION", 286, 291]]], ["In roughly decreasing order of difficulty, these include:Discussion(a) The SEIR framework is limited to acute, immunizing infectious diseases that spread person-to-person, so our methods do not apply directly to tuberculosis, HIV/AIDS, many foodborne and waterborne diseases, pneumococcal and meningococcal diseases, and other infectious diseases of major public health importance. (b) We have assumed that contact intervals are independent of infectious periods, which is unrealistic.", [["infectious diseases", "DISEASE", 122, 141], ["tuberculosis", "DISEASE", 212, 224], ["HIV/AIDS", "DISEASE", 226, 234], ["foodborne and waterborne diseases", "DISEASE", 241, 274], ["pneumococcal and meningococcal diseases", "DISEASE", 276, 315], ["infectious diseases", "DISEASE", 327, 346], ["person", "SPECIES", 154, 160], ["person", "SPECIES", 164, 170], ["HIV", "SPECIES", 226, 229], ["HIV", "SPECIES", 226, 229], ["pneumococcal", "SPECIES", 276, 288], ["meningococcal", "SPECIES", 293, 306], ["acute, immunizing infectious diseases", "PROBLEM", 104, 141], ["tuberculosis", "PROBLEM", 212, 224], ["HIV/AIDS", "PROBLEM", 226, 234], ["waterborne diseases", "PROBLEM", 255, 274], ["pneumococcal and meningococcal diseases", "PROBLEM", 276, 315], ["roughly", "OBSERVATION_MODIFIER", 3, 10], ["decreasing", "OBSERVATION_MODIFIER", 11, 21], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["tuberculosis", "OBSERVATION", 212, 224], ["meningococcal diseases", "OBSERVATION", 293, 315], ["infectious", "OBSERVATION_MODIFIER", 327, 337]]], ["Both are affected by the interaction between the host and the pathogen. (c) We have assumed that infection times, times of onset of infectiousness, and times of recovery from infectiousness are observed, which is unrealistic.", [["infection", "DISEASE", 97, 106], ["infection", "PROBLEM", 97, 106], ["infectiousness", "PROBLEM", 132, 146], ["infectiousness", "PROBLEM", 175, 189], ["infection", "OBSERVATION", 97, 106]]], ["In the analysis of the Los Angeles County household data in Section 4, we were forced to assume constant latent, incubation, and infectious periods because we had only symptom onset times.", [["constant", "OBSERVATION_MODIFIER", 96, 104], ["latent", "OBSERVATION", 105, 111]]], ["The implicit assumption of constant latent, incubation, and infectious periods in methods based on generation and serial intervals was one of our main criticisms in Section 1.", [["constant latent, incubation", "PROBLEM", 27, 54], ["constant", "OBSERVATION_MODIFIER", 27, 35], ["latent", "OBSERVATION_MODIFIER", 36, 42], ["infectious", "OBSERVATION_MODIFIER", 60, 70]]], ["Unfortunately, our analysis merely made these same assumptions explicit. (d) We assumed that the contact interval distribution is identically distributed for all ordered pairs ij such that C ij = 1, which is unrealistic.", [["our analysis", "TEST", 15, 27], ["all ordered pairs ij", "TREATMENT", 158, 178], ["C ij", "TREATMENT", 189, 193], ["ij", "ANATOMY", 191, 193]]], ["For instance, age was found to have an effect on pH1N1 transmission in most of the papers cited in Section 4 France et al., 2010; Morgan et al., 2010; Carcione et al., 2011; .", [["pH1N1", "DISEASE", 49, 54], ["pH1N1 transmission", "TREATMENT", 49, 67]]], ["The effects of covariates on the transmission of disease is a central concern of infectious disease epidemiology.Discussion(e) There are several technical issues that need further exploration.", [["disease", "PROBLEM", 49, 56], ["infectious disease epidemiology", "PROBLEM", 81, 112], ["several technical issues", "PROBLEM", 137, 161], ["further exploration", "TEST", 172, 191], ["disease", "OBSERVATION", 49, 56], ["infectious", "OBSERVATION", 81, 91]]], ["A more rigorous theoretical analysis of convergence of the marginal Nelson-Aalen estimator, including the smoothing step, is needed to better understand the conditions under which it will work.", [["marginal", "OBSERVATION_MODIFIER", 59, 67]]], ["Convergence criteria need to be more carefully examined, confidence intervals for small samples need to be developed, and more general stopping times for the end of observation need to be considered.DiscussionNonetheless, survival analysis based on contact intervals is a powerful framework for the development of statistical methods in infectious disease epidemiology.", [["small samples", "PROBLEM", 82, 95], ["survival analysis", "TEST", 222, 239], ["infectious", "OBSERVATION", 337, 347]]], ["These methods have important theoretical and practical advantages over methods based on generation or serial intervals, including greater flexibility in the choice of an underlying transmission model, greater clarity about data requirements and analytical assumptions, the exploitation of information contributed by uninfected person-time, and validity throughout the course of an epidemic.", [["person", "SPECIES", 327, 333], ["practical advantages over methods", "TREATMENT", 45, 78]]], ["The theory and methods of survival analysis offer many possibilities for overcoming the limitations listed above.DiscussionThe arguments for convergence of the Nelson-Aalen estimator given in Section 2 are largely heuristic, but the theoretical analysis required to address limitation (e) is complicated by the smoothing step.", [["survival analysis", "TEST", 26, 43], ["the Nelson-Aalen estimator", "TREATMENT", 156, 182], ["the theoretical analysis", "TEST", 229, 253]]], ["In simulations, the performance of the marginal Nelson-Aalen estimator did not appear sensitive to the smoothing method.", [["the smoothing method", "TREATMENT", 99, 119]]], ["However, a smoother designed specifically for hazard functions, such as that of M\u00fcller and Wang (1994) , may improve performance under certain conditions.", [["hazard functions", "TEST", 46, 62]]], ["Another technical limitation is that the variance estimates based on equation (40) treat the estimated transmission network probabilities as known, ignoring a component of the variance that may be important in small samples.", [["samples", "ANATOMY", 216, 223], ["the estimated transmission network probabilities", "PROBLEM", 89, 137], ["may be", "UNCERTAINTY", 190, 196], ["small", "OBSERVATION_MODIFIER", 210, 215]]], ["These and other technical issues need to be resolved with more rigorous theoretical analysis and further simulation studies.DiscussionLimitation (d) can be addressed by incorporating the marginal Nelson-Aalen estimate into a semiparametric regression model for the effects of covariates on the hazard of infectious contact.", [["rigorous theoretical analysis", "TEST", 63, 92], ["further simulation studies", "TEST", 97, 123], ["a semiparametric regression model", "TREATMENT", 223, 256], ["infectious", "OBSERVATION", 304, 314]]], ["Suppose the hazard of infectious contact from person i to person j at infectiousness age \u03c4 of i isDiscussionwhere \u03b2 is a parameter vector and X ij is a vector of infectiousness covariates for i, susceptibility covariates for j, and pairwise covariates for ij.", [["X ij", "DNA", 142, 146], ["person", "SPECIES", 46, 52], ["person", "SPECIES", 58, 64], ["a parameter vector", "TREATMENT", 119, 137], ["ij", "TREATMENT", 256, 258], ["infectious", "OBSERVATION", 22, 32], ["ij", "ANATOMY", 256, 258]]], ["This would yield a semiparametric estimator of the effects of covariates on infectiousness and susceptibility that is similar in spirit to the Cox proportional hazards model.", [["infectiousness", "PROBLEM", 76, 90]]], ["In infectious disease epidemiology, these covariate effects are usually a higher priority than the distribution of infectiousness over time, so the marginal Nelson-Aalen estimator may find its most important applications behind the scenes of this regression model.", [["infectious disease", "DISEASE", 3, 21], ["infectiousness", "PROBLEM", 115, 129], ["Aalen estimator", "TREATMENT", 164, 179], ["infectious", "OBSERVATION_MODIFIER", 3, 13], ["infectiousness", "OBSERVATION", 115, 129]]], ["A semiparametric Bayesian approach would use a prior process instead of a marginal Nelson-Aalen estimator.", [["A semiparametric Bayesian approach", "TREATMENT", 0, 34], ["a prior process", "TREATMENT", 45, 60]]], ["A profile sampler would take advantage of the fact that the marginal Nelson-Aalen estimate is an efficient numerical method of obtaining a likelihood maximized over all possible contact interval distributions for a given set of infection times, infectiousness onset times, and recovery times.DiscussionLimitation (b) could be addressed by using multivariate survival methods to estimate the joint distribution of the contact interval and the infectious period, and limitation (a) could be addressed by allowing individuals to experience multiple infection events or infection events of different types (e.g., new infection, carriage, relapse).DiscussionSurvival analysis based on contact intervals is a promising approach to the statistical analysis of infectious disease data.", [["infection", "DISEASE", 228, 237], ["infection", "DISEASE", 546, 555], ["infection", "DISEASE", 566, 575], ["infection", "DISEASE", 613, 622], ["infectious disease", "DISEASE", 753, 771], ["A profile sampler", "TREATMENT", 0, 17], ["infection times", "PROBLEM", 228, 243], ["multivariate survival methods", "TREATMENT", 345, 374], ["multiple infection events", "PROBLEM", 537, 562], ["infection events", "PROBLEM", 566, 582], ["new infection", "PROBLEM", 609, 622], ["DiscussionSurvival analysis", "TEST", 643, 670], ["the statistical analysis", "TEST", 725, 749], ["infectious disease data", "TEST", 753, 776], ["infection", "OBSERVATION", 228, 237], ["joint", "ANATOMY", 391, 396], ["infectious", "OBSERVATION_MODIFIER", 442, 452], ["infection", "OBSERVATION", 546, 555], ["infection", "OBSERVATION", 566, 575], ["new", "OBSERVATION_MODIFIER", 609, 612], ["infection", "OBSERVATION", 613, 622], ["infectious", "OBSERVATION", 753, 763]]], ["The marginal Nelson-Aalen estimator extends a beautiful and powerful set of nonparametric methods from standard survival analysis to infectious disease epidemiology.", [["marginal", "OBSERVATION_MODIFIER", 4, 12]]], ["The simulations in Section 3 show that these methods are reliable, and the data analysis in Section 4 shows that the nonparametric methods in this paper are an important extension of the parametric methods in Kenah (2010) .", [["the data analysis", "TEST", 71, 88]]], ["Each of the ingredients of this approach have been applied to infectious diseases before: counting processes and martingales by Becker (1989) and Rhodes et al. (1996) , the EM algorithm by Becker (1997) , and summation over possible transmission networks by Wallinga and Teunis (2004) .", [["infectious diseases", "DISEASE", 62, 81], ["this approach", "TREATMENT", 27, 40], ["infectious diseases", "PROBLEM", 62, 81], ["infectious", "OBSERVATION_MODIFIER", 62, 72]]], ["The marginal Nelson-Aalen estimator combines these in a novel and useful way, correcting approaches based on generation and serial intervals, generalizing the chain binomial model, and pointing the way to more flexible and practical statistical methods for infectious disease epidemiology.", [["serial intervals", "TEST", 124, 140], ["infectious disease epidemiology", "PROBLEM", 257, 288], ["marginal", "OBSERVATION_MODIFIER", 4, 12], ["Nelson", "OBSERVATION", 13, 19]]], ["Wallinga, J. and P. Teunis (2004)A. Partially-observed transmission networksIn a partially-observed transmission network, we observe the infectors of a subset of all infected persons.", [["persons", "ORGANISM", 175, 182], ["persons", "SPECIES", 175, 182], ["infected", "OBSERVATION", 166, 174]]], ["By taking V j = v j for all j such that the infector is observed, equations (28) through (33) define a marginal Nelson-Aalen estimator that takes this additional information into account.", [["all j", "TREATMENT", 24, 29]]], ["The variance estimate in equation (43) can be used to obtain confidence intervals via equation (44).B. Contact intervals and chain binomial modelsIn this appendix, we show that the methods of Section 2 reproduce classical chain-binomial models when the contact interval distribution is discrete.", [["appendix", "ANATOMY", 154, 162], ["discrete", "OBSERVATION_MODIFIER", 286, 294]]], ["In the case of a continuous contact interval distribution (Kenah et al., 2008; Kenah, 2010) , the likelihood when who-infectedwhom is not observed isB.", [["isB", "PROTEIN", 147, 150]]], ["Contact intervals and chain binomial models, this is equivalent to the integrated likelihood maximized by the EM algorithm in Section 2.B. Contact intervals and chain binomial modelsWhen the contact interval and latent period distributions are discrete, we must account for the possibility of tied infectious contact times.", [["latent", "OBSERVATION_MODIFIER", 212, 218], ["must account for the possibility", "UNCERTAINTY", 257, 289], ["infectious", "OBSERVATION", 298, 308]]], ["Instead of each infected person j having a single infector, the source of his or her infection can be any nonempty subset V j \u2286 V j .", [["infection", "DISEASE", 85, 94], ["person", "SPECIES", 25, 31], ["her infection", "PROBLEM", 81, 94], ["infection", "OBSERVATION", 85, 94], ["j \u2286 V j", "OBSERVATION_MODIFIER", 124, 131]]], ["Equation (64) contains all terms inB.", [["Equation", "TEST", 0, 8]]], ["Contact intervals and chain binomial modelsSince 1 \u2212 \u03bb(\u03c4 ) can be interpreted as an infection escape probability, the likelihood in equation (68) is precisely the same as that of a chain-binomial model (Rampey et al., 1992) .", [["infection", "DISEASE", 84, 93], ["an infection escape probability", "PROBLEM", 81, 112], ["infection", "OBSERVATION", 84, 93]]], ["Therefore, chain-binomial models can be defined in terms of contact interval distributions, and the methods of this paper can be seen as an extension of chain-binomial models to continuous time.Marginal Kaplan\u2212Meier estimatesTime since onset of infection (\u03c4) Survival Fig. 3 .", [["infection", "DISEASE", 245, 254], ["chain-binomial models", "PROBLEM", 11, 32], ["infection", "PROBLEM", 245, 254], ["binomial models", "OBSERVATION", 17, 32], ["infection", "OBSERVATION", 245, 254]]], ["Estimates of the cumulative hazard and survival functions for mass-action models with a Weibull(.5, 5) normalized contact interval distribution using the methods from Section 2.4, with (left) and without (right) data on who-infected-whom.", [["mass", "PROBLEM", 62, 66], ["the methods", "TEST", 150, 161], ["right", "ANATOMY_MODIFIER", 205, 210]]], ["The true cumulative hazard function (top) and survival function (bottom) are indicated with dashed lines.", [["lines", "CELL", 99, 104], ["dashed lines", "CELL_LINE", 92, 104], ["dashed lines", "TREATMENT", 92, 104]]], ["The point clouds are point estimates at the 5 th , 10 th , 25 th , 50 th , 75 th , 90 th , and 95 th percentiles of the possible contact intervals in each of 1,000 simulations.", [["clouds", "OBSERVATION_MODIFIER", 10, 16], ["possible", "UNCERTAINTY", 120, 128], ["contact intervals", "OBSERVATION", 129, 146]]], ["Note the deviation of the marginal Nelson-Aalen and Kaplan-Meier estimates from the true functions.", [["marginal", "OBSERVATION_MODIFIER", 26, 34]]], ["The assumed latent period for all analyses was 2 days, so symptom onset occurs on day 2 after the onset of infectiousness.", [["infectiousness", "PROBLEM", 107, 121], ["latent", "OBSERVATION_MODIFIER", 12, 18], ["infectiousness", "OBSERVATION", 107, 121]]], ["Note the large jumps on days 1, 2, and 3 following the onset of infectiousness and the small jumps on days 5 and 6.Incubation, Latent, InfectiousDays since onset of infectiousness Cumulative hazard 2, 0, 6 days 2, 1, 5 days 1, 0, 5 days Fig. 6 .", [["infectiousness", "PROBLEM", 64, 78], ["the small jumps", "PROBLEM", 83, 98], ["large", "OBSERVATION_MODIFIER", 9, 14], ["jumps", "OBSERVATION", 15, 20], ["infectiousness", "OBSERVATION", 64, 78], ["small", "OBSERVATION_MODIFIER", 87, 92], ["jumps", "OBSERVATION", 93, 98]]], ["Sensitivity analyses for the nonparametric analysis of the LA county household data.", [["LA", "CHEMICAL", 59, 61], ["Sensitivity analyses", "TEST", 0, 20], ["the nonparametric analysis", "TEST", 25, 51]]], ["There is little sensitivity to the assumed incubation and infectious periods.", [["little sensitivity", "PROBLEM", 9, 27], ["infectious", "OBSERVATION", 58, 68]]], ["There is greater sensitivity to the assumed latent period, but there is good evidence for transmission on the day prior to symptom onset and little evidence of significant transmission \u2265 2 days prior to symptom onset Donnelly et al., 2011) .", [["symptom onset", "PROBLEM", 123, 136], ["greater", "OBSERVATION_MODIFIER", 9, 16], ["latent", "OBSERVATION_MODIFIER", 44, 50], ["little evidence of", "UNCERTAINTY", 141, 159], ["significant", "OBSERVATION_MODIFIER", 160, 171]]]], "093ed8906315e3316b01987797ba47e3612ff032": [["We present here the design of the Mechanical Ventilator Milano (MVM), a novel mechanical ventilator designed for mass scale production in response to the COVID-19 pandemics, to compensate for the dramatic shortage of such ventilators in many countries.", [["the Mechanical Ventilator Milano (MVM)", "TREATMENT", 30, 68], ["a novel mechanical ventilator", "TREATMENT", 70, 99], ["mass scale production", "PROBLEM", 113, 134], ["the COVID", "TREATMENT", 150, 159], ["such ventilators", "TREATMENT", 217, 233]]], ["This ventilator is an electro-mechanical equivalent of the old, reliable Manley Ventilator.", [["This ventilator", "TREATMENT", 0, 15], ["reliable Manley Ventilator", "TREATMENT", 64, 90], ["mechanical equivalent", "OBSERVATION", 30, 51], ["Manley Ventilator", "OBSERVATION", 73, 90]]], ["Our design is optimized to permit large sale production in short time and at a limited cost, relying on off-the-shelf components, readily available worldwide from hardware suppliers.", [["hardware suppliers", "TREATMENT", 163, 181], ["large", "OBSERVATION_MODIFIER", 34, 39], ["sale production", "OBSERVATION", 40, 55], ["hardware", "OBSERVATION", 163, 171]]], ["Operation of the MVM requires only a source of compressed oxygen (or compressed medical air) and electrical power.", [["oxygen", "CHEMICAL", 58, 64], ["oxygen", "CHEMICAL", 58, 64], ["MVM", "ORGANISM", 17, 20], ["oxygen", "SIMPLE_CHEMICAL", 58, 64], ["the MVM", "PROBLEM", 13, 20], ["compressed oxygen", "TREATMENT", 47, 64]]], ["The MVM control and monitoring unit can be connected and networked via WiFi so that no additional electrical connections are necessary other than the connection to the electrical power.", [["The MVM control", "TREATMENT", 0, 15], ["additional electrical connections", "TREATMENT", 87, 120]]]], "ce3339fa40331ed208b06a0725c65f779cd2a16e": [["Jean-Fran\u00e7ois Gautier 1,2 and Yann Ravussin 3To the Editor:Jean-Fran\u00e7ois Gautier 1,2 and Yann Ravussin 3As the ongoing COVID-19 pandemic rapidly progresses across the globe, quickly obtaining accurate information on symptoms and their progression is vital.", [["globe", "ORGAN", 167, 172], ["Jean-Fran\u00e7ois Gautier", "TREATMENT", 59, 80], ["Yann Ravussin", "TREATMENT", 89, 102], ["symptoms", "PROBLEM", 216, 224], ["globe", "ANATOMY", 167, 172]]], ["Since most affected patients have mild to no symptoms, it remains crucial to quickly relate any commonly observed symptoms and to do so widely.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["symptoms", "PROBLEM", 45, 53], ["any commonly observed symptoms", "PROBLEM", 92, 122], ["mild", "OBSERVATION_MODIFIER", 34, 38]]], ["Cough, fever, and/or trouble breathing are the major symptoms that have been publicly communicated in a consistent manner.", [["Cough", "DISEASE", 0, 5], ["fever", "DISEASE", 7, 12], ["trouble breathing", "DISEASE", 21, 38], ["Cough", "PROBLEM", 0, 5], ["fever", "PROBLEM", 7, 12], ["trouble breathing", "PROBLEM", 21, 38], ["the major symptoms", "PROBLEM", 43, 61], ["fever", "OBSERVATION", 7, 12]]], ["Meanwhile, the people with the greatest knowledge of current symptoms are the healthcare workers in the countries being most affected (e.g. Italy, France, Iran), yet they also have the least time to transmit this important information to the greater public.Jean-Fran\u00e7ois Gautier 1,2 and Yann Ravussin 3One of the authors (Jean-Fran\u00e7ois Gautier), an endocrinologist in Paris, has transformed his Diabetes and Endocrinology inpatient beds at l'Hopital Lariboisiere, as have other specialized units, into an inpatient unit totally dedicated to COVID-19-positive patients.", [["Diabetes", "DISEASE", 395, 403], ["people", "ORGANISM", 15, 21], ["COVID-19", "GENE_OR_GENE_PRODUCT", 541, 549], ["patients", "ORGANISM", 559, 567], ["people", "SPECIES", 15, 21], ["patients", "SPECIES", 559, 567], ["current symptoms", "PROBLEM", 53, 69], ["his Diabetes", "PROBLEM", 391, 403], ["COVID", "TEST", 541, 546]]], ["His recent interactions with patients and other doctors have rapidly led to the realization that sudden loss of smell (anosmia) and/or taste (ageusia) may be experienced in the infected, symptoms not commonly reported in China.", [["sudden loss of smell", "DISEASE", 97, 117], ["anosmia", "DISEASE", 119, 126], ["patients", "ORGANISM", 29, 37], ["smell", "ORGANISM_SUBDIVISION", 112, 117], ["patients", "SPECIES", 29, 37], ["sudden loss of smell (anosmia)", "PROBLEM", 97, 127], ["taste (ageusia)", "PROBLEM", 135, 150], ["symptoms", "PROBLEM", 187, 195], ["infected", "OBSERVATION", 177, 185]]], ["The other author (Yann Ravussin), an obesity researcher currently living in Geneva, has recently experienced a rapid onset of anosmia following 2 to 3 days of strong fatigue and headache.", [["obesity", "DISEASE", 37, 44], ["anosmia", "DISEASE", 126, 133], ["fatigue", "DISEASE", 166, 173], ["headache", "DISEASE", 178, 186], ["anosmia", "PROBLEM", 126, 133], ["strong fatigue", "PROBLEM", 159, 173], ["headache", "PROBLEM", 178, 186], ["obesity", "OBSERVATION", 37, 44], ["fatigue", "OBSERVATION", 166, 173], ["headache", "OBSERVATION", 178, 186]]], ["Having presented no fever, coughing, or breathing problems, he initially decided that COVID-19 was unlikely based on readily available news outlets and official governmental websites (CDC, Swiss Government Health) yet was subsequently told he likely had the virus but did not reach the criteria for testing based on age and/or symptoms.", [["fever", "DISEASE", 20, 25], ["coughing", "DISEASE", 27, 35], ["fever", "PROBLEM", 20, 25], ["coughing", "PROBLEM", 27, 35], ["breathing problems", "PROBLEM", 40, 58], ["the virus", "PROBLEM", 254, 263], ["testing", "TEST", 299, 306], ["symptoms", "PROBLEM", 327, 335], ["no", "UNCERTAINTY", 17, 19], ["fever", "OBSERVATION", 20, 25]]], ["Yet it is slowly emerging that these symptoms are quite common.", [["these symptoms", "PROBLEM", 31, 45], ["slowly", "OBSERVATION_MODIFIER", 10, 16]]], ["Anosmia has been reported to be found in upwards of 2/3 of patients in Germany by epidemiologist Hendrik Streek (1) while Italian and Swiss doctors are reporting similar findings with many also displaying ageusia.", [["Anosmia", "DISEASE", 0, 7], ["ageusia", "DISEASE", 205, 212], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["Anosmia", "PROBLEM", 0, 7]]], ["Numbers from South Korea suggest that 30% of positive patients had anosmia as the primary presenting symptom.Jean-Fran\u00e7ois Gautier 1,2 and Yann Ravussin 3Dr.", [["anosmia", "DISEASE", 67, 74], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["anosmia", "PROBLEM", 67, 74], ["the primary presenting symptom", "PROBLEM", 78, 108]]], ["Ravussin's frustration on the paucity of information related to the anosmia found online and in normal media outlets pushed him to contact various medical doctors directly working with infected patients on three continents and all confirmed that this presenting symptom is common knowledge within the medical professional communities directly fighting the COVID-19 virus.Jean-Fran\u00e7ois Gautier 1,2 and Yann Ravussin 3We are writing to the Editors to make sure this information is more widely circulated among readers of the Journal and hope/suggest that people who present with anosmia and/or ageusia without other symptoms are admitted for testing and realize that they may be affected by the current pandemic.", [["Ravussin", "CHEMICAL", 0, 8], ["anosmia", "DISEASE", 68, 75], ["anosmia", "DISEASE", 577, 584], ["ageusia", "DISEASE", 592, 599], ["patients", "ORGANISM", 194, 202], ["COVID-19 virus", "ORGANISM", 356, 370], ["people", "ORGANISM", 553, 559], ["patients", "SPECIES", 194, 202], ["people", "SPECIES", 553, 559], ["COVID-19 virus", "SPECIES", 356, 370], ["Ravussin's frustration", "PROBLEM", 0, 22], ["the anosmia", "PROBLEM", 64, 75], ["this presenting symptom", "PROBLEM", 246, 269], ["the COVID", "TEST", 352, 361], ["anosmia", "PROBLEM", 577, 584], ["other symptoms", "PROBLEM", 608, 622], ["testing", "TEST", 640, 647]]], ["This moment in our lives will be complicated, stressful, and full of unknowns but with better knowledge transfer should come better decision-making to keep us and our loved ones safe.O", [["O", "CHEMICAL", 183, 184], ["O", "SPECIES", 183, 184]]]], "PMC7380916": [["We read with interest the Article by Giulio Cavalli and colleagues1 that described the effects of the interleukin-1 receptor antagonist anakinra in patients who were critically ill with COVID-19.", [["anakinra", "CHEMICAL", 136, 144], ["critically ill", "DISEASE", 166, 180], ["COVID-19", "CHEMICAL", 186, 194], ["interleukin-1 receptor", "GENE_OR_GENE_PRODUCT", 102, 124], ["anakinra", "SIMPLE_CHEMICAL", 136, 144], ["patients", "ORGANISM", 148, 156], ["interleukin-1 receptor", "PROTEIN", 102, 124], ["patients", "SPECIES", 148, 156], ["the interleukin-1 receptor antagonist anakinra", "TREATMENT", 98, 144], ["COVID", "TEST", 186, 191]]], ["The authors reported promising effects of high-dose anakinra treatment, including improvement of respiratory function and better survival compared with a historical control group that received standard treatment.", [["respiratory", "ANATOMY", 97, 108], ["anakinra", "CHEMICAL", 52, 60], ["anakinra", "SIMPLE_CHEMICAL", 52, 60], ["high-dose anakinra treatment", "TREATMENT", 42, 70], ["respiratory function", "PROBLEM", 97, 117], ["a historical control group", "TREATMENT", 152, 178], ["standard treatment", "TREATMENT", 193, 211], ["respiratory function", "OBSERVATION", 97, 117]]], ["Although these results are encouraging, there are notable differences in patient characteristics between the groups that might have confounded the observed effects.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["notable", "OBSERVATION_MODIFIER", 50, 57], ["differences", "OBSERVATION_MODIFIER", 58, 69]]]], "980c9a5471f622c6e0db6c29581eaf4aa0bacaf4": [["Pulmonary Pathology of Early Phase 2019 Novel Coronavirus PneumoniaTo the Editor: We read the publication on \"Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer\" with great interest.", [["Pulmonary", "ANATOMY", 110, 119], ["lung cancer", "ANATOMY", 210, 221], ["coronavirus", "DISEASE", 156, 167], ["COVID-19)", "CHEMICAL", 169, 178], ["pneumonia", "DISEASE", 179, 188], ["lung cancer", "DISEASE", 210, 221], ["Pulmonary", "ORGAN", 0, 9], ["coronavirus", "ORGANISM", 156, 167], ["patients", "ORGANISM", 196, 204], ["lung cancer", "CANCER", 210, 221], ["patients", "SPECIES", 196, 204], ["novel coronavirus", "PROBLEM", 150, 167], ["COVID", "TEST", 169, 174], ["pneumonia", "PROBLEM", 179, 188], ["lung cancer", "PROBLEM", 210, 221], ["Pathology", "OBSERVATION", 10, 19], ["Early Phase", "OBSERVATION_MODIFIER", 23, 34], ["Pulmonary", "ANATOMY", 110, 119], ["pneumonia", "OBSERVATION", 179, 188], ["lung", "ANATOMY", 210, 214], ["cancer", "OBSERVATION", 215, 221]]], ["1 Tian et al. 1 concluded that \"the lungs of both patients exhibited edema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration, and multinucleated giant cells\" and noted that \"these changes likely represent an early phase of the lung pathology of COVID-19 pneumonia.\"", [["lungs", "ANATOMY", 36, 41], ["edema", "ANATOMY", 69, 74], ["exudate", "ANATOMY", 90, 97], ["pneumocytes", "ANATOMY", 129, 140], ["cellular", "ANATOMY", 166, 174], ["multinucleated giant cells", "ANATOMY", 193, 219], ["lung", "ANATOMY", 290, 294], ["edema", "DISEASE", 69, 74], ["COVID", "DISEASE", 308, 313], ["pneumonia", "DISEASE", 317, 326], ["lungs", "ORGAN", 36, 41], ["patients", "ORGANISM", 50, 58], ["edema", "PATHOLOGICAL_FORMATION", 69, 74], ["pneumocytes", "CELL", 129, 140], ["cellular", "CELL", 166, 174], ["multinucleated giant cells", "CELL", 193, 219], ["lung", "ORGAN", 290, 294], ["multinucleated giant cells", "CELL_TYPE", 193, 219], ["patients", "SPECIES", 50, 58], ["edema", "PROBLEM", 69, 74], ["proteinaceous exudate", "PROBLEM", 76, 97], ["focal reactive hyperplasia of pneumocytes", "PROBLEM", 99, 140], ["patchy inflammatory cellular infiltration", "PROBLEM", 146, 187], ["multinucleated giant cells", "PROBLEM", 193, 219], ["the lung pathology", "PROBLEM", 286, 304], ["COVID", "TEST", 308, 313], ["pneumonia", "PROBLEM", 317, 326], ["lungs", "ANATOMY", 36, 41], ["edema", "OBSERVATION", 69, 74], ["proteinaceous", "OBSERVATION_MODIFIER", 76, 89], ["exudate", "OBSERVATION_MODIFIER", 90, 97], ["focal", "OBSERVATION_MODIFIER", 99, 104], ["reactive", "OBSERVATION_MODIFIER", 105, 113], ["hyperplasia", "OBSERVATION", 114, 125], ["pneumocytes", "ANATOMY", 129, 140], ["patchy", "OBSERVATION_MODIFIER", 146, 152], ["inflammatory", "OBSERVATION_MODIFIER", 153, 165], ["cellular infiltration", "OBSERVATION", 166, 187], ["multinucleated", "OBSERVATION_MODIFIER", 193, 207], ["giant cells", "OBSERVATION", 208, 219], ["early", "OBSERVATION_MODIFIER", 271, 276], ["phase", "OBSERVATION_MODIFIER", 277, 282], ["lung", "ANATOMY", 290, 294], ["pathology", "OBSERVATION", 295, 304], ["pneumonia", "OBSERVATION", 317, 326]]], ["Although this pathologic finding might be a lung abnormality in COVID-19, it should not be referred to as COVID-19 pneumonia because the patients did not have pneumonia.", [["lung", "ANATOMY", 44, 48], ["lung abnormality", "DISEASE", 44, 60], ["pneumonia", "DISEASE", 115, 124], ["pneumonia", "DISEASE", 159, 168], ["lung", "ORGAN", 44, 48], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["a lung abnormality", "PROBLEM", 42, 60], ["COVID", "TEST", 64, 69], ["COVID", "TEST", 106, 111], ["pneumonia", "PROBLEM", 115, 124], ["pneumonia", "PROBLEM", 159, 168], ["might be", "UNCERTAINTY", 33, 41], ["lung", "ANATOMY", 44, 48], ["abnormality", "OBSERVATION", 49, 60], ["pneumonia", "OBSERVATION", 115, 124], ["pneumonia", "OBSERVATION", 159, 168]]], ["In a previous report of a case with pneumonia and severe respiratory distress, fibromyxoid exudates and hyaline mem-brane formation were the main histopathologic findings.", [["respiratory", "ANATOMY", 57, 68], ["fibromyxoid exudates", "ANATOMY", 79, 99], ["hyaline mem-brane", "ANATOMY", 104, 121], ["pneumonia", "DISEASE", 36, 45], ["respiratory distress", "DISEASE", 57, 77], ["fibromyxoid exudates", "PATHOLOGICAL_FORMATION", 79, 99], ["hyaline mem-brane", "TISSUE", 104, 121], ["pneumonia", "PROBLEM", 36, 45], ["severe respiratory distress", "PROBLEM", 50, 77], ["fibromyxoid exudates", "PROBLEM", 79, 99], ["hyaline mem-brane formation", "PROBLEM", 104, 131], ["pneumonia", "OBSERVATION", 36, 45], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["respiratory distress", "OBSERVATION", 57, 77], ["fibromyxoid exudates", "OBSERVATION", 79, 99], ["hyaline mem-brane", "OBSERVATION", 104, 121], ["main", "OBSERVATION_MODIFIER", 141, 145]]], ["2 Asymptomatic or mildly symptomatic COVID-19 is possible 3 and the pathologic findings in the lungs mentioned by Tian et al. 1 To the Editor: Thank you for forwarding the letter by Joob and Wiwanitkit 1 regarding our recent paper \"Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer.\" 2 We thank Dr. Joob and Dr. Wiwanitkit for their interest in our work and appreciate their comments.Pulmonary Pathology of Early Phase 2019 Novel Coronavirus PneumoniaIn our paper, we described two patients who came to the hospital for elective surgical resections of SCLC at the time when COVID-19 was spreading in Wuhan and even more so in hospitals, but when stringent infection preventive measures had not yet been implemented owing to low public awareness.", [["lungs", "ANATOMY", 95, 100], ["Pulmonary", "ANATOMY", 232, 241], ["lung cancer", "ANATOMY", 332, 343], ["SCLC", "ANATOMY", 614, 618], ["coronavirus", "DISEASE", 278, 289], ["COVID-19)", "CHEMICAL", 291, 300], ["pneumonia", "DISEASE", 301, 310], ["lung cancer", "DISEASE", 332, 343], ["SCLC", "DISEASE", 614, 618], ["infection", "DISEASE", 718, 727], ["lungs", "ORGAN", 95, 100], ["coronavirus", "ORGANISM", 278, 289], ["patients", "ORGANISM", 318, 326], ["lung cancer", "CANCER", 332, 343], ["Pulmonary", "ORGAN", 446, 455], ["patients", "ORGANISM", 544, 552], ["SCLC", "CANCER", 614, 618], ["patients", "SPECIES", 318, 326], ["patients", "SPECIES", 544, 552], ["mildly symptomatic COVID", "PROBLEM", 18, 42], ["the pathologic findings in the lungs", "PROBLEM", 64, 100], ["novel coronavirus", "PROBLEM", 272, 289], ["COVID", "TEST", 291, 296], ["pneumonia", "PROBLEM", 301, 310], ["lung cancer", "PROBLEM", 332, 343], ["Pulmonary Pathology", "TEST", 446, 465], ["elective surgical resections", "TREATMENT", 582, 610], ["SCLC", "PROBLEM", 614, 618], ["COVID", "TEST", 636, 641], ["stringent infection preventive measures", "PROBLEM", 708, 747], ["mildly", "OBSERVATION_MODIFIER", 18, 24], ["symptomatic", "OBSERVATION_MODIFIER", 25, 36], ["pathologic", "OBSERVATION", 68, 78], ["lungs", "ANATOMY", 95, 100], ["Pulmonary", "ANATOMY", 232, 241], ["pneumonia", "OBSERVATION", 301, 310], ["lung", "ANATOMY", 332, 336], ["cancer", "OBSERVATION", 337, 343], ["Pathology", "OBSERVATION", 456, 465], ["Early Phase", "OBSERVATION_MODIFIER", 469, 480], ["resections", "OBSERVATION", 600, 610], ["SCLC", "OBSERVATION", 614, 618], ["infection", "OBSERVATION", 718, 727]]], ["Afterward, both patients were confirmed to have developed COVID-19 pneumonia.", [["pneumonia", "DISEASE", 67, 76], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["COVID-19 pneumonia", "PROBLEM", 58, 76], ["pneumonia", "OBSERVATION", 67, 76]]], ["Retrospective reviews revealed radiographic changes in the patients' lungs around the time of the operation.", [["lungs", "ANATOMY", 69, 74], ["patients", "ORGANISM", 59, 67], ["lungs", "ORGAN", 69, 74], ["patients", "SPECIES", 59, 67], ["Retrospective reviews", "TEST", 0, 21], ["radiographic changes in the patients' lungs", "PROBLEM", 31, 74], ["the operation", "TREATMENT", 94, 107], ["lungs", "ANATOMY", 69, 74], ["operation", "OBSERVATION", 98, 107]]], ["Both patients had a history of exposure to the virus.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["the virus", "PROBLEM", 43, 52]]], ["Although the patients did not exhibit symptoms at the time of the operation, subsequent pathologic examination revealed changes as reported in the paper; 2 thus, this represents the early changes seen in COVID-19 pneumonia.", [["pneumonia", "DISEASE", 213, 222], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["symptoms", "PROBLEM", 38, 46], ["the operation", "TREATMENT", 62, 75], ["subsequent pathologic examination", "TEST", 77, 110], ["the early changes", "PROBLEM", 178, 195], ["COVID", "TEST", 204, 209], ["pneumonia", "PROBLEM", 213, 222], ["pneumonia", "OBSERVATION", 213, 222]]], ["As we know, many diseases can have radiographic or pathologic changes before clinical symptoms develop.Pulmonary Pathology of Early Phase 2019 Novel Coronavirus PneumoniaTo be more specific, what the physician finds and what the patient feels are not always synchronized.", [["Pulmonary", "ANATOMY", 103, 112], ["Pulmonary", "ORGAN", 103, 112], ["patient", "ORGANISM", 229, 236], ["patient", "SPECIES", 229, 236], ["many diseases", "PROBLEM", 12, 25], ["radiographic or pathologic changes", "PROBLEM", 35, 69], ["clinical symptoms", "PROBLEM", 77, 94], ["Pulmonary Pathology", "TEST", 103, 122], ["Novel Coronavirus PneumoniaTo", "PROBLEM", 143, 172], ["Pathology", "OBSERVATION", 113, 122], ["Early Phase", "OBSERVATION_MODIFIER", 126, 137]]], ["Post operation on day 1, patient 1 had increased white blood cell count and lymphocytopenia, which are not consistent with the usual nonspecific postoperative responses.", [["white blood cell", "ANATOMY", 49, 65], ["lymphocytopenia", "DISEASE", 76, 91], ["patient", "ORGANISM", 25, 32], ["white blood cell", "CELL", 49, 65], ["patient", "SPECIES", 25, 32], ["increased white blood cell count", "PROBLEM", 39, 71], ["lymphocytopenia", "PROBLEM", 76, 91], ["cell count", "OBSERVATION", 61, 71], ["lymphocytopenia", "OBSERVATION", 76, 91], ["not consistent with", "UNCERTAINTY", 103, 122], ["nonspecific", "OBSERVATION_MODIFIER", 133, 144]]], ["Instead, they are consistent with what has been described in many patients with COVID-19.", [["COVID-19", "CHEMICAL", 80, 88], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["COVID", "TEST", 80, 85], ["consistent with", "UNCERTAINTY", 18, 33]]], ["Patient 2 exhibited evident ground-glass opacity in the lungs as early as on day 2 post operation.", [["lungs", "ANATOMY", 56, 61], ["lungs", "ORGAN", 56, 61], ["Patient", "SPECIES", 0, 7], ["ground-glass opacity in the lungs", "PROBLEM", 28, 61], ["ground-", "OBSERVATION", 28, 35], ["glass opacity", "OBSERVATION", 35, 48], ["lungs", "ANATOMY", 56, 61]]], ["These are signs of early COVID-19 pneumonia, given the subsequent development of respiratory symptoms and more typical radiographic changes, as well as positive nucleic acid tests.Pulmonary Pathology of Early Phase 2019 Novel Coronavirus PneumoniaDr.", [["respiratory", "ANATOMY", 81, 92], ["Pulmonary", "ANATOMY", 180, 189], ["pneumonia", "DISEASE", 34, 43], ["respiratory symptoms", "DISEASE", 81, 101], ["nucleic acid", "CHEMICAL", 161, 173], ["Pulmonary", "ORGAN", 180, 189], ["early COVID-19 pneumonia", "PROBLEM", 19, 43], ["respiratory symptoms", "PROBLEM", 81, 101], ["more typical radiographic changes", "PROBLEM", 106, 139], ["positive nucleic acid tests", "PROBLEM", 152, 179], ["Pulmonary Pathology", "TEST", 180, 199], ["Early Phase", "PROBLEM", 203, 214], ["Novel Coronavirus PneumoniaDr", "PROBLEM", 220, 249], ["signs of", "UNCERTAINTY", 10, 18], ["early", "OBSERVATION_MODIFIER", 19, 24], ["pneumonia", "OBSERVATION", 34, 43], ["respiratory symptoms", "OBSERVATION", 81, 101], ["Pathology", "OBSERVATION", 190, 199], ["Early Phase", "OBSERVATION_MODIFIER", 203, 214], ["Coronavirus PneumoniaDr", "OBSERVATION", 226, 249]]], ["Joob and Dr. Wiwanitkit compared our findings with those described by Xu et al. 3 The latter is a case report of a postmortem core biopsy in which the patient died of the disease.", [["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["a postmortem core biopsy", "TEST", 113, 137], ["the disease", "PROBLEM", 167, 178], ["disease", "OBSERVATION", 171, 178]]], ["Changes there represent a late, advanced stage of COVID-19 pneumonia.", [["COVID", "DISEASE", 50, 55], ["pneumonia", "DISEASE", 59, 68], ["COVID-19 pneumonia", "PROBLEM", 50, 68], ["late", "OBSERVATION_MODIFIER", 26, 30], ["pneumonia", "OBSERVATION", 59, 68]]], ["We know that diseases evolve and progress in a subpopulation of patients.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["diseases", "OBSERVATION", 13, 21]]], ["For most fatal acute infectious diseases, pathologic studies are on autopsies, which only reveal the most advanced stage of the disease.", [["infectious diseases", "DISEASE", 21, 40], ["most fatal acute infectious diseases", "PROBLEM", 4, 40], ["pathologic studies", "TEST", 42, 60], ["autopsies", "TEST", 68, 77], ["the disease", "PROBLEM", 124, 135], ["fatal", "OBSERVATION_MODIFIER", 9, 14], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["infectious", "OBSERVATION", 21, 31], ["most advanced", "OBSERVATION_MODIFIER", 101, 114], ["disease", "OBSERVATION", 128, 135]]], ["Even though the two patients referred to in our paper eventually progressed to severe pneumonia (one died), our findings in their lobectomy specimens represent the early, presymptomatic stage of the disease.", [["lobectomy specimens", "ANATOMY", 130, 149], ["pneumonia", "DISEASE", 86, 95], ["patients", "ORGANISM", 20, 28], ["lobectomy specimens", "CANCER", 130, 149], ["patients", "SPECIES", 20, 28], ["severe pneumonia", "PROBLEM", 79, 95], ["their lobectomy specimens", "TEST", 124, 149], ["the disease", "PROBLEM", 195, 206], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["pneumonia", "OBSERVATION", 86, 95], ["lobectomy", "OBSERVATION", 130, 139], ["early", "OBSERVATION_MODIFIER", 164, 169], ["presymptomatic", "OBSERVATION_MODIFIER", 171, 185], ["disease", "OBSERVATION", 199, 206]]], ["For these reasons, what we have reported 2 is particularly valuable in helping us understand the evolution of the disease better and is not just a simple \"snapshot\" of the disease.", [["the disease", "PROBLEM", 110, 121], ["the disease", "PROBLEM", 168, 179], ["disease", "OBSERVATION", 114, 121], ["disease", "OBSERVATION", 172, 179]]], ["In other words, it is more important to learn about the dynamic \"live\" pathology than \"dead\" pathology.Pulmonary Pathology of Early Phase 2019 Novel Coronavirus PneumoniaWith more data accumulating, we now know that the underlying pathology of COVID-19 is that of diffuse alveolar damage in which hyaline membrane formation is only one of the histologic changes and usually appears late.", [["Pulmonary", "ANATOMY", 103, 112], ["alveolar", "ANATOMY", 272, 280], ["hyaline membrane", "ANATOMY", 297, 313], ["COVID", "DISEASE", 244, 249], ["alveolar damage", "DISEASE", 272, 287], ["COVID-19", "CHEMICAL", 244, 252], ["Pulmonary", "ORGAN", 103, 112], ["alveolar", "TISSUE", 272, 280], ["hyaline membrane", "CELLULAR_COMPONENT", 297, 313], ["Pulmonary Pathology", "TEST", 103, 122], ["COVID", "TEST", 244, 249], ["diffuse alveolar damage", "PROBLEM", 264, 287], ["hyaline membrane formation", "PROBLEM", 297, 323], ["the histologic changes", "PROBLEM", 339, 361], ["Pathology", "OBSERVATION", 113, 122], ["Early Phase", "OBSERVATION_MODIFIER", 126, 137], ["diffuse", "OBSERVATION_MODIFIER", 264, 271], ["alveolar damage", "OBSERVATION", 272, 287], ["hyaline membrane formation", "OBSERVATION", 297, 323], ["histologic", "OBSERVATION", 343, 353]]], ["We saw in our two patients that its progression starts with an exudative process.Pulmonary Pathology of Early Phase 2019 Novel Coronavirus PneumoniaFinally, what we have described in the article should not be interpreted as pathologic changes of asymptomatic or mild COVID-19 because both patients progressed to severe disease and one died.", [["patients", "ORGANISM", 18, 26], ["Pulmonary", "ORGAN", 81, 90], ["patients", "ORGANISM", 289, 297], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 289, 297], ["an exudative process", "PROBLEM", 60, 80], ["Pulmonary Pathology", "TEST", 81, 100], ["Novel Coronavirus PneumoniaFinally", "PROBLEM", 121, 155], ["asymptomatic or mild COVID", "PROBLEM", 246, 272], ["severe disease", "PROBLEM", 312, 326], ["exudative", "OBSERVATION", 63, 72], ["Pathology", "OBSERVATION", 91, 100], ["Early Phase", "OBSERVATION_MODIFIER", 104, 115], ["mild", "OBSERVATION_MODIFIER", 262, 266], ["severe", "OBSERVATION_MODIFIER", 312, 318], ["disease", "OBSERVATION", 319, 326]]], ["Most patients with asymptomatic or mild COVID-19 should not have any lung pathology at all, although the patients may be positive for either viral sequence in pharyngeal swab polymerase chain reaction or serologic tests.", [["lung", "ANATOMY", 69, 73], ["patients", "ORGANISM", 5, 13], ["lung", "ORGAN", 69, 73], ["patients", "ORGANISM", 105, 113], ["viral sequence", "DNA", 141, 155], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 105, 113], ["asymptomatic or mild COVID", "PROBLEM", 19, 45], ["any lung pathology", "PROBLEM", 65, 83], ["viral sequence in pharyngeal swab polymerase chain reaction", "PROBLEM", 141, 200], ["serologic tests", "TEST", 204, 219], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["lung", "ANATOMY", 69, 73], ["pathology", "OBSERVATION", 74, 83], ["pharyngeal swab", "ANATOMY", 159, 174]]]], "0532ce84e0335775dd8100e9cb62bdfcf948ce21": [["IntroductionItaly joined the list of SARS-CoV-2 1 -affected countries on 31 January when two Chinese tourists in Rome tested positive for coronavirus disease.", [["SARS", "DISEASE", 37, 41], ["coronavirus disease", "DISEASE", 138, 157], ["coronavirus", "ORGANISM", 138, 149], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["coronavirus disease", "PROBLEM", 138, 157], ["coronavirus disease", "OBSERVATION", 138, 157]]], ["As of March 12 th , the spread of the coronavirus is mainly concentrated in the North of Italy and more precisely in the regions of Lombardy, Veneto, Emilia Romagna and Piedmont.", [["coronavirus", "DISEASE", 38, 49], ["coronavirus", "ORGANISM", 38, 49], ["the coronavirus", "PROBLEM", 34, 49], ["spread", "OBSERVATION_MODIFIER", 24, 30], ["coronavirus", "OBSERVATION", 38, 49], ["mainly", "OBSERVATION_MODIFIER", 53, 59], ["concentrated", "OBSERVATION_MODIFIER", 60, 72], ["North", "OBSERVATION_MODIFIER", 80, 85], ["regions", "ANATOMY_MODIFIER", 121, 128], ["Lombardy", "ANATOMY_MODIFIER", 132, 140], ["Veneto", "ANATOMY", 142, 148], ["Emilia Romagna", "OBSERVATION", 150, 164], ["Piedmont", "OBSERVATION_MODIFIER", 169, 177]]], ["The largest number of infections is recorded in the cities of Bergamo, Lodi, Cremona, Brescia, Milan and Pavia, while Piacenza and Parma are the most affected cities of Emilia Romagna.", [["infections", "DISEASE", 22, 32], ["infections", "PROBLEM", 22, 32], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["infections", "OBSERVATION", 22, 32], ["Brescia", "ANATOMY", 86, 93], ["Pavia", "ANATOMY", 105, 110], ["Emilia Romagna", "OBSERVATION", 169, 183]]], ["The other cities affected by the contagion were found in the Veneto region in the city of Padua mostly.", [["Veneto", "ANATOMY", 61, 67]]], ["On March 9 th nationwide lockdown came into force to prevent SARS-CoV-2 spreading further.IntroductionThe basic reproduction number, R0, is the number of secondary infections resulting from a single primary infection into an otherwise susceptible population.", [["SARS", "DISEASE", 61, 65], ["infections", "DISEASE", 164, 174], ["primary infection", "DISEASE", 199, 216], ["SARS", "PROBLEM", 61, 65], ["CoV", "PROBLEM", 66, 69], ["secondary infections", "PROBLEM", 154, 174], ["a single primary infection", "PROBLEM", 190, 216], ["SARS", "OBSERVATION", 61, 65], ["secondary", "OBSERVATION_MODIFIER", 154, 163], ["infections", "OBSERVATION", 164, 174], ["primary", "OBSERVATION_MODIFIER", 199, 206], ["infection", "OBSERVATION", 207, 216], ["otherwise", "OBSERVATION_MODIFIER", 225, 234], ["susceptible", "OBSERVATION_MODIFIER", 235, 246], ["population", "OBSERVATION", 247, 257]]], ["It is used to measure the transmission potential of a disease and is the most widely used estimator of how severe an epidemic outbreak can be.", [["a disease", "PROBLEM", 52, 61], ["disease", "OBSERVATION", 54, 61], ["severe", "OBSERVATION_MODIFIER", 107, 113]]], ["If R0 < 1, on average an infectious individual infects less than one person and the contagion is expected to stop spreading.", [["person", "SPECIES", 69, 75], ["an infectious individual infects", "PROBLEM", 22, 54], ["infectious", "OBSERVATION_MODIFIER", 25, 35]]], ["In the present study the R0 value for SARS-CoV-2 was assessed analyzing data derived from the early phase of the outbreak in Italy.", [["SARS-CoV", "SPECIES", 38, 46], ["the R0 value", "TEST", 21, 33], ["SARS-CoV", "TEST", 38, 46], ["analyzing data", "TEST", 62, 76]]], ["In particular, the spread of SARS-CoV-2 was analyzed in 9 cities (those with the largest number of infections) fitting the wellestablished SIR-model to available data.Materials and methodsA well-known mathematical description of the spread of a disease in a population is the SIR model, which divides the population of N individuals into three compartments (varying as a function of time, t): S(t) are those susceptible but not yet infected with the disease, I(t) is the number of infectious individuals and R(t) are those individuals who have recovered from the disease and now have immunity to it.", [["SARS", "DISEASE", 29, 33], ["infections", "DISEASE", 99, 109], ["SARS-CoV-2", "ORGANISM", 29, 39], ["R(t)", "GENE_OR_GENE_PRODUCT", 508, 512], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "PROBLEM", 29, 33], ["CoV", "TEST", 34, 37], ["infections", "PROBLEM", 99, 109], ["a disease", "PROBLEM", 243, 252], ["the disease", "PROBLEM", 559, 570], ["spread", "OBSERVATION_MODIFIER", 19, 25], ["infections", "OBSERVATION", 99, 109], ["disease", "OBSERVATION", 245, 252], ["population", "OBSERVATION_MODIFIER", 305, 315], ["disease", "OBSERVATION", 450, 457], ["infectious", "OBSERVATION", 481, 491], ["disease", "OBSERVATION", 563, 570]]], ["The SIR model describes the change in the population of each compartment in terms of two parameters, \u03b2 and \u03b3, with \u03b2 describing the effective transmission rate of the disease and \u03b3 is the mean recovery rate.", [["\u03b2", "PROTEIN", 101, 102], ["\u03b2", "PROTEIN", 115, 116], ["the disease", "PROBLEM", 163, 174], ["change", "OBSERVATION_MODIFIER", 28, 34], ["disease", "OBSERVATION", 167, 174]]], ["According to the SIR model, new infections occur as a result of contact between infectives and susceptibles.", [["infections", "DISEASE", 32, 42], ["new infections", "PROBLEM", 28, 42], ["contact between infectives and susceptibles", "PROBLEM", 64, 107], ["new", "OBSERVATION_MODIFIER", 28, 31], ["infections", "OBSERVATION", 32, 42]]], ["The rate at which new infections occur is \u03b2 \u00b7 S \u00b7 I. When a new infection occurs, the individual infected moves from the susceptible compartment to the infective compartment.", [["infections", "DISEASE", 22, 32], ["infection", "DISEASE", 64, 73], ["The rate", "TEST", 0, 8], ["new infections", "PROBLEM", 18, 32], ["a new infection", "PROBLEM", 58, 73], ["new", "OBSERVATION_MODIFIER", 18, 21], ["infections", "OBSERVATION", 22, 32], ["new", "OBSERVATION_MODIFIER", 60, 63], ["infection", "OBSERVATION", 64, 73], ["individual", "OBSERVATION_MODIFIER", 86, 96], ["infected", "OBSERVATION", 97, 105], ["infective compartment", "OBSERVATION", 152, 173]]], ["The other process that can occur is that infective individuals can enter the removed class at a rate \u03b3 \u00b7 I. Assuming that at the outset of an epidemic nearly everyone is susceptible, the basic reproduction number is given by R0 = \u03b2/\u03b3.", [["infective individuals", "PROBLEM", 41, 62]]], ["J o u r n a l P r e -p r o o f 2019-nCoV reproduction number based on the outbreak in Italy 3 The SIR model can be expressed by the following set of ordinary differential equations:Materials and methodswhere the disease transmission rate \u03b2 >0 and the recovery rate \u03b3 > 0 (and with 1/ \u03b3 representing the duration of the infection).", [["infection", "DISEASE", 319, 328], ["the disease transmission rate", "TEST", 208, 237], ["the recovery rate", "TEST", 247, 264], ["the infection", "PROBLEM", 315, 328], ["infection", "OBSERVATION", 319, 328]]], ["A detailed description of the model is provided elsewhere [1, 2] .Materials and methodsIn this paper the spread of SARS-CoV-2 was analyzed in the cities of Bergamo, Lodi, Cremona, Brescia, Milan, Pavia, Piacenza and Parma fitting the SIR-model to SARS-CoV-2 cases in the population in the interval between February 25 -March 12, 2020.", [["SARS", "DISEASE", 115, 119], ["SARS", "DISEASE", 247, 251], ["SARS-CoV", "SPECIES", 115, 123], ["SARS-CoV", "SPECIES", 247, 255], ["SARS", "PROBLEM", 115, 119], ["CoV", "TEST", 120, 123], ["Piacenza", "TREATMENT", 203, 211], ["Brescia", "ANATOMY", 180, 187]]], ["Furthermore, R0 was assessed fitting the SIR-model to the reported cases of COVID-19 in the whole country.", [["COVID", "TEST", 76, 81]]], ["The number of confirmed cases of COVID-19 cases was collected from the Italian Ministry of Health [3].", [["COVID", "DISEASE", 33, 38], ["COVID", "TEST", 33, 38]]], ["Table 1 shows R0 values for SARS-CoV-2 assessed in the 9 Italian cities reporting the largest number of cases.", [["SARS", "DISEASE", 28, 32], ["SARS-CoV", "SPECIES", 28, 36], ["R0 values", "TEST", 14, 23], ["SARS", "PROBLEM", 28, 32], ["CoV", "TEST", 33, 36], ["largest", "OBSERVATION_MODIFIER", 86, 93]]], ["The SIR model fits well to the reported COVID-19 data with r 2 in the range 0.85-0.99.", [["COVID", "DNA", 40, 45], ["COVID", "TEST", 40, 45]]], ["It is plausible that lower r 2 values reflect a poorer fit in the initial data, where official estimates are most likely subject to a large uncertainty.", [["most likely", "UNCERTAINTY", 109, 120], ["large", "OBSERVATION_MODIFIER", 134, 139]]], ["Furthermore, it should be noted that the present study only considers data between February 25 and March 12.", [["the present study", "TEST", 37, 54]]], ["This is because the nationwide lockdown established on March 9 is likely to alter the initial R0 value in the following days [6] .Results and discussionsPrevious work has only focused to the assessment of R0 analyzing data collected from the Wuhan region or Mainland China.", [["the assessment", "TEST", 187, 201], ["R0 analyzing data", "TEST", 205, 222]]], ["Our results suggest that R0 values associated with the Italian outbreak (at time of writing) may range from 2.43 to 3.10, when using data from February 25, 2020 through March 12, 2020, thus confirming the pandemic potential of SARS-CoV-2.", [["SARS", "DISEASE", 227, 231], ["SARS-CoV-2", "ORGANISM", 227, 237], ["SARS-CoV", "SPECIES", 227, 235], ["R0 values", "PROBLEM", 25, 34], ["SARS", "PROBLEM", 227, 231], ["CoV", "TEST", 232, 235]]], ["This is consistent with [4] , reporting R0 values in the range 2.0 to 3.1 and with [5] and [7] reporting R0 values in the range 1.4-3.9 and 2.47-2.86, respectively.", [["R0 values", "TEST", 40, 49], ["R0 values", "TEST", 105, 114], ["consistent with", "UNCERTAINTY", 8, 23]]], ["In another study Zhao and colleagues [8] reported similar values, with R0 ranging from 2.24 to 3.58 while Chen and coworkers [9] estimated R0 for SARS-CoV-2 to be slightly higher, i.e. 3.58.", [["SARS", "DISEASE", 146, 150], ["SARS-CoV", "SPECIES", 146, 154], ["R0", "TEST", 71, 73], ["SARS", "TEST", 146, 150], ["CoV", "TEST", 151, 154], ["slightly higher", "PROBLEM", 163, 178]]], ["Figure 1 shows the SIR model fitted to the data of infectious and recovered people in the early phase of the outbreak in Italy (February 25 -March 12, 2020) .", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["infectious", "PROBLEM", 51, 61], ["infectious", "OBSERVATION", 51, 61], ["early phase", "OBSERVATION_MODIFIER", 90, 101]]], ["The J o u r n a l P r e -p r o o f 2019-nCoV reproduction number based on the outbreak in Italy 4 SIR model fits very well reported data, both for the number of infectious people (r 2 = 0.99) and for the number of recovered people (r 2 = 0.98).", [["people", "ORGANISM", 172, 178], ["people", "ORGANISM", 224, 230], ["people", "SPECIES", 172, 178], ["people", "SPECIES", 224, 230], ["infectious", "OBSERVATION", 161, 171]]], ["However, the doubling time in a disease outbreak is not constant and for the outbreak of SARS-CoV-2 it has changed in recent weeks and will continue to change with time.Results and discussionsIn the present study the date of epidemic outbreak was assessed extrapolating to t = 0 the fitting function associated with the infectious population (figure 1).", [["SARS", "DISEASE", 89, 93], ["SARS-CoV-2", "ORGANISM", 89, 99], ["SARS-CoV", "SPECIES", 89, 97], ["a disease outbreak", "PROBLEM", 30, 48], ["epidemic outbreak", "PROBLEM", 225, 242], ["the infectious population", "PROBLEM", 316, 341], ["disease", "OBSERVATION", 32, 39], ["infectious", "OBSERVATION_MODIFIER", 320, 330]]], ["February 1 st was obtained as a possible date of epidemic outbreak in Italy, in good agreement with official data reporting the first confirmed cases of SARS-CoV-2 on January 31 st .Results and discussionsUltimately, it is worth noticing that SARS-CoV-2 has a latent phase during which the individual is infected but not yet infectious (median incubation 4.5 -5.8 days [11] ).", [["SARS", "DISEASE", 153, 157], ["SARS", "DISEASE", 243, 247], ["SARS-CoV-2", "ORGANISM", 243, 253], ["SARS-CoV", "SPECIES", 153, 161], ["SARS", "PROBLEM", 153, 157], ["CoV", "TEST", 158, 161], ["SARS", "PROBLEM", 243, 247], ["CoV", "TEST", 248, 251], ["infected", "OBSERVATION", 304, 312]]], ["This delay between the acquisition of infection and the infectious state can be incorporated within the SIR model by adding a latent population (i.e. SEIR model).", [["infection", "DISEASE", 38, 47], ["This delay", "PROBLEM", 0, 10], ["infection", "PROBLEM", 38, 47], ["the infectious state", "PROBLEM", 52, 72], ["a latent population", "TREATMENT", 124, 143], ["infection", "OBSERVATION", 38, 47], ["infectious", "OBSERVATION", 56, 66]]], ["Since the latency delays the start of the individual's infectious period, the secondary spread from an infected individual will occur at a later time compared with an SIR model, which has no latency.", [["the secondary spread", "PROBLEM", 74, 94], ["an infected individual", "PROBLEM", 100, 122], ["an SIR model", "TEST", 164, 176], ["latency", "PROBLEM", 191, 198], ["latency", "OBSERVATION_MODIFIER", 10, 17], ["infectious", "OBSERVATION", 55, 65], ["secondary", "OBSERVATION_MODIFIER", 78, 87], ["spread", "OBSERVATION_MODIFIER", 88, 94], ["infected", "OBSERVATION", 103, 111], ["no", "UNCERTAINTY", 188, 190], ["latency", "OBSERVATION_MODIFIER", 191, 198]]], ["Therefore, including a longer latency period will result in slower initial growth of the outbreak.", [["growth", "OBSERVATION_MODIFIER", 75, 81]]], ["In conclusion, despite the Italian outbreak being the worst in Europe and the worst outside of Asia so far, our findings would seem to suggest that the R0 value of SARS-CoV-2 is in the range 2.43 to 3.10, consistent with R0 values reported for Wuhan or the Chinese Mainland.", [["SARS", "DISEASE", 164, 168], ["SARS-CoV-2", "ORGANISM", 164, 174], ["SARS-CoV", "SPECIES", 164, 172], ["the R0 value", "TEST", 148, 160], ["SARS", "TEST", 164, 168], ["CoV", "TEST", 169, 172], ["consistent with", "UNCERTAINTY", 205, 220]]], ["Mitigation strategies (e.g. social distancing, quarantine measures, travel restrictions) are essential to contrast further epidemic spreading, especially in countries experiencing a lag time behind the Italian outbreak.", [["Mitigation strategies", "TREATMENT", 0, 21], ["quarantine measures", "TREATMENT", 47, 66]]]], "PMC7152114": [["Chemical Structure and Pharmacology ::: Leflunomide and Malononitrilamides ::: SMALL MOLECULESLeflunomide (N-(4)) trifluoro-methylphenyl-5-methylisoxawol-4-carboximide) is a prodrug and is rapidly converted to its biologically active metabolite teriflunomide (A771703).", [["Leflunomide", "CHEMICAL", 40, 51], ["Malononitrilamides", "CHEMICAL", 56, 74], ["MOLECULESLeflunomide", "CHEMICAL", 85, 105], ["N-(4)) trifluoro-methylphenyl-5-methylisoxawol-4-carboximide", "CHEMICAL", 107, 167], ["teriflunomide", "CHEMICAL", 245, 258], ["A771703", "CHEMICAL", 260, 267], ["Leflunomide", "CHEMICAL", 40, 51], ["Malononitrilamides", "CHEMICAL", 56, 74], ["MOLECULESLeflunomide", "CHEMICAL", 85, 105], ["N-(4)) trifluoro-methylphenyl-5-methylisoxawol-4-carboximide", "CHEMICAL", 107, 167], ["teriflunomide", "CHEMICAL", 245, 258], ["A771703", "CHEMICAL", 260, 267], ["Leflunomide", "SIMPLE_CHEMICAL", 40, 51], ["Malononitrilamides", "SIMPLE_CHEMICAL", 56, 74], ["N-(4)) trifluoro-methylphenyl-5-methylisoxawol-4-carboximide", "SIMPLE_CHEMICAL", 107, 167], ["teriflunomide", "SIMPLE_CHEMICAL", 245, 258], ["A771703", "SIMPLE_CHEMICAL", 260, 267], ["Leflunomide", "TREATMENT", 40, 51], ["SMALL MOLECULESLeflunomide", "TEST", 79, 105], ["trifluoro", "TEST", 114, 123], ["methylphenyl", "TREATMENT", 124, 136], ["methylisoxawol", "TREATMENT", 139, 153], ["carboximide", "TREATMENT", 156, 167], ["its biologically active metabolite teriflunomide", "TREATMENT", 210, 258]]], ["Serum levels of teriflunomide are referred to as leflunomide levels.", [["Serum", "ANATOMY", 0, 5], ["teriflunomide", "CHEMICAL", 16, 29], ["leflunomide", "CHEMICAL", 49, 60], ["teriflunomide", "CHEMICAL", 16, 29], ["leflunomide", "CHEMICAL", 49, 60], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["teriflunomide", "SIMPLE_CHEMICAL", 16, 29], ["leflunomide", "SIMPLE_CHEMICAL", 49, 60], ["Serum levels", "TEST", 0, 12], ["teriflunomide", "TREATMENT", 16, 29], ["leflunomide levels", "TEST", 49, 67]]], ["The half-life of teriflunomide is long in humans (approximately 15 days).", [["teriflunomide", "CHEMICAL", 17, 30], ["teriflunomide", "CHEMICAL", 17, 30], ["teriflunomide", "SIMPLE_CHEMICAL", 17, 30], ["humans", "ORGANISM", 42, 48], ["humans", "SPECIES", 42, 48], ["humans", "SPECIES", 42, 48], ["teriflunomide", "TREATMENT", 17, 30]]], ["The drug enters the enterohepatic recirculation and is excreted by the intestinal and urinary systems in equal proportions.", [["intestinal", "ANATOMY", 71, 81], ["urinary", "ANATOMY", 86, 93], ["intestinal", "ORGAN", 71, 81], ["urinary", "ORGANISM_SUBDIVISION", 86, 93], ["enterohepatic recirculation", "OBSERVATION", 20, 47], ["intestinal", "ANATOMY", 71, 81], ["urinary systems", "ANATOMY", 86, 101], ["equal proportions", "OBSERVATION", 105, 122]]], ["Leflunomide is insoluble in water and is suspended in 1% carboxymethylcellulose for oral administration.Chemical Structure and Pharmacology ::: Leflunomide and Malononitrilamides ::: SMALL MOLECULESThe MNAs are designed to be structurally similar to A771726.", [["oral", "ANATOMY", 84, 88], ["Leflunomide", "CHEMICAL", 0, 11], ["carboxymethylcellulose", "CHEMICAL", 57, 79], ["Leflunomide", "CHEMICAL", 144, 155], ["Malononitrilamides", "CHEMICAL", 160, 178], ["A771726", "CHEMICAL", 250, 257], ["Leflunomide", "CHEMICAL", 0, 11], ["carboxymethylcellulose", "CHEMICAL", 57, 79], ["Leflunomide", "CHEMICAL", 144, 155], ["Malononitrilamides", "CHEMICAL", 160, 178], ["A771726", "CHEMICAL", 250, 257], ["Leflunomide", "SIMPLE_CHEMICAL", 0, 11], ["carboxymethylcellulose", "SIMPLE_CHEMICAL", 57, 79], ["oral", "ORGANISM_SUBDIVISION", 84, 88], ["Leflunomide", "SIMPLE_CHEMICAL", 144, 155], ["Malononitrilamides", "SIMPLE_CHEMICAL", 160, 178], ["A771726", "CELL", 250, 257], ["Leflunomide", "TREATMENT", 0, 11], ["1% carboxymethylcellulose", "TREATMENT", 54, 79], ["oral administration", "TREATMENT", 84, 103], ["Leflunomide", "TREATMENT", 144, 155], ["Malononitrilamides", "TREATMENT", 160, 178], ["SMALL MOLECULESThe MNAs", "PROBLEM", 183, 206], ["insoluble", "OBSERVATION_MODIFIER", 15, 24], ["MOLECULESThe MNAs", "OBSERVATION", 189, 206]]], ["Oral bioavailability of FK778 is not substantially affected by food, and no gender effect on pharmacokinetics was observed in phase I studies.Mechanism of Action ::: Leflunomide and Malononitrilamides ::: SMALL MOLECULESLeflunomide and its analogues have strong antiproliferative effects on both T lymphocytes and B lymphocytes, thus limiting the formation of antibodies.41,228 Inhibition of pyrimidine synthesis is the most important mechanism of action as leflunomide directly inhibits the enzyme dihydroorotate dehydrogenase.289 Lymphocytes rely entirely on the de novo pathway of pyrimidine biosynthesis and cannot use another, the so-called \u201cpyrimidine salvage pathway.\u201d", [["Oral", "ANATOMY", 0, 4], ["T lymphocytes", "ANATOMY", 296, 309], ["B lymphocytes", "ANATOMY", 314, 327], ["Lymphocytes", "ANATOMY", 532, 543], ["FK778", "CHEMICAL", 24, 29], ["Leflunomide", "CHEMICAL", 166, 177], ["Malononitrilamides", "CHEMICAL", 182, 200], ["pyrimidine", "CHEMICAL", 392, 402], ["leflunomide", "CHEMICAL", 458, 469], ["dihydroorotate", "CHEMICAL", 499, 513], ["pyrimidine", "CHEMICAL", 584, 594], ["pyrimidine", "CHEMICAL", 647, 657], ["FK778", "CHEMICAL", 24, 29], ["Leflunomide", "CHEMICAL", 166, 177], ["Malononitrilamides", "CHEMICAL", 182, 200], ["pyrimidine", "CHEMICAL", 392, 402], ["leflunomide", "CHEMICAL", 458, 469], ["dihydroorotate", "CHEMICAL", 499, 513], ["pyrimidine", "CHEMICAL", 584, 594], ["pyrimidine", "CHEMICAL", 647, 657], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["FK778", "SIMPLE_CHEMICAL", 24, 29], ["Leflunomide", "SIMPLE_CHEMICAL", 166, 177], ["Malononitrilamides", "SIMPLE_CHEMICAL", 182, 200], ["T lymphocytes", "CELL", 296, 309], ["B lymphocytes", "CELL", 314, 327], ["pyrimidine", "SIMPLE_CHEMICAL", 392, 402], ["leflunomide", "SIMPLE_CHEMICAL", 458, 469], ["dihydroorotate dehydrogenase", "GENE_OR_GENE_PRODUCT", 499, 527], ["Lymphocytes", "CELL", 532, 543], ["pyrimidine", "SIMPLE_CHEMICAL", 584, 594], ["pyrimidine", "SIMPLE_CHEMICAL", 647, 657], ["T lymphocytes", "CELL_TYPE", 296, 309], ["B lymphocytes", "CELL_TYPE", 314, 327], ["antibodies", "PROTEIN", 360, 370], ["enzyme dihydroorotate dehydrogenase", "PROTEIN", 492, 527], ["Lymphocytes", "CELL_TYPE", 532, 543], ["gender effect on pharmacokinetics", "PROBLEM", 76, 109], ["Leflunomide", "TREATMENT", 166, 177], ["Malononitrilamides", "TREATMENT", 182, 200], ["SMALL MOLECULESLeflunomide and its analogues", "PROBLEM", 205, 249], ["strong antiproliferative effects", "PROBLEM", 255, 287], ["B lymphocytes", "PROBLEM", 314, 327], ["the formation of antibodies", "PROBLEM", 343, 370], ["pyrimidine synthesis", "TREATMENT", 392, 412], ["leflunomide", "TREATMENT", 458, 469], ["the enzyme dihydroorotate dehydrogenase", "PROBLEM", 488, 527], ["Lymphocytes", "TEST", 532, 543], ["pyrimidine biosynthesis", "TREATMENT", 584, 607], ["pyrimidine salvage pathway", "TREATMENT", 647, 673], ["MOLECULESLeflunomide", "OBSERVATION", 211, 231], ["strong", "OBSERVATION_MODIFIER", 255, 261], ["antiproliferative", "OBSERVATION_MODIFIER", 262, 279], ["lymphocytes", "ANATOMY", 298, 309], ["lymphocytes", "ANATOMY", 316, 327]]], ["Dihydroorotate dehydrogenase inhibition leads to depletion of the nucleotide precursors uridine triphosphate and cytidine triphosphate which are necessary for the synthesis of RNA and DNA, and hence strongly suppress DNA and RNA synthesis.Mechanism of Action ::: Leflunomide and Malononitrilamides ::: SMALL MOLECULESThe in vivo mechanism of action of leflunomide may depend on factors such as drug levels, disposable uridine pools, and the immune activation pathway involved.", [["Dihydroorotate", "CHEMICAL", 0, 14], ["nucleotide", "CHEMICAL", 66, 76], ["uridine triphosphate", "CHEMICAL", 88, 108], ["cytidine triphosphate", "CHEMICAL", 113, 134], ["Leflunomide", "CHEMICAL", 263, 274], ["Malononitrilamides", "CHEMICAL", 279, 297], ["leflunomide", "CHEMICAL", 352, 363], ["uridine", "CHEMICAL", 418, 425], ["Dihydroorotate", "CHEMICAL", 0, 14], ["nucleotide", "CHEMICAL", 66, 76], ["uridine triphosphate", "CHEMICAL", 88, 108], ["cytidine triphosphate", "CHEMICAL", 113, 134], ["Leflunomide", "CHEMICAL", 263, 274], ["Malononitrilamides", "CHEMICAL", 279, 297], ["leflunomide", "CHEMICAL", 352, 363], ["uridine", "CHEMICAL", 418, 425], ["Dihydroorotate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 28], ["uridine triphosphate", "SIMPLE_CHEMICAL", 88, 108], ["cytidine triphosphate", "SIMPLE_CHEMICAL", 113, 134], ["DNA", "CELLULAR_COMPONENT", 184, 187], ["DNA", "CELLULAR_COMPONENT", 217, 220], ["Leflunomide", "SIMPLE_CHEMICAL", 263, 274], ["Malononitrilamides", "SIMPLE_CHEMICAL", 279, 297], ["leflunomide", "SIMPLE_CHEMICAL", 352, 363], ["uridine", "SIMPLE_CHEMICAL", 418, 425], ["Dihydroorotate dehydrogenase", "PROTEIN", 0, 28], ["Dihydroorotate dehydrogenase inhibition", "TREATMENT", 0, 39], ["the nucleotide precursors uridine triphosphate", "TREATMENT", 62, 108], ["cytidine triphosphate", "TREATMENT", 113, 134], ["the synthesis of RNA", "PROBLEM", 159, 179], ["DNA", "PROBLEM", 184, 187], ["RNA synthesis", "PROBLEM", 225, 238], ["Leflunomide", "TREATMENT", 263, 274], ["Malononitrilamides", "TREATMENT", 279, 297], ["SMALL MOLECULESThe", "PROBLEM", 302, 320], ["leflunomide", "TREATMENT", 352, 363], ["drug levels", "TEST", 394, 405], ["disposable uridine pools", "TREATMENT", 407, 431], ["RNA synthesis", "OBSERVATION", 225, 238], ["MOLECULESThe", "OBSERVATION", 308, 320]]], ["Studies have indicated that, in addition to inhibition of dihydroorotate dehydrogenase, leflunomide and the MNAs may act through inhibition of tyrosine kinases.", [["dihydroorotate", "CHEMICAL", 58, 72], ["leflunomide", "CHEMICAL", 88, 99], ["tyrosine", "CHEMICAL", 143, 151], ["dihydroorotate", "CHEMICAL", 58, 72], ["leflunomide", "CHEMICAL", 88, 99], ["tyrosine", "CHEMICAL", 143, 151], ["dihydroorotate dehydrogenase", "GENE_OR_GENE_PRODUCT", 58, 86], ["leflunomide", "SIMPLE_CHEMICAL", 88, 99], ["MNAs", "SIMPLE_CHEMICAL", 108, 112], ["dihydroorotate dehydrogenase", "PROTEIN", 58, 86], ["tyrosine kinases", "PROTEIN", 143, 159], ["Studies", "TEST", 0, 7], ["dihydroorotate dehydrogenase", "TREATMENT", 58, 86], ["leflunomide", "TREATMENT", 88, 99], ["the MNAs", "TREATMENT", 104, 112], ["tyrosine kinases", "TREATMENT", 143, 159]]], ["Phosphorylation of the epidermal growth factor receptor of human fibroblasts has been shown to be inhibited by leflunomide.160 It was shown that leflunomide directly inhibited the interleukin (IL)-2-stimulated protein tyrosine kinase activity of p56lck and p59fyn,160 which is associated with activation through the T-cell receptor/CD3 complex.", [["fibroblasts", "ANATOMY", 65, 76], ["T-cell", "ANATOMY", 316, 322], ["leflunomide", "CHEMICAL", 111, 122], ["leflunomide", "CHEMICAL", 145, 156], ["tyrosine", "CHEMICAL", 218, 226], ["leflunomide", "CHEMICAL", 111, 122], ["leflunomide", "CHEMICAL", 145, 156], ["tyrosine", "CHEMICAL", 218, 226], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 23, 55], ["human", "ORGANISM", 59, 64], ["fibroblasts", "CELL", 65, 76], ["leflunomide", "SIMPLE_CHEMICAL", 111, 122], ["leflunomide", "SIMPLE_CHEMICAL", 145, 156], ["interleukin (IL)-2", "GENE_OR_GENE_PRODUCT", 180, 198], ["protein tyrosine kinase", "GENE_OR_GENE_PRODUCT", 210, 233], ["p56lck", "GENE_OR_GENE_PRODUCT", 246, 252], ["p59fyn", "GENE_OR_GENE_PRODUCT", 257, 263], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 316, 331], ["CD3", "GENE_OR_GENE_PRODUCT", 332, 335], ["epidermal growth factor receptor", "PROTEIN", 23, 55], ["human fibroblasts", "CELL_TYPE", 59, 76], ["interleukin (IL)-2", "PROTEIN", 180, 198], ["protein tyrosine kinase", "PROTEIN", 210, 233], ["p56lck", "PROTEIN", 246, 252], ["p59fyn", "PROTEIN", 257, 263], ["T-cell receptor", "PROTEIN", 316, 331], ["CD3 complex", "PROTEIN", 332, 343], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["Phosphorylation", "TREATMENT", 0, 15], ["the epidermal growth factor receptor of human fibroblasts", "TREATMENT", 19, 76], ["leflunomide", "TREATMENT", 111, 122], ["leflunomide", "TREATMENT", 145, 156], ["the interleukin (IL)", "TREATMENT", 176, 196], ["p56lck", "TEST", 246, 252], ["p59fyn", "TEST", 257, 263], ["epidermal", "OBSERVATION_MODIFIER", 23, 32], ["growth", "OBSERVATION_MODIFIER", 33, 39], ["CD3 complex", "OBSERVATION", 332, 343]]], ["At higher concentrations, A771726 also inhibited IL-2-induced tyrosine phosphorylation of Janus kinase (JAK)1 and JAK3 protein tyrosine kinases.60 Leflunomide analogues have also been shown to possess strong inhibitory activity on the antiapoptotic tyrosine kinase Bruton\u2019s tyrosine kinase, a key factor for T-cell-independent antibody formation.150 The hypothesis that leflunomide may exhibit more than one mechanism of action in vivo was further illustrated in mice where uridine restored proliferation and IgM production by lipopolysaccharide-stimulated B cells, whereas suppression of IgG production was not reversed.", [["T-cell", "ANATOMY", 308, 314], ["B cells", "ANATOMY", 557, 564], ["A771726", "CHEMICAL", 26, 33], ["tyrosine", "CHEMICAL", 62, 70], ["tyrosine", "CHEMICAL", 127, 135], ["Leflunomide", "CHEMICAL", 147, 158], ["tyrosine", "CHEMICAL", 249, 257], ["tyrosine", "CHEMICAL", 274, 282], ["leflunomide", "CHEMICAL", 370, 381], ["uridine", "CHEMICAL", 474, 481], ["lipopolysaccharide", "CHEMICAL", 527, 545], ["A771726", "CHEMICAL", 26, 33], ["tyrosine", "CHEMICAL", 62, 70], ["tyrosine", "CHEMICAL", 127, 135], ["Leflunomide", "CHEMICAL", 147, 158], ["tyrosine", "CHEMICAL", 249, 257], ["tyrosine", "CHEMICAL", 274, 282], ["leflunomide", "CHEMICAL", 370, 381], ["uridine", "CHEMICAL", 474, 481], ["A771726", "SIMPLE_CHEMICAL", 26, 33], ["IL-2", "GENE_OR_GENE_PRODUCT", 49, 53], ["tyrosine", "AMINO_ACID", 62, 70], ["Janus kinase (JAK)1", "GENE_OR_GENE_PRODUCT", 90, 109], ["JAK3 protein tyrosine kinases", "GENE_OR_GENE_PRODUCT", 114, 143], ["Bruton\u2019s tyrosine kinase", "GENE_OR_GENE_PRODUCT", 265, 289], ["T-cell", "CELL", 308, 314], ["leflunomide", "SIMPLE_CHEMICAL", 370, 381], ["mice", "ORGANISM", 463, 467], ["uridine", "SIMPLE_CHEMICAL", 474, 481], ["IgM", "GENE_OR_GENE_PRODUCT", 509, 512], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 527, 545], ["B cells", "CELL", 557, 564], ["IgG", "GENE_OR_GENE_PRODUCT", 589, 592], ["Janus kinase (JAK)1", "PROTEIN", 90, 109], ["JAK3 protein tyrosine kinases", "PROTEIN", 114, 143], ["antiapoptotic tyrosine kinase", "PROTEIN", 235, 264], ["Bruton\u2019s tyrosine kinase", "PROTEIN", 265, 289], ["IgM", "PROTEIN", 509, 512], ["lipopolysaccharide-stimulated B cells", "CELL_LINE", 527, 564], ["IgG", "PROTEIN", 589, 592], ["mice", "SPECIES", 463, 467], ["mice", "SPECIES", 463, 467], ["IL", "TEST", 49, 51], ["tyrosine phosphorylation of Janus kinase (JAK)", "TREATMENT", 62, 108], ["JAK3 protein tyrosine kinases", "TEST", 114, 143], ["Leflunomide analogues", "TREATMENT", 147, 168], ["the antiapoptotic tyrosine kinase", "TREATMENT", 231, 264], ["tyrosine kinase", "TEST", 274, 289], ["T-cell", "PROBLEM", 308, 314], ["independent antibody formation", "PROBLEM", 315, 345], ["leflunomide", "TREATMENT", 370, 381], ["uridine restored proliferation", "TREATMENT", 474, 504], ["IgM production", "PROBLEM", 509, 523], ["lipopolysaccharide", "TEST", 527, 545], ["stimulated B cells", "PROBLEM", 546, 564], ["IgG production", "PROBLEM", 589, 603], ["antibody formation", "OBSERVATION", 327, 345]]], ["This phenomenon correlated in a dose-dependent manner with tyrosine phosphorylation of JAK3 and STAT6 proteins, known to be involved in IL-4-induced signal transduction pathways.228 This double in vivo mechanism of action was confirmed in rats, in which xenoreactivity was counteracted by the administration of uridine, whereas alloreactivity was not.42", [["tyrosine", "CHEMICAL", 59, 67], ["uridine", "CHEMICAL", 311, 318], ["tyrosine", "CHEMICAL", 59, 67], ["uridine", "CHEMICAL", 311, 318], ["tyrosine", "AMINO_ACID", 59, 67], ["JAK3", "GENE_OR_GENE_PRODUCT", 87, 91], ["STAT6", "GENE_OR_GENE_PRODUCT", 96, 101], ["IL-4", "GENE_OR_GENE_PRODUCT", 136, 140], ["rats", "ORGANISM", 239, 243], ["uridine", "SIMPLE_CHEMICAL", 311, 318], ["JAK3", "PROTEIN", 87, 91], ["STAT6 proteins", "PROTEIN", 96, 110], ["IL-4", "PROTEIN", 136, 140], ["rats", "SPECIES", 239, 243], ["This phenomenon", "PROBLEM", 0, 15], ["a dose-dependent manner", "TREATMENT", 30, 53], ["tyrosine phosphorylation of JAK3", "TREATMENT", 59, 91], ["STAT6 proteins", "TEST", 96, 110], ["uridine", "TREATMENT", 311, 318]]]], "PMC7275929": [["IntroductionWith the coronavirus disease-19 (COVID-19) infection worldwide, early detection [1] is necessary to ensure prevention and timely treatment.", [["coronavirus disease", "DISEASE", 21, 40], ["COVID-19", "CHEMICAL", 45, 53], ["infection", "DISEASE", 55, 64], ["coronavirus disease-19", "ORGANISM", 21, 43], ["COVID-19", "ORGANISM", 45, 53], ["coronavirus disease-19 (COVID-19", "SPECIES", 21, 53], ["the coronavirus disease", "PROBLEM", 17, 40], ["COVID", "TEST", 45, 50], ["infection", "PROBLEM", 55, 64], ["timely treatment", "TREATMENT", 134, 150], ["coronavirus disease", "OBSERVATION", 21, 40]]], ["The method proposed as gold standard for detection of the \u201cgenetic sequence of COVID-19 nucleic acid\u201d is the reverse-transcriptase polymerase chain reaction (RT-PCR).", [["COVID-19 nucleic acid", "CHEMICAL", 79, 100], ["COVID", "TEST", 79, 84], ["nucleic acid", "TEST", 88, 100], ["the reverse-transcriptase polymerase chain reaction", "PROBLEM", 105, 156], ["RT-PCR", "TEST", 158, 164]]], ["However, this RT-PCR test has limitations.", [["this RT-PCR test", "TEST", 9, 25]]], ["First, false-negative results may occur with PCR test because of technical procedural error, insufficient \u201cviral\u201d material in the specimen, and incorrect sampling location of the swab test.", [["specimen", "ANATOMY", 130, 138], ["PCR test", "TEST", 45, 53], ["technical procedural error", "PROBLEM", 65, 91], ["insufficient \u201cviral\u201d material in the specimen", "PROBLEM", 93, 138], ["the swab test", "TEST", 175, 188]]], ["Therefore, the PCR tests for COVID-19 have high specificity but sensitivity has been reported to be as low as 59%.", [["COVID-19", "DNA", 29, 37], ["the PCR tests", "TEST", 11, 24], ["COVID", "TEST", 29, 34], ["sensitivity", "TEST", 64, 75]]], ["Second, the RT-PCR test is a time-consuming process.", [["the RT-PCR test", "TEST", 8, 23]]], ["The result of these limitations is the delay for medical isolation with risk of infection transmission, which may be a problem for a patient needing access to the operating room.", [["infection", "DISEASE", 80, 89], ["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["medical isolation", "TREATMENT", 49, 66], ["infection transmission", "PROBLEM", 80, 102], ["infection", "OBSERVATION", 80, 89]]], ["At the end, this test is not available everywhere.IntroductionIn orthopaedic trauma surgery or emergency, abdomen and pelvis CT or cervical, dorsal, and lumbar spine CT are performed to investigate patients; the result is a non-real chest CT scan, but this CT incorporates usually the thorax; therefore, lung parenchyma information can be obtained, and manifestations of COVID-19 diagnosed.", [["abdomen", "ANATOMY", 106, 113], ["pelvis", "ANATOMY", 118, 124], ["cervical", "ANATOMY", 131, 139], ["dorsal", "ANATOMY", 141, 147], ["lumbar spine", "ANATOMY", 153, 165], ["thorax", "ANATOMY", 285, 291], ["lung parenchyma", "ANATOMY", 304, 319], ["trauma", "DISEASE", 77, 83], ["abdomen", "ORGAN", 106, 113], ["pelvis", "ORGAN", 118, 124], ["cervical", "MULTI-TISSUE_STRUCTURE", 131, 139], ["lumbar spine", "MULTI-TISSUE_STRUCTURE", 153, 165], ["patients", "ORGANISM", 198, 206], ["chest", "ORGAN", 233, 238], ["thorax", "ORGAN", 285, 291], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 304, 319], ["patients", "SPECIES", 198, 206], ["this test", "TEST", 12, 21], ["IntroductionIn orthopaedic trauma surgery", "TREATMENT", 50, 91], ["emergency, abdomen and pelvis CT or cervical, dorsal, and lumbar spine CT", "TEST", 95, 168], ["a non-real chest CT scan", "TEST", 222, 246], ["this CT", "TEST", 252, 259], ["COVID", "TEST", 371, 376], ["abdomen", "ANATOMY", 106, 113], ["pelvis", "ANATOMY", 118, 124], ["cervical", "ANATOMY", 131, 139], ["dorsal", "ANATOMY", 141, 147], ["lumbar spine", "ANATOMY", 153, 165], ["chest", "ANATOMY", 233, 238], ["thorax", "ANATOMY", 285, 291], ["lung", "ANATOMY", 304, 308], ["parenchyma", "ANATOMY_MODIFIER", 309, 319]]], ["For these patients, without waiting multiple hours for the result of the PCR test, CT scan could be an added value for the diagnosis, at least if imaging of COVID-19 disease is characteristic on chest [2, 3].", [["chest", "ANATOMY", 195, 200], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["the PCR test", "TEST", 69, 81], ["CT scan", "TEST", 83, 90], ["imaging", "TEST", 146, 153], ["COVID", "TEST", 157, 162], ["disease", "PROBLEM", 166, 173], ["chest", "ANATOMY", 195, 200]]], ["As there are some differences between PCR test and CT scan concerning the evolution of the disease, chest CT scan when performed may also be a help in managing patients, and particularly for \u201cisolation and de-isolation\u201d of patients.IntroductionTherefore, we retrospectively analyzed the chest CT images performed during the pandemic period of 118 orthopaedic and traumatic patients, patients with or without COVID-19 infection.", [["traumatic", "DISEASE", 363, 372], ["infection", "DISEASE", 417, 426], ["chest", "ORGAN", 100, 105], ["patients", "ORGANISM", 160, 168], ["patients", "ORGANISM", 223, 231], ["patients", "ORGANISM", 373, 381], ["patients", "ORGANISM", 383, 391], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 223, 231], ["patients", "SPECIES", 373, 381], ["patients", "SPECIES", 383, 391], ["PCR test", "TEST", 38, 46], ["CT scan", "TEST", 51, 58], ["the disease", "PROBLEM", 87, 98], ["chest CT scan", "TEST", 100, 113], ["\u201cisolation", "TREATMENT", 191, 201], ["de-isolation", "TREATMENT", 206, 218], ["the chest CT images", "TEST", 283, 302], ["COVID-19 infection", "PROBLEM", 408, 426], ["disease", "OBSERVATION", 91, 98], ["chest", "ANATOMY", 100, 105], ["chest", "ANATOMY", 287, 292], ["infection", "OBSERVATION", 417, 426]]], ["We evaluate the image reports of chest CT, the PCR results, and the pathways of the orthopaedic patients to the dedicated COVID-19 operating rooms and wards.", [["chest", "ANATOMY", 33, 38], ["chest", "ORGAN", 33, 38], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["chest CT", "TEST", 33, 41], ["the PCR", "TEST", 43, 50], ["chest", "ANATOMY", 33, 38]]], ["The objective of our study was to familiarize orthopaedists with the value and limit of chest CT in orthopaedic surgery.Study population: 118 orthopaedic and trauma patients with chest CT scan ::: Material and methodsThe regional health system of Belgium and France was reorganized after 15 March 2020 to maximize the number of beds needed for COVID-19 patients.", [["chest", "ANATOMY", 88, 93], ["trauma", "DISEASE", 158, 164], ["chest", "ORGANISM_SUBDIVISION", 88, 93], ["patients", "ORGANISM", 165, 173], ["patients", "ORGANISM", 353, 361], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 353, 361], ["our study", "TEST", 17, 26], ["chest CT", "TEST", 88, 96], ["orthopaedic surgery", "TREATMENT", 100, 119], ["chest CT scan", "TEST", 179, 192], ["COVID", "TEST", 344, 349], ["chest", "ANATOMY", 88, 93], ["chest", "ANATOMY", 179, 184], ["regional", "OBSERVATION_MODIFIER", 221, 229]]], ["Under this new system, two site hospitals (CH EpiCURA sites Baudour and Hornu, Belgium, and Clinique Geoffroy Saint Hilaire, Paris, France) were elected to treat orthopaedic and trauma patients with suspected COVID-19 patients.", [["trauma", "DISEASE", 178, 184], ["COVID", "DISEASE", 209, 214], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 218, 226]]], ["Chest CT scan data are coming from these two medical centres.Study population: 118 orthopaedic and trauma patients with chest CT scan ::: Material and methodsTo better understand the values of chest CT scans in the orthopaedic and trauma population, we extracted our data from a series of 4182 patients who had 5282 CT scans performed on four different CT's from 1 March 2020 to 10 May 2020.", [["trauma", "DISEASE", 99, 105], ["trauma", "DISEASE", 231, 237], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 294, 302], ["Chest CT scan data", "TEST", 0, 18], ["chest CT scan", "TEST", 120, 133], ["chest CT scans", "TEST", 193, 207], ["CT scans", "TEST", 316, 324], ["four different CT's", "TEST", 338, 357], ["chest", "ANATOMY", 120, 125], ["chest", "ANATOMY", 193, 198]]], ["Among the 5282 CT exams, 1397 were chest CT scans, with 1143 performed for COVID-19 screening.", [["CT exams", "TEST", 15, 23], ["chest CT scans", "TEST", 35, 49], ["COVID", "TEST", 75, 80], ["screening", "TEST", 84, 93], ["chest", "ANATOMY", 35, 40]]], ["One CT was dedicated to patients with suspicion of COVID-19 and among the 1397 chest CT scans (Fig. 1 shows the flowchart of our study), we selected all the chest CT performed for patients who presented to the Emergency Department of the hospital with a diagnosis of trauma or patients needing hospitalization for surgical treatment.", [["trauma", "DISEASE", 267, 273], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 180, 188], ["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 277, 285], ["One CT", "TEST", 0, 6], ["COVID", "TEST", 51, 56], ["the 1397 chest CT scans", "TEST", 70, 93], ["our study", "TEST", 125, 134], ["all the chest CT", "TEST", 149, 165], ["trauma", "PROBLEM", 267, 273], ["surgical treatment", "TREATMENT", 314, 332], ["chest", "ANATOMY", 79, 84], ["chest", "ANATOMY", 157, 162], ["trauma", "OBSERVATION", 267, 273]]], ["Whether it was a non-real chest CT scan incorporating the thorax and performed for trauma surgery, or a real chest CT scan performed for screening COVID-19, the name of the CT was called chest CT scan in the article according to the fact that the manifestations of COVID-19 on lung parenchyma were diagnosed with the same accuracy on the two types of CT scan; however, the radiation dose was different.Study population: 118 orthopaedic and trauma patients with chest CT scan ::: Material and methodsOur retrospective cohort with chest CT scan during this period was composed of 118 patients (37 men; 88 women; age range, 19\u201393 years; mean age 66.5 years); 46 patients who presented to the Emergency Department of the hospital during this period with a diagnosis of fracture, or trauma.", [["thorax", "ANATOMY", 58, 64], ["lung parenchyma", "ANATOMY", 277, 292], ["trauma", "DISEASE", 83, 89], ["COVID-19", "CHEMICAL", 265, 273], ["trauma", "DISEASE", 440, 446], ["fracture", "DISEASE", 765, 773], ["trauma", "DISEASE", 778, 784], ["COVID-19", "CHEMICAL", 265, 273], ["thorax", "ORGAN", 58, 64], ["COVID-19", "GENE_OR_GENE_PRODUCT", 265, 273], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 277, 292], ["patients", "ORGANISM", 447, 455], ["chest", "ORGAN", 529, 534], ["patients", "ORGANISM", 582, 590], ["men", "ORGANISM", 595, 598], ["women", "ORGANISM", 603, 608], ["patients", "ORGANISM", 659, 667], ["patients", "SPECIES", 447, 455], ["patients", "SPECIES", 582, 590], ["men", "SPECIES", 595, 598], ["women", "SPECIES", 603, 608], ["patients", "SPECIES", 659, 667], ["a non-real chest CT scan", "TEST", 15, 39], ["trauma surgery", "TREATMENT", 83, 97], ["a real chest CT scan", "TEST", 102, 122], ["screening COVID", "TEST", 137, 152], ["the CT", "TEST", 169, 175], ["chest CT scan", "TEST", 187, 200], ["COVID", "TEST", 265, 270], ["CT scan", "TEST", 351, 358], ["the radiation dose", "TREATMENT", 369, 387], ["chest CT scan", "TEST", 461, 474], ["chest CT scan", "TEST", 529, 542], ["fracture", "PROBLEM", 765, 773], ["trauma", "PROBLEM", 778, 784], ["chest", "ANATOMY", 26, 31], ["thorax", "ANATOMY", 58, 64], ["chest", "ANATOMY", 109, 114], ["chest", "ANATOMY", 187, 192], ["lung", "ANATOMY", 277, 281], ["parenchyma", "ANATOMY_MODIFIER", 282, 292], ["chest", "ANATOMY", 461, 466], ["chest", "ANATOMY", 529, 534], ["fracture", "OBSERVATION", 765, 773]]], ["In addition, 72 patients needing hospitalization for planning a non-deferrable elective treatment (spine, arthroplasty) were included.CT technique and image interpretation ::: Material and methodsTwo CT scanners (Siemens) were used for all thorax and chest CT examinations.", [["spine", "ANATOMY", 99, 104], ["thorax", "ANATOMY", 240, 246], ["patients", "ORGANISM", 16, 24], ["thorax", "ORGAN", 240, 246], ["patients", "SPECIES", 16, 24], ["a non-deferrable elective treatment (spine, arthroplasty)", "TREATMENT", 62, 119], ["CT technique", "TEST", 134, 146], ["Two CT scanners (Siemens)", "TEST", 196, 221], ["all thorax and chest CT examinations", "TEST", 236, 272], ["spine", "ANATOMY", 99, 104], ["arthroplasty", "OBSERVATION", 106, 118], ["thorax", "ANATOMY", 240, 246], ["chest", "ANATOMY", 251, 256]]], ["The examination was performed with a patient in a supine position.", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["The examination", "TEST", 0, 15]]], ["Technologists who performed CT of patients with suspected COVID-19 were required to wear protective garments.CT technique and image interpretation ::: Material and methodsCT technique.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["CT", "TEST", 28, 30], ["protective garments", "TREATMENT", 89, 108], ["CT technique", "TEST", 109, 121], ["Material and methodsCT technique", "TREATMENT", 151, 183]]], ["A standard CT protocol was applied for spine and \u201cpolytrauma\u201d patients.", [["spine", "ANATOMY", 39, 44], ["polytrauma", "DISEASE", 50, 60], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["A standard CT protocol", "TEST", 0, 22], ["spine", "ANATOMY", 39, 44], ["polytrauma", "OBSERVATION", 50, 60]]], ["For chest, a standard low dose chest CT protocol was applied when possible; the main scanning parameters were as follow: tube voltage = 120 kV, automatic tube current modulation (30\u201370 mAs), matrix = 512 \u00d7 512; slice thickness = 1 mm, field of view = 350 mm \u00d7 350 mm.", [["chest", "ANATOMY", 4, 9], ["chest", "ORGAN", 4, 9], ["tube", "TISSUE", 121, 125], ["a standard low dose chest CT protocol", "TREATMENT", 11, 48], ["the main scanning parameters", "TEST", 76, 104], ["tube voltage", "TEST", 121, 133], ["automatic tube current modulation", "TREATMENT", 144, 177], ["matrix", "TEST", 191, 197], ["slice thickness", "TEST", 211, 226], ["field of view", "TEST", 235, 248], ["chest", "ANATOMY", 4, 9], ["chest", "ANATOMY", 31, 36], ["tube", "OBSERVATION", 154, 158]]], ["All images were then reconstructed with a slice thickness of 0.625\u20131.250 mm with the same increment.CT technique and image interpretation ::: Material and methodsCT review.", [["All images", "TEST", 0, 10], ["a slice thickness", "TEST", 40, 57], ["CT technique", "TEST", 100, 112]]], ["Every chest CT examination was read first by one radiologist and the report was then checked by another radiologist.", [["chest", "ANATOMY", 6, 11], ["chest", "ORGAN", 6, 11], ["Every chest CT examination", "TEST", 0, 26], ["chest", "ANATOMY", 6, 11]]], ["One of the radiologists had more than 30 years\u2019 experience in interpreting chest CT.", [["chest", "ANATOMY", 75, 80], ["chest", "ORGANISM_SUBDIVISION", 75, 80], ["interpreting chest CT", "TEST", 62, 83], ["chest", "ANATOMY", 75, 80]]], ["The most common initial CT findings of COVID-19 pneumonia (Fig. 2) are bilateral, sub-pleural ground-glass opacity (GGO), ill-defined margins, basal consolidation, and a slight right lower lobe predilection; however, the initial imaging findings are not organism specific and can overlap with other atypical viral pneumonias as H1N1 influenza, cytomegalovirus pneumonia.", [["margins", "ANATOMY", 134, 141], ["right lower lobe", "ANATOMY", 177, 193], ["pneumonia", "DISEASE", 48, 57], ["GGO", "DISEASE", 116, 119], ["right lower lobe predilection", "DISEASE", 177, 206], ["viral pneumonias", "DISEASE", 308, 324], ["influenza", "DISEASE", 333, 342], ["cytomegalovirus pneumonia", "DISEASE", 344, 369], ["cytomegalovirus", "ORGANISM", 344, 359], ["H1N1 influenza", "SPECIES", 328, 342], ["COVID", "TEST", 39, 44], ["pneumonia", "PROBLEM", 48, 57], ["bilateral, sub-pleural ground-glass opacity", "PROBLEM", 71, 114], ["ill-defined margins", "PROBLEM", 122, 141], ["basal consolidation", "PROBLEM", 143, 162], ["a slight right lower lobe predilection", "PROBLEM", 168, 206], ["the initial imaging", "TEST", 217, 236], ["other atypical viral pneumonias", "PROBLEM", 293, 324], ["H1N1 influenza", "PROBLEM", 328, 342], ["cytomegalovirus pneumonia", "PROBLEM", 344, 369], ["pneumonia", "OBSERVATION", 48, 57], ["bilateral", "ANATOMY_MODIFIER", 71, 80], ["sub", "OBSERVATION_MODIFIER", 82, 85], ["pleural", "ANATOMY", 86, 93], ["ground", "ANATOMY_MODIFIER", 94, 100], ["glass opacity", "OBSERVATION", 101, 114], ["GGO", "OBSERVATION_MODIFIER", 116, 119], ["ill-defined", "OBSERVATION_MODIFIER", 122, 133], ["margins", "OBSERVATION_MODIFIER", 134, 141], ["basal", "ANATOMY_MODIFIER", 143, 148], ["consolidation", "OBSERVATION", 149, 162], ["slight", "OBSERVATION_MODIFIER", 170, 176], ["right lower lobe", "ANATOMY", 177, 193], ["predilection", "OBSERVATION", 194, 206], ["atypical", "OBSERVATION_MODIFIER", 299, 307], ["viral", "OBSERVATION_MODIFIER", 308, 313], ["pneumonias", "OBSERVATION", 314, 324], ["cytomegalovirus", "OBSERVATION_MODIFIER", 344, 359], ["pneumonia", "OBSERVATION", 360, 369]]], ["In patients with CT findings suggestive of COVID-19 pneumonia, the radiologists informed the clinician immediately.", [["pneumonia", "DISEASE", 52, 61], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["CT findings", "TEST", 17, 28], ["COVID-19 pneumonia", "PROBLEM", 43, 61], ["suggestive of", "UNCERTAINTY", 29, 42], ["pneumonia", "OBSERVATION", 52, 61]]], ["The clinician would then order immediate isolation of the patient for clinical monitoring and treatment.CT technique and image interpretation ::: Material and methodsCT terminology.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["clinical monitoring", "TEST", 70, 89], ["treatment", "TREATMENT", 94, 103], ["CT technique", "TEST", 104, 116]]], ["Despite imaging findings are not organism specific and can overlap with H1N1 influenza, since the 2019\u20132020 seasonal (influenza virus) flu-epidemic ended in early March 2020 in Belgium and in France, and since this period was the pandemic period of COVID-19, patients with a diagnosis of viral pneumonia with common aspect of COVID-19 made by radiologists were defined as positive CT cases.", [["influenza", "DISEASE", 77, 86], ["influenza virus) flu-epidemic", "DISEASE", 118, 147], ["viral pneumonia", "DISEASE", 288, 303], ["influenza virus", "ORGANISM", 118, 133], ["patients", "ORGANISM", 259, 267], ["influenza virus", "SPECIES", 118, 133], ["patients", "SPECIES", 259, 267], ["imaging findings", "TEST", 8, 24], ["organism", "PROBLEM", 33, 41], ["H1N1 influenza", "PROBLEM", 72, 86], ["seasonal (influenza virus) flu-epidemic", "PROBLEM", 108, 147], ["COVID", "TEST", 249, 254], ["viral pneumonia", "PROBLEM", 288, 303], ["COVID", "TEST", 326, 331], ["viral", "OBSERVATION_MODIFIER", 288, 293], ["pneumonia", "OBSERVATION", 294, 303]]], ["This definition of positive case was applied for patients whether they had or not positive PCR results and/or clinical symptoms.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["positive PCR results", "PROBLEM", 82, 102], ["clinical symptoms", "PROBLEM", 110, 127]]], ["Patients with a normal CT scan were defined as negative CT cases.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["a normal CT scan", "TEST", 14, 30], ["CT cases", "TEST", 56, 64]]], ["When the radiologist was not able to determine clearly, it was a doubtful CT case.", [["a doubtful CT case", "TEST", 63, 81]]], ["Patients with another diagnosis made by radiologists were defined as alternative pathology CT cases.Orthopaedic patients and chest CT scans ::: Material and methodsThe clinical pathway started with evaluation of flu-like symptoms and body temperature control, defining the patient as symptomatic or not.", [["body", "ANATOMY", 234, 238], ["flu", "DISEASE", 212, 215], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 112, 120], ["body", "ORGANISM_SUBDIVISION", 234, 238], ["patient", "ORGANISM", 273, 280], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 112, 120], ["patient", "SPECIES", 273, 280], ["alternative pathology CT cases", "TEST", 69, 99], ["chest CT scans", "TEST", 125, 139], ["evaluation", "TEST", 198, 208], ["flu", "PROBLEM", 212, 215], ["symptoms", "PROBLEM", 221, 229], ["body temperature control", "TREATMENT", 234, 258], ["symptomatic", "PROBLEM", 284, 295], ["chest", "ANATOMY", 125, 130]]], ["Symptomatic patients were admitted directly to the COVID-19 ward, following the dedicated pathway for COVID-19, whatever initial chest CT and PCR results.", [["chest", "ANATOMY", 129, 134], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["COVID", "TEST", 102, 107], ["initial chest CT", "TEST", 121, 137], ["PCR", "TEST", 142, 145], ["chest", "ANATOMY", 129, 134]]], ["Depending on clinical status, the information obtained from the Chest CT scan according to the result of the PCR (gold standard) was graded from 0 (no or low value) to 3 (high value):Grade 0.", [["the Chest CT scan", "TEST", 60, 77], ["the PCR", "TEST", 105, 112], ["Chest", "ANATOMY", 64, 69]]], ["When a non-symptomatic patient was defined negative CT and positive PCR case, after getting the result of the swab test several hours after the chest CT scan, the chest CT scan was considered as \u201cno or low value\u201d.", [["chest", "ANATOMY", 163, 168], ["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["CT", "TEST", 52, 54], ["the swab test", "TEST", 106, 119], ["the chest CT scan", "TEST", 140, 157], ["the chest CT scan", "TEST", 159, 176], ["low value\u201d", "PROBLEM", 202, 212], ["chest", "ANATOMY", 144, 149], ["chest", "ANATOMY", 163, 168]]], ["Non-symptomatic patients were first admitted in a single room of the \u201cwaiting ward,\u201d waiting for the result of the PCR test.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["the PCR test", "TEST", 111, 123]]], ["When negative result, the patients were directed to the usual ward.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["When positive result, the patient was moved to the dedicated COVID-19 ward.", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33]]], ["At the end, the CT add no information for the process.Grade 1.", [["CT", "DNA", 16, 18], ["the CT", "TEST", 12, 18]]], ["When a non-symptomatic patient was defined negative CT and unknown or negative initial PCR case, the chest CT scan was considered as \u201chelp in managing patient\u201d.", [["chest", "ANATOMY", 101, 106], ["patient", "ORGANISM", 23, 30], ["chest", "ORGAN", 101, 106], ["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 23, 30], ["patient", "SPECIES", 151, 158], ["CT", "TEST", 52, 54], ["the chest CT scan", "TEST", 97, 114], ["chest", "ANATOMY", 101, 106]]], ["Patients with both negative tests were admitted to the usual ward, choosing single rooms when available.Grade 2.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["When a symptomatic patient was defined positive CT, whatever the result of the initial PCR, the chest CT scan was considered as \u201cadded value\u201d by identification of pulmonary lesions that could change the surgery indication: For example in hip surgery for femoral neck fractures, moving from a postero-lateral approach to an anterior approach (in supine position), and avoiding cement; with as potential advantage, reducing respiratory complications in a patient with abnormal chest.", [["pulmonary lesions", "ANATOMY", 163, 180], ["hip", "ANATOMY", 238, 241], ["femoral neck", "ANATOMY", 254, 266], ["respiratory", "ANATOMY", 422, 433], ["chest", "ANATOMY", 475, 480], ["pulmonary lesions", "DISEASE", 163, 180], ["fractures", "DISEASE", 267, 276], ["respiratory complications", "DISEASE", 422, 447], ["patient", "ORGANISM", 19, 26], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 163, 180], ["hip", "ORGANISM_SUBDIVISION", 238, 241], ["femoral neck", "MULTI-TISSUE_STRUCTURE", 254, 266], ["patient", "ORGANISM", 453, 460], ["chest", "ORGANISM_SUBDIVISION", 475, 480], ["patient", "SPECIES", 19, 26], ["patient", "SPECIES", 453, 460], ["positive CT", "TEST", 39, 50], ["the initial PCR", "TEST", 75, 90], ["the chest CT scan", "TEST", 92, 109], ["pulmonary lesions", "PROBLEM", 163, 180], ["the surgery", "TREATMENT", 199, 210], ["hip surgery", "TREATMENT", 238, 249], ["femoral neck fractures", "PROBLEM", 254, 276], ["a postero-lateral approach", "TREATMENT", 290, 316], ["an anterior approach", "TREATMENT", 320, 340], ["cement", "TREATMENT", 376, 382], ["reducing respiratory complications", "PROBLEM", 413, 447], ["abnormal chest", "PROBLEM", 466, 480], ["chest", "ANATOMY", 96, 101], ["pulmonary", "ANATOMY", 163, 172], ["lesions", "OBSERVATION", 173, 180], ["hip", "ANATOMY", 238, 241], ["surgery", "OBSERVATION", 242, 249], ["femoral", "ANATOMY_MODIFIER", 254, 261], ["neck", "ANATOMY", 262, 266], ["fractures", "OBSERVATION", 267, 276], ["anterior", "ANATOMY_MODIFIER", 323, 331], ["cement", "OBSERVATION", 376, 382], ["respiratory complications", "OBSERVATION", 422, 447], ["chest", "ANATOMY", 475, 480]]], ["Another example is elderly patients with proximal femoral fractures and comorbidities; they may present with oxygen desaturation on ambient air but without fever; when cognitive functions are low, it may difficult to know if this oxygen desaturation is just related to the fracture or to an associated COVID-19 pneumonia.Grade 3.", [["femoral", "ANATOMY", 50, 57], ["proximal femoral fractures", "DISEASE", 41, 67], ["oxygen", "CHEMICAL", 109, 115], ["desaturation", "DISEASE", 116, 128], ["fever", "DISEASE", 156, 161], ["oxygen", "CHEMICAL", 230, 236], ["desaturation", "DISEASE", 237, 249], ["fracture", "DISEASE", 273, 281], ["pneumonia", "DISEASE", 311, 320], ["oxygen", "CHEMICAL", 109, 115], ["oxygen", "CHEMICAL", 230, 236], ["patients", "ORGANISM", 27, 35], ["femoral", "MULTI-TISSUE_STRUCTURE", 50, 57], ["oxygen", "SIMPLE_CHEMICAL", 109, 115], ["oxygen", "SIMPLE_CHEMICAL", 230, 236], ["patients", "SPECIES", 27, 35], ["proximal femoral fractures", "PROBLEM", 41, 67], ["comorbidities", "PROBLEM", 72, 85], ["oxygen desaturation", "PROBLEM", 109, 128], ["fever", "PROBLEM", 156, 161], ["this oxygen desaturation", "PROBLEM", 225, 249], ["the fracture", "PROBLEM", 269, 281], ["an associated COVID-19 pneumonia", "PROBLEM", 288, 320], ["proximal", "ANATOMY_MODIFIER", 41, 49], ["femoral", "ANATOMY", 50, 57], ["fractures", "OBSERVATION", 58, 67], ["comorbidities", "OBSERVATION", 72, 85], ["oxygen desaturation", "OBSERVATION", 109, 128], ["without", "UNCERTAINTY", 148, 155], ["fracture", "OBSERVATION", 273, 281], ["pneumonia", "OBSERVATION", 311, 320]]], ["When a non-symptomatic patient was defined as positive CT and unknown or negative initial PCR case, the chest CT scan was considered as \u201chigh value.\u201d", [["chest", "ANATOMY", 104, 109], ["patient", "ORGANISM", 23, 30], ["chest", "ORGAN", 104, 109], ["patient", "SPECIES", 23, 30], ["positive CT", "TEST", 46, 57], ["the chest CT scan", "TEST", 100, 117], ["chest", "ANATOMY", 104, 109]]], ["For patients totally asymptomatic for COVID-19, the consequence of a positive chest CT was postponing surgery when not very urgent, or changing the pathway and operating room when very urgent as open fracture.Quantifying the burden of chest imaging on the CT scan service and exposure to radiation ::: Material and methodsTo attempt to quantify the impact that COVID-19 has on a busy CT scanning department, we check the volume of surgical trauma patients requiring chest CT scanning in 2018 during the same period (1 March to 10 May 2018).", [["chest", "ANATOMY", 235, 240], ["fracture", "DISEASE", 200, 208], ["trauma", "DISEASE", 440, 446], ["patients", "ORGANISM", 4, 12], ["chest", "ORGAN", 78, 83], ["chest", "ORGANISM_SUBDIVISION", 235, 240], ["patients", "ORGANISM", 447, 455], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 447, 455], ["COVID", "TEST", 38, 43], ["a positive chest CT", "TEST", 67, 86], ["surgery", "TREATMENT", 102, 109], ["open fracture", "PROBLEM", 195, 208], ["chest imaging", "TEST", 235, 248], ["the CT scan", "TEST", 252, 263], ["chest CT scanning", "TEST", 466, 483], ["chest", "ANATOMY", 78, 83], ["fracture", "OBSERVATION", 200, 208], ["chest", "ANATOMY", 235, 240], ["chest", "ANATOMY", 466, 471]]], ["This year 2018 was taken as comparison since was the 2017\u20132018 seasonal (influenza virus) flu-epidemic ended in early March 2018 in Belgium which allows comparison for the periods.", [["influenza virus) flu-epidemic", "DISEASE", 73, 102], ["influenza virus", "ORGANISM", 73, 88], ["influenza virus", "SPECIES", 73, 88], ["seasonal (influenza virus) flu-epidemic", "PROBLEM", 63, 102]]], ["From 1 March 2018 to 10 May 2018, 4700 CT scans, among the 4700 CT exams, 989 were chest CT scans.", [["CT scans", "TEST", 39, 47], ["the 4700 CT exams", "TEST", 55, 72], ["chest CT scans", "TEST", 83, 97], ["chest", "ANATOMY", 83, 88]]], ["Seven chest CT scans were performed for these 129 patients who presented to the emergency department in 2018 with a diagnosis of trauma.Quantifying the burden of chest imaging on the CT scan service and exposure to radiation ::: Material and methodsWe calculated, as percentage, the increase in CT numbers and we evaluated roughly the time required to perform each investigation.", [["chest", "ANATOMY", 6, 11], ["chest", "ANATOMY", 162, 167], ["trauma", "DISEASE", 129, 135], ["patients", "ORGANISM", 50, 58], ["chest", "ORGANISM_SUBDIVISION", 162, 167], ["patients", "SPECIES", 50, 58], ["Seven chest CT scans", "TEST", 0, 20], ["trauma", "PROBLEM", 129, 135], ["chest imaging", "TEST", 162, 175], ["the CT scan", "TEST", 179, 190], ["CT numbers", "TEST", 295, 305], ["each investigation", "TEST", 360, 378], ["chest", "ANATOMY", 6, 11], ["trauma", "OBSERVATION", 129, 135], ["chest", "ANATOMY", 162, 167], ["increase", "OBSERVATION_MODIFIER", 283, 291]]], ["The number and percentage chest CT in trauma and in orthopaedics was determined to provide a numerator, and the total workload of the CT scan department for COVID-19 was denominator.", [["trauma", "DISEASE", 38, 44], ["percentage chest CT", "TEST", 15, 34], ["the CT scan department", "TEST", 130, 152], ["COVID", "TEST", 157, 162], ["chest", "ANATOMY", 26, 31]]], ["The evaluation was done during the pandemic and during the same previous period.Quantifying the burden of chest imaging on the CT scan service and exposure to radiation ::: Material and methodsFor patients undergoing chest computed tomography (CT) examinations, patient dose calculations were based on the characteristics of 16-slice CT scanner.", [["chest", "ANATOMY", 106, 111], ["chest", "ORGANISM_SUBDIVISION", 106, 111], ["patients", "ORGANISM", 197, 205], ["patient", "ORGANISM", 262, 269], ["patients", "SPECIES", 197, 205], ["patient", "SPECIES", 262, 269], ["The evaluation", "TEST", 0, 14], ["chest imaging", "TEST", 106, 119], ["the CT scan", "TEST", 123, 134], ["chest computed tomography", "TEST", 217, 242], ["CT) examinations", "TEST", 244, 260], ["patient dose calculations", "TEST", 262, 287], ["slice CT scanner", "TEST", 328, 344], ["chest", "ANATOMY", 106, 111], ["chest", "ANATOMY", 217, 222]]], ["The dose\u2013length product (DLP) was used to quantify the amount of radiation used to perform chest CT examinations [4].", [["chest", "ANATOMY", 91, 96], ["DLP", "PROTEIN", 25, 28], ["The dose\u2013length product (DLP)", "TREATMENT", 0, 29], ["radiation", "TREATMENT", 65, 74], ["chest CT examinations", "TEST", 91, 112], ["chest", "ANATOMY", 91, 96]]], ["The principal concern for any patient undergoing a diagnostic chest CT examination is the risk of developing a radiation-induced cancer, which may be fatal.", [["chest", "ANATOMY", 62, 67], ["cancer", "ANATOMY", 129, 135], ["cancer", "DISEASE", 129, 135], ["patient", "ORGANISM", 30, 37], ["chest", "ORGAN", 62, 67], ["cancer", "CANCER", 129, 135], ["patient", "SPECIES", 30, 37], ["a diagnostic chest CT examination", "TEST", 49, 82], ["a radiation-induced cancer", "PROBLEM", 109, 135], ["chest", "ANATOMY", 62, 67], ["radiation", "OBSERVATION", 111, 120], ["cancer", "OBSERVATION", 129, 135], ["may be", "UNCERTAINTY", 143, 149], ["fatal", "OBSERVATION_MODIFIER", 150, 155]]], ["The total patient risk is related to the effective dose, which depends on the dose to each organ, as well as its radio-sensitivity, and is measured in sieverts (Sv) [4].", [["organ", "ANATOMY", 91, 96], ["patient", "ORGANISM", 10, 17], ["organ", "ORGAN", 91, 96], ["patient", "SPECIES", 10, 17], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["At the (low) doses associated with diagnostic radiologic examinations, the radiation risk is generally taken to be proportional to the cumulative organ dose.", [["organ", "ANATOMY", 146, 151], ["organ", "ORGAN", 146, 151], ["diagnostic radiologic examinations", "TEST", 35, 69], ["the radiation risk", "PROBLEM", 71, 89], ["the cumulative organ dose", "TREATMENT", 131, 156]]], ["The radiation risk from two CT scans, for example, would be approximately twice the risk of a single scan, irrespective of the time interval between the two CT scans.Statistical analysis ::: Material and methodsVariables when continuous were displayed as mean and range; categorical variables were analyzed as counts and percentages.Statistical analysis ::: Material and methodsUsing the RT-PCR test as reference, sensitivity, specificity, and positive predictive value (PPV) of chest CT imaging were calculated with a 95% confidence interval.", [["The radiation risk", "PROBLEM", 0, 18], ["two CT scans", "TEST", 24, 36], ["a single scan", "TEST", 92, 105], ["the two CT scans", "TEST", 149, 165], ["methodsVariables", "TEST", 204, 220], ["categorical variables", "TEST", 271, 292], ["percentages", "TEST", 321, 332], ["the RT-PCR test", "TEST", 384, 399], ["specificity", "TEST", 427, 438], ["PPV", "TEST", 471, 474], ["chest CT imaging", "TEST", 479, 495], ["radiation risk", "OBSERVATION_MODIFIER", 4, 18], ["chest", "ANATOMY", 479, 484]]], ["For patients with a negative RT-PCR test but a positive CT result, iterative chest CT images were reviewed to confirm the imaging diagnosis if available.Statistical analysis ::: Material and methodsFor patients with multiple PCR tests (with a minimum time interval of 3 days), the conversion of PCR test (negative to positive, or positive to negative) was analyzed in correlation with serial chest CT scans if available.", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 202, 210], ["a negative RT-PCR test", "TEST", 18, 40], ["iterative chest CT images", "TEST", 67, 92], ["the imaging diagnosis", "TEST", 118, 139], ["multiple PCR tests", "TEST", 216, 234], ["the conversion of PCR test", "TEST", 277, 303], ["serial chest CT scans", "TEST", 385, 406], ["chest", "ANATOMY", 77, 82], ["chest", "ANATOMY", 392, 397]]], ["Change in PCR and CT may reflect viral proliferation or the reverse, clearance in infected patients.General description of the population during the pandemic ::: ResultsOne thousand three hundred ninety-seven patients with chest CT scan were available for analysis: 829 patients were negative CT cases, 449 patients were positive CT cases, and 119 probable CT cases.", [["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 209, 217], ["patients", "ORGANISM", 270, 278], ["patients", "ORGANISM", 307, 315], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 209, 217], ["patients", "SPECIES", 270, 278], ["patients", "SPECIES", 307, 315], ["Change in PCR", "TEST", 0, 13], ["CT", "TEST", 18, 20], ["viral proliferation", "PROBLEM", 33, 52], ["chest CT scan", "TEST", 223, 236], ["analysis", "TEST", 256, 264], ["CT cases", "TEST", 293, 301], ["CT cases", "TEST", 330, 338], ["CT cases", "TEST", 357, 365], ["may reflect", "UNCERTAINTY", 21, 32], ["viral proliferation", "OBSERVATION", 33, 52], ["infected", "OBSERVATION_MODIFIER", 82, 90], ["chest", "ANATOMY", 223, 228]]], ["Among the 1397 patients (Fig. 1) addressed to the radiologic department for a chest CT scan exam, 1143 were addressed for suspicion of COVID-19 and 254 addressed for chest CT scan for another pathology (cancer, thoracic pain without diagnosis, pulmonary embolism, infection non COVID\u2026).", [["cancer", "ANATOMY", 203, 209], ["thoracic", "ANATOMY", 211, 219], ["pulmonary", "ANATOMY", 244, 253], ["cancer", "DISEASE", 203, 209], ["thoracic pain", "DISEASE", 211, 224], ["pulmonary embolism", "DISEASE", 244, 262], ["infection", "DISEASE", 264, 273], ["patients", "ORGANISM", 15, 23], ["cancer", "CANCER", 203, 209], ["thoracic", "ORGAN", 211, 219], ["pulmonary", "ORGAN", 244, 253], ["patients", "SPECIES", 15, 23], ["a chest CT scan exam", "TEST", 76, 96], ["COVID", "TEST", 135, 140], ["chest CT scan", "TEST", 166, 179], ["another pathology (cancer", "PROBLEM", 184, 209], ["thoracic pain", "PROBLEM", 211, 224], ["pulmonary embolism", "PROBLEM", 244, 262], ["infection", "PROBLEM", 264, 273], ["chest", "ANATOMY", 78, 83], ["chest", "ANATOMY", 166, 171], ["cancer", "OBSERVATION", 203, 209], ["thoracic", "ANATOMY", 211, 219], ["pulmonary", "ANATOMY", 244, 253], ["embolism", "OBSERVATION", 254, 262]]], ["The 254 chest CT scans performed for another indication were considered as a \u201cphotography of the general population\u201d in absence of suspicion of COVID-19.General description of the population during the pandemic ::: ResultsAmong these 254 patients addressed for another indication than COVID-19 and without any orthopedic or trauma pathology, 15% (38 patients) had a positive COVID-pattern CT scan.", [["trauma", "DISEASE", 324, 330], ["patients", "ORGANISM", 238, 246], ["patients", "ORGANISM", 350, 358], ["patients", "SPECIES", 238, 246], ["patients", "SPECIES", 350, 358], ["The 254 chest CT scans", "TEST", 0, 22], ["a \u201cphotography", "TEST", 75, 89], ["COVID", "TEST", 144, 149], ["COVID", "TEST", 285, 290], ["any orthopedic or trauma pathology", "PROBLEM", 306, 340], ["CT scan", "TEST", 389, 396], ["chest", "ANATOMY", 8, 13]]], ["During the study period (1 March 2020 to 10 May 2020), the confirmed (by ministry of health) number of COVID-19 patients was 4500 per million (0.45%) habitants for a population of 11.5 million in Belgium (Fig. 3).", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["COVID", "TEST", 103, 108]]], ["With these data, the expected confirmed (with PCR) number of COVID-19 patients should have been between one and two cases for 254 patients.General description of the population during the pandemic ::: ResultsWith these data, we can remark that among 254 patients without suspicion of COVID-19, there is a large discrepancy between the 38 (15%) cases with positive radiologic findings (Fig. 4) and the number of confirmed expected cases (only one or two, 0.45%) in the general population of the country when \u201cconfirmed\u201d is synonymous of a positive PCR test during this period (Fig. 3).", [["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 254, 262], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 254, 262], ["these data", "TEST", 5, 15], ["PCR", "TEST", 46, 49], ["COVID", "TEST", 61, 66], ["these data", "TEST", 213, 223], ["COVID", "TEST", 284, 289], ["a large discrepancy", "PROBLEM", 303, 322], ["positive radiologic findings", "PROBLEM", 355, 383], ["a positive PCR test", "PROBLEM", 536, 555], ["large", "OBSERVATION_MODIFIER", 305, 310], ["discrepancy", "OBSERVATION", 311, 322]]], ["Even if it is well known that confirmed cases are lower than the real number of cases (due to the low number of PCR test performed during this period) the difference is huge, but may be also explained by the heterogeneous repartition of the disease in the country, with a higher frequency in towns population as in our area.General description of the population during the pandemic ::: ResultsEven if the two populations are not the same, and even if sensitivity, specificity, accuracy of chest CT in indicating COVID-19 infection are not words possible to use in this comparison, there were 30 times more patients with positive chest CT findings in the general population than with RT-PCR results as reference, so probably a better sensitivity with chest CT scan (Figs.", [["infection", "DISEASE", 521, 530], ["patients", "ORGANISM", 606, 614], ["patients", "SPECIES", 606, 614], ["COVID-19", "SPECIES", 512, 520], ["PCR test", "TEST", 112, 120], ["the disease", "PROBLEM", 237, 248], ["chest CT", "TEST", 489, 497], ["COVID-19 infection", "PROBLEM", 512, 530], ["positive chest CT findings", "PROBLEM", 620, 646], ["RT-PCR", "TEST", 683, 689], ["chest CT scan", "TEST", 750, 763], ["huge", "OBSERVATION_MODIFIER", 169, 173], ["may be also explained", "UNCERTAINTY", 179, 200], ["heterogeneous", "OBSERVATION_MODIFIER", 208, 221], ["repartition", "OBSERVATION", 222, 233], ["disease", "OBSERVATION", 241, 248], ["higher", "OBSERVATION_MODIFIER", 272, 278], ["frequency", "OBSERVATION_MODIFIER", 279, 288], ["chest", "ANATOMY", 489, 494], ["infection", "OBSERVATION", 521, 530], ["chest", "ANATOMY", 629, 634], ["chest", "ANATOMY", 750, 755]]], ["4 and 5).General description of the population during the pandemic ::: ResultsTo explore this high sensibility among the 1143 patients addressed for suspicion of COVID-19, we randomly selected 135 patients who also performed a RT-PCR.", [["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 197, 205], ["COVID", "TEST", 162, 167], ["a RT-PCR", "TREATMENT", 225, 233]]], ["Among the 135 patients, 66 (49%) chest CT were positive for COVID, and only 39 (59%) of 66 PCR tests were positive for COVID (Figs.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["chest CT", "TEST", 33, 41], ["COVID", "TEST", 60, 65], ["PCR tests", "TEST", 91, 100], ["COVID (Figs", "PROBLEM", 119, 130], ["chest", "ANATOMY", 33, 38]]], ["Among the 60 chest CT negative for COVID, 8 (13%) PCR were positive for COVID.", [["chest CT", "TEST", 13, 21], ["COVID", "TEST", 35, 40], ["PCR", "TEST", 50, 53], ["COVID", "PROBLEM", 72, 77], ["chest", "ANATOMY", 13, 18]]], ["For nine patients, the CT was doubtful, with three (33%) positive PCR.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["the CT", "TEST", 19, 25], ["positive PCR", "PROBLEM", 57, 69]]], ["With PCR results as reference and doubtful CT excluded, the sensitivity, specificity, positive predictive value of chest CT in indicating COVID-19 infection were 83%, 66%, and 59% respectively (p = 0.001).Diagnosis ::: Orthopaedic and trauma population: chest CT and PCR results ::: ResultsAmong the 118 patients with chest CT, 80 (68%) were totally asymptomatic; there were 16 patients with positive COVID-19 chest CT findings (Fig. 5), and 12 of these 16 were totally asymptomatic.", [["infection", "DISEASE", 147, 156], ["trauma", "DISEASE", 235, 241], ["patients", "ORGANISM", 304, 312], ["patients", "ORGANISM", 378, 386], ["patients", "SPECIES", 304, 312], ["patients", "SPECIES", 378, 386], ["COVID-19", "SPECIES", 138, 146], ["PCR", "TEST", 5, 8], ["doubtful CT", "TEST", 34, 45], ["the sensitivity", "TEST", 56, 71], ["chest CT", "TEST", 115, 123], ["COVID", "TEST", 138, 143], ["infection", "PROBLEM", 147, 156], ["p", "TEST", 194, 195], ["chest CT", "TEST", 254, 262], ["PCR", "TEST", 267, 270], ["chest CT", "TEST", 318, 326], ["totally asymptomatic", "PROBLEM", 342, 362], ["positive COVID", "TEST", 392, 406], ["chest CT findings", "TEST", 410, 427], ["totally asymptomatic", "PROBLEM", 462, 482], ["chest", "ANATOMY", 115, 120], ["chest", "ANATOMY", 254, 259], ["chest", "ANATOMY", 318, 323], ["chest", "ANATOMY", 410, 415], ["asymptomatic", "OBSERVATION", 470, 482]]], ["There was no significant difference (p = 0.10) with the general population (ODR 0.62; 95% 0.34\u20131.14).", [["significant difference", "PROBLEM", 13, 35], ["ODR", "TEST", 76, 79], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["Among these 16 patients with positive chest CT, 15 had PCR performed: 13 (86%) PCR were positive for COVID-19, and two were negative.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["positive chest CT", "TEST", 29, 46], ["PCR", "TEST", 55, 58], ["PCR", "TEST", 79, 82], ["COVID", "TEST", 101, 106], ["chest", "ANATOMY", 38, 43], ["negative", "OBSERVATION", 124, 132]]], ["This frequency is similar to the frequency observed in the randomly selected patients previously described (Fig. 5) and addressed for suspicion of COVID-19.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["COVID", "TEST", 147, 152]]], ["Among the 102 patients who had a negative chest CT scan, 32 patients had a PCR test performed; and of these 32, three were positive.", [["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 60, 68], ["a negative chest CT scan", "TEST", 31, 55], ["a PCR test", "TEST", 73, 83], ["chest", "ANATOMY", 42, 47], ["positive", "OBSERVATION", 123, 131]]], ["The median time interval observed between the 39 paired chest CT exams and RT-PCR assays was 1.2 day (range, 0\u20133 days).", [["chest", "ANATOMY", 56, 61], ["the 39 paired chest CT exams", "TEST", 42, 70], ["RT-PCR assays", "TEST", 75, 88], ["chest", "ANATOMY", 56, 61]]], ["With PCR results as reference, the sensitivity, specificity, and positive predictive value of chest CT in indicating COVID-19 infection were 81%, 93%, and 86%, respectively (p = 0.001).", [["chest", "ANATOMY", 94, 99], ["infection", "DISEASE", 126, 135], ["chest", "ORGAN", 94, 99], ["COVID-19", "SPECIES", 117, 125], ["PCR", "TEST", 5, 8], ["the sensitivity", "TEST", 31, 46], ["specificity", "TEST", 48, 59], ["chest CT", "TEST", 94, 102], ["COVID", "TEST", 117, 122], ["infection", "PROBLEM", 126, 135], ["chest", "ANATOMY", 94, 99]]], ["Specificity and positive predictive value were highly increased as regards to the general population group in this specific trauma group.Analysis of multiple RT-PCR assays ::: Orthopaedic and trauma population: chest CT and PCR results ::: ResultsAmong the 39 patients with paired chest CT scan and PCR, 28 patients underwent multiple RT-PCR assays.", [["chest", "ANATOMY", 211, 216], ["trauma", "DISEASE", 124, 130], ["trauma", "DISEASE", 192, 198], ["patients", "ORGANISM", 260, 268], ["patients", "ORGANISM", 307, 315], ["patients", "SPECIES", 260, 268], ["patients", "SPECIES", 307, 315], ["Specificity", "TEST", 0, 11], ["positive predictive value", "PROBLEM", 16, 41], ["Analysis", "TEST", 137, 145], ["multiple RT-PCR assays", "TEST", 149, 171], ["chest CT", "TEST", 211, 219], ["PCR", "TEST", 224, 227], ["paired chest CT scan", "TEST", 274, 294], ["PCR", "TEST", 299, 302], ["multiple RT-PCR assays", "TEST", 326, 348], ["chest", "ANATOMY", 211, 216], ["chest", "ANATOMY", 281, 286]]], ["For those 28 patients who had repeat follow-up RT-PCR testing (with a time interval of more than 3 days), the mean interval time between initial negative to positive RT-PCR results was 6.2 days with a range of one to 15 days.Analysis of multiple RT-PCR assays ::: Orthopaedic and trauma population: chest CT and PCR results ::: ResultsIn the subgroup of 14 patients positive for CT and positive for PCR results, 93% (13/14) of patients showed initial positive chest CT imaging before the initial positive RT-PCR results with a delay of three days (1 to 15 days).", [["chest", "ANATOMY", 299, 304], ["trauma", "DISEASE", 280, 286], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 357, 365], ["patients", "ORGANISM", 427, 435], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 357, 365], ["patients", "SPECIES", 427, 435], ["PCR testing", "TEST", 50, 61], ["PCR", "TEST", 169, 172], ["Analysis", "TEST", 225, 233], ["multiple RT-PCR assays", "TEST", 237, 259], ["chest CT", "TEST", 299, 307], ["PCR", "TEST", 312, 315], ["CT", "TEST", 379, 381], ["PCR", "TEST", 399, 402], ["chest CT imaging", "TEST", 460, 476], ["chest", "ANATOMY", 299, 304], ["chest", "ANATOMY", 460, 465]]], ["As explanation of this delay, seven patients had two negative RT-PCR before moving to a positive PCR result.Analysis of multiple RT-PCR assays ::: Orthopaedic and trauma population: chest CT and PCR results ::: ResultsIn the subgroup of three patients with initial negative CT, two had positive initial RT-PCR with a delay of two days, and one case showed initial negative RT-PCR results, moving to a second positive PCR after seven days, while CT remaining negative and patient symptomatic.Initial information ::: Information obtained from the 118 chest CT scans for the orthopaedist surgeons ::: Results", [["chest", "ANATOMY", 182, 187], ["trauma", "DISEASE", 163, 169], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 243, 251], ["patient", "ORGANISM", 471, 478], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 243, 251], ["patient", "SPECIES", 471, 478], ["this delay", "PROBLEM", 18, 28], ["a positive PCR result", "PROBLEM", 86, 107], ["Analysis", "TEST", 108, 116], ["multiple RT-PCR assays", "TEST", 120, 142], ["chest CT", "TEST", 182, 190], ["PCR", "TEST", 195, 198], ["CT", "TEST", 274, 276], ["positive initial RT-PCR", "PROBLEM", 286, 309], ["a second positive PCR", "PROBLEM", 399, 420], ["CT", "TEST", 445, 447], ["symptomatic", "PROBLEM", 479, 490], ["chest CT scans", "TEST", 549, 563], ["chest", "ANATOMY", 182, 187], ["chest", "ANATOMY", 549, 554]]]], "1aa3d8e4824c9ea70928487e62c7b1e16111d425": [["Increased airway smooth muscle (ASM) in asthma may be due to hyperplasia or hypertrophy of ASM cells.", [["airway smooth muscle", "ANATOMY", 10, 30], ["ASM", "ANATOMY", 32, 35], ["ASM cells", "ANATOMY", 91, 100], ["asthma", "DISEASE", 40, 46], ["hyperplasia", "DISEASE", 61, 72], ["hypertrophy", "DISEASE", 76, 87], ["airway smooth muscle", "TISSUE", 10, 30], ["ASM", "MULTI-TISSUE_STRUCTURE", 32, 35], ["ASM cells", "CELL", 91, 100], ["ASM cells", "CELL_TYPE", 91, 100], ["Increased airway smooth muscle (ASM)", "PROBLEM", 0, 36], ["asthma", "PROBLEM", 40, 46], ["hyperplasia", "PROBLEM", 61, 72], ["hypertrophy of ASM cells", "PROBLEM", 76, 100], ["airway", "ANATOMY", 10, 16], ["smooth muscle", "ANATOMY", 17, 30], ["ASM", "ANATOMY", 32, 35], ["asthma", "OBSERVATION", 40, 46], ["may be due to", "UNCERTAINTY", 47, 60], ["hyperplasia", "OBSERVATION", 61, 72], ["hypertrophy", "OBSERVATION", 76, 87], ["ASM cells", "OBSERVATION", 91, 100]]], ["The contribution of extracellular matrix (ECM) within ASM bundles has not previously been accounted for when estimating ASM cell volume.", [["extracellular matrix", "ANATOMY", 20, 40], ["ECM", "ANATOMY", 42, 45], ["ASM bundles", "ANATOMY", 54, 65], ["ASM cell", "ANATOMY", 120, 128], ["extracellular matrix", "CELLULAR_COMPONENT", 20, 40], ["ECM", "CELLULAR_COMPONENT", 42, 45], ["ASM bundles", "CELLULAR_COMPONENT", 54, 65], ["ASM cell", "CELL", 120, 128], ["extracellular matrix (ECM) within ASM bundles", "PROBLEM", 20, 65], ["estimating ASM cell volume", "TEST", 109, 135], ["extracellular matrix", "OBSERVATION", 20, 40]]], ["Aim To estimate the mean ASM cell volume in ASM bundles in asthma.", [["ASM cell", "ANATOMY", 25, 33], ["ASM bundles", "ANATOMY", 44, 55], ["asthma", "DISEASE", 59, 65], ["ASM cell", "CELL", 25, 33], ["ASM bundles", "TISSUE", 44, 55], ["the mean ASM cell volume", "TEST", 16, 40], ["asthma", "PROBLEM", 59, 65], ["mean ASM cell volume", "OBSERVATION", 20, 40], ["bundles", "OBSERVATION_MODIFIER", 48, 55], ["asthma", "OBSERVATION", 59, 65]]], ["Methods Post-mortem tissues from control subjects (C n = 9); nonfatal (NFA n = 11) and fatal (FA n = 10) cases of asthma were studied.", [["Post-mortem tissues", "ANATOMY", 8, 27], ["NFA", "DISEASE", 71, 74], ["asthma", "DISEASE", 114, 120], ["Post-mortem tissues", "TISSUE", 8, 27], ["nonfatal (NFA n", "TEST", 61, 76], ["fatal (FA n", "PROBLEM", 87, 98], ["asthma", "PROBLEM", 114, 120], ["asthma", "OBSERVATION", 114, 120]]], ["On 30 mm transverse airway sections stained with haematoxylin, the volume density (NV) of ASM cell nuclei was estimated using an optical disector (\u00a51000).", [["airway sections", "ANATOMY", 20, 35], ["ASM cell nuclei", "ANATOMY", 90, 105], ["haematoxylin", "CHEMICAL", 49, 61], ["airway sections", "MULTI-TISSUE_STRUCTURE", 20, 35], ["haematoxylin", "SIMPLE_CHEMICAL", 49, 61], ["ASM cell nuclei", "CELL", 90, 105], ["haematoxylin", "TREATMENT", 49, 61], ["the volume density", "TEST", 63, 81], ["ASM cell nuclei", "PROBLEM", 90, 105], ["airway", "ANATOMY", 20, 26], ["volume density", "OBSERVATION", 67, 81], ["ASM cell nuclei", "OBSERVATION", 90, 105]]], ["The mean cell volume (VC = 1/NV) was calculated, correcting for the volume fraction of ASM (fASM) within the ASM bundle (corrected VC = 1/(NV \u00a5 fASM)). fASM was estimated on 0.5 mm thick sections of the same airway stained with Masson's trichrome.", [["cell", "ANATOMY", 9, 13], ["ASM", "ANATOMY", 87, 90], ["ASM bundle", "ANATOMY", 109, 119], ["sections", "ANATOMY", 187, 195], ["airway", "ANATOMY", 208, 214], ["cell", "CELL", 9, 13], ["ASM", "TISSUE", 87, 90], ["airway", "MULTI-TISSUE_STRUCTURE", 208, 214], ["fASM", "PROTEIN", 152, 156], ["The mean cell volume", "TEST", 0, 20], ["VC", "TEST", 22, 24], ["the volume fraction", "TEST", 64, 83], ["the ASM bundle", "TEST", 105, 119], ["corrected VC", "TEST", 121, 133], ["fASM", "TEST", 152, 156], ["Masson's trichrome", "PROBLEM", 228, 246], ["mean cell volume", "OBSERVATION", 4, 20], ["ASM", "ANATOMY", 87, 90], ["ASM bundle", "ANATOMY", 109, 119], ["airway", "ANATOMY", 208, 214]]], ["Basement membrane perimeter (Pbm) was used to indicate airway size.", [["Basement membrane", "ANATOMY", 0, 17], ["airway", "ANATOMY", 55, 61], ["Basement membrane", "CELLULAR_COMPONENT", 0, 17], ["airway", "MULTI-TISSUE_STRUCTURE", 55, 61], ["Basement membrane perimeter (Pbm)", "TREATMENT", 0, 33], ["airway", "ANATOMY", 55, 61], ["size", "OBSERVATION_MODIFIER", 62, 66]]], ["Results Table shows Mean \u03ee SD. (one-way ANOVA) *p < 0.05 for C v FA, NFA v FA.", [["C v FA", "SIMPLE_CHEMICAL", 61, 67], ["NFA v FA", "SIMPLE_CHEMICAL", 69, 77], ["Mean", "TEST", 20, 24], ["C v FA", "TEST", 61, 67]]]], "2ab6f8a828ae542db8edb2149159d583d6a46566": [["IntroductionMathematical epidemic models are crucial tools to understand, analyze, predict and control infectious diseases.", [["infectious diseases", "DISEASE", 103, 122], ["infectious diseases", "PROBLEM", 103, 122]]], ["However epidemic modeling has been a long standing challenge because of its complexity.", [["epidemic modeling", "PROBLEM", 8, 25], ["a long standing challenge", "TREATMENT", 35, 60]]], ["The epidemiology of communicable diseases such as hepatitis B, tuberculosis, influenza and HIV involves an interplay between the nature of infectious organisms, evolving and mutating over time, and their transmission dynamics through direct or indirect individual contacts.", [["communicable diseases", "DISEASE", 20, 41], ["hepatitis B", "DISEASE", 50, 61], ["tuberculosis", "DISEASE", 63, 75], ["influenza", "DISEASE", 77, 86], ["HIV", "DISEASE", 91, 94], ["hepatitis B", "ORGANISM", 50, 61], ["HIV", "SPECIES", 91, 94], ["hepatitis B", "SPECIES", 50, 61], ["HIV", "SPECIES", 91, 94], ["communicable diseases", "PROBLEM", 20, 41], ["hepatitis B", "PROBLEM", 50, 61], ["tuberculosis", "PROBLEM", 63, 75], ["influenza", "PROBLEM", 77, 86], ["HIV", "PROBLEM", 91, 94], ["infectious organisms", "PROBLEM", 139, 159], ["communicable diseases", "OBSERVATION", 20, 41], ["tuberculosis", "OBSERVATION", 63, 75], ["infectious", "OBSERVATION", 139, 149]]], ["Therefore, it requires both biological and sociological perspectives when mathematically modeling the outbreak.Previous worksEarly contributions to infectious disease modeling were pioneered mostly by public health physicians.", [["mathematically modeling the outbreak", "PROBLEM", 74, 110], ["infectious disease modeling", "PROBLEM", 148, 175], ["infectious", "OBSERVATION_MODIFIER", 148, 158]]], ["The first known result in mathematical epidemiology was to appraise the effectiveness of a controversial inoculation against smallpox in 1760 by a mathematician, Daniel Bernoulli (1766) .", [["smallpox", "DISEASE", 125, 133], ["a controversial inoculation", "TREATMENT", 89, 116]]], ["In 1889, P. D. En'ko contributed to the development of theoretical basis of epidemiology (Dietz, 1988) , correlating a discrete time model with actual cases of a measles epidemic, and Hamer developed a discrete time model to understand the spread of the measles epidemic in 1906 (Hamer, 1906) .", [["measles", "DISEASE", 162, 169], ["measles", "DISEASE", 254, 261], ["a measles epidemic", "PROBLEM", 160, 178]]], ["Ross assumed that the rate of a new infection was proportional to the numbers of susceptible and infectious individuals, and developed the ordinary differential equation models of vector-borne diseases to first model malaria in 1911 (Ross, 1911) .", [["infection", "DISEASE", 36, 45], ["vector-borne diseases", "DISEASE", 180, 201], ["malaria", "DISEASE", 217, 224], ["a new infection", "PROBLEM", 30, 45], ["susceptible and infectious individuals", "PROBLEM", 81, 119], ["borne diseases", "PROBLEM", 187, 201], ["first model malaria", "PROBLEM", 205, 224], ["new", "OBSERVATION_MODIFIER", 32, 35], ["infection", "OBSERVATION", 36, 45], ["infectious", "OBSERVATION_MODIFIER", 97, 107], ["malaria", "OBSERVATION", 217, 224]]], ["The Kermack and McKendrick epidemic model is a standard SIR model, consisting of three compartments that are Susceptible (S), Infected (I) and Recovered (R) , and assumes that the sizes of the compartments are large enough so that each compartment is assumed to be homogeneous, or at least there is homogeneous mixing in each subgroup if the population is stratified by activity levels.", [["McKendrick", "OBSERVATION_MODIFIER", 16, 26], ["epidemic model", "OBSERVATION", 27, 41], ["standard SIR model", "OBSERVATION_MODIFIER", 47, 65], ["Susceptible", "OBSERVATION_MODIFIER", 109, 120], ["sizes", "OBSERVATION_MODIFIER", 180, 185], ["compartments", "ANATOMY_MODIFIER", 193, 205], ["large", "OBSERVATION", 210, 215], ["assumed to be", "UNCERTAINTY", 251, 264], ["homogeneous", "OBSERVATION", 265, 276], ["homogeneous", "OBSERVATION_MODIFIER", 299, 310], ["mixing", "OBSERVATION", 311, 317]]], ["The compartment model has been often used, modified and applied to different epidemic models (Brauer & Castillo-Chavez, 2011; Hethcote, 2000; Keeling & Rohani, 2008) , as well as other phenomena in social networking, viral marketing, sensor networking, etc. However, at the beginning stage of a disease outbreak, there are a relatively small number of infected individuals, and the transmission of the infection is stochastic rather than homogeneous where the individual contacts between members of the population are distinguishable and traceable.", [["infection", "DISEASE", 402, 411], ["a disease outbreak", "PROBLEM", 293, 311], ["infected individuals", "PROBLEM", 352, 372], ["the infection", "PROBLEM", 398, 411], ["compartment model", "OBSERVATION", 4, 21], ["disease", "OBSERVATION", 295, 302], ["relatively", "OBSERVATION_MODIFIER", 325, 335], ["small", "OBSERVATION_MODIFIER", 336, 341], ["number", "OBSERVATION_MODIFIER", 342, 348], ["infected", "OBSERVATION_MODIFIER", 352, 360], ["individuals", "OBSERVATION", 361, 372], ["infection", "OBSERVATION", 402, 411], ["homogeneous", "OBSERVATION_MODIFIER", 438, 449]]], ["To describe the early stage of an epidemic, stochastic branching process, first formulated by Galton and Watson in 1874, was used to model the reproduction of a population from generation to generation.", [["an epidemic, stochastic branching process", "PROBLEM", 31, 72], ["early stage", "OBSERVATION_MODIFIER", 16, 27], ["epidemic", "OBSERVATION", 34, 42], ["stochastic branching process", "OBSERVATION", 44, 72]]], ["Gets et al. (Lloyd-Smith and SchreiberGetz, 2006) introduced a natural generalization of the basic reproductive ratio that was critical in controlling disease outbreak.", [["controlling disease outbreak", "PROBLEM", 139, 167]]], ["In the stochastic branching process model, the major interest is placed on finding the probability that the disease eventually dies out, i.e., the probability of ultimate extinction, during the transmission.Previous worksBesides the mathematical models to predict epidemics, the temporal and spatial proximity of subjects has been studied and used to characterize an epidemic that occurs through direct contacts at different places and times.", [["the disease", "PROBLEM", 104, 115], ["ultimate extinction", "PROBLEM", 162, 181], ["epidemics", "PROBLEM", 264, 273], ["stochastic", "OBSERVATION", 7, 17], ["branching process", "OBSERVATION", 18, 35], ["major", "OBSERVATION_MODIFIER", 47, 52], ["disease", "OBSERVATION", 108, 115], ["ultimate", "OBSERVATION_MODIFIER", 162, 170], ["extinction", "OBSERVATION", 171, 181], ["temporal", "OBSERVATION_MODIFIER", 279, 287]]], ["Earlier, spatial patterns were analyzed to describe the geographical spread of plant and human diseases (Campbell & Noe, 1985; Nicot, Rouse, & Yandell, 1984; Snow, 1855) .", [["plant and human diseases", "DISEASE", 79, 103], ["human", "ORGANISM", 89, 94], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["Campbell & Noe, 1985; Nicot, Rouse, & Yandell, 1984; Snow, 1855)", "SPECIES", 105, 169]]], ["John Snow (Snow, 1855) greatly contributed to the early medical geography by mapping and analyzing the major cholera outbreak of London in 1854.", [["cholera", "DISEASE", 109, 116]]], ["However, it was later realized that the disease outbreak patterns needed to be explained not only spatially but also temporally.", [["the disease outbreak patterns", "PROBLEM", 36, 65], ["disease", "OBSERVATION", 40, 47]]], ["Recently, the spatio-temporal analysis and autocorrelation were used to analyze fatal infectious human diseases such as Dengue fever epidemics in Southern Vietnam (Cuong et al., 2013) , and the spread of Severe Acute Respiratory Syndrome (SARS) in mainland China (Cao et al., 2016) , etc. Cao, in the analysis of the spread of SARS in China (Cao et al., 2016) , used Bayesian Maximum Entropy modeling and observed the empirical covariance based on a fitted theoretical covariance model with behavior of sine fluctuation in space and exponential decay in time.Background of MERS outbreak in South KoreaIn this section, we provide the introduction and statistical summary of the MERS outbreak in South Korea to have the general picture of the outbreak though it may be known or published earlier.Background of MERS outbreak in South KoreaMiddle East Respiratory Syndrome (MERS) is an infectious illness caused by a coronavirus that was first identified in Saudi Arabia in 2012.", [["Dengue fever", "DISEASE", 120, 132], ["Acute Respiratory Syndrome", "DISEASE", 211, 237], ["SARS", "DISEASE", 239, 243], ["SARS", "DISEASE", 327, 331], ["KoreaMiddle East Respiratory Syndrome", "DISEASE", 831, 868], ["MERS", "DISEASE", 870, 874], ["infectious illness", "DISEASE", 882, 900], ["coronavirus", "DISEASE", 913, 924], ["human", "ORGANISM", 97, 102], ["coronavirus", "ORGANISM", 913, 924], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 204, 244], ["the spatio-temporal analysis", "TEST", 10, 38], ["fatal infectious human diseases", "PROBLEM", 80, 111], ["Dengue fever epidemics", "PROBLEM", 120, 142], ["Severe Acute Respiratory Syndrome", "PROBLEM", 204, 237], ["SARS", "PROBLEM", 239, 243], ["SARS", "PROBLEM", 327, 331], ["Bayesian Maximum Entropy modeling", "TREATMENT", 367, 400], ["a fitted theoretical covariance model", "TREATMENT", 448, 485], ["sine fluctuation in space", "PROBLEM", 503, 528], ["MERS outbreak", "PROBLEM", 808, 821], ["Respiratory Syndrome", "PROBLEM", 848, 868], ["an infectious illness", "PROBLEM", 879, 900], ["a coronavirus", "PROBLEM", 911, 924], ["Severe", "OBSERVATION_MODIFIER", 204, 210], ["Acute", "OBSERVATION_MODIFIER", 211, 216], ["Respiratory Syndrome", "OBSERVATION", 217, 237], ["spread", "OBSERVATION_MODIFIER", 317, 323], ["MERS", "OBSERVATION", 573, 577], ["MERS", "OBSERVATION", 808, 812], ["Respiratory Syndrome", "OBSERVATION", 848, 868], ["infectious", "OBSERVATION_MODIFIER", 882, 892], ["coronavirus", "OBSERVATION", 913, 924]]], ["It resulted in a total of 2220 laboratory-confirmed cases including 790 related deaths with a case-fatality rate of 35:6% as of May 2018 according to World Health Organization (WHO).", [["deaths", "DISEASE", 80, 86], ["fatality rate", "TEST", 99, 112]]], ["The outbreak of MERS in South Korea started in May 2015 and officially ended in December 2015.", [["MERS", "DISEASE", 16, 20]]], ["The index case of the outbreak in South Korea was a 68 year-old male who developed symptoms on May 11, 2015 and sought care at two outpatient clinics and two hospitals according to WHO.", [["symptoms", "PROBLEM", 83, 91], ["index", "OBSERVATION_MODIFIER", 4, 9]]], ["As a result, he exposed MERS to a number of medical staff, hospital patients, their family members and visitors, but was not diagnosed with MERS until May 20, 2015, nine days later.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76]]], ["The last patient, diagnosed also with lymphoma, spent 172 days in quarantine after being diagnosed with MERS on June 7, 2015 and died on November 25, 2015.", [["lymphoma", "ANATOMY", 38, 46], ["lymphoma", "DISEASE", 38, 46], ["patient", "ORGANISM", 9, 16], ["lymphoma", "CANCER", 38, 46], ["patient", "SPECIES", 9, 16], ["lymphoma", "PROBLEM", 38, 46], ["lymphoma", "OBSERVATION", 38, 46]]], ["The Ministry of Health and Welfare (MoHW) in South Korea declared a formal end to the MERS virus outbreak on December 23, 2015, which was the 218th day since the confirmation of the first patient.", [["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 188, 195]]], ["The end date was achieved after 28 days without any new infection, or twice the maximum incubation period for the MERS virus.", [["infection", "DISEASE", 56, 65], ["MERS virus", "ORGANISM", 114, 124], ["MERS virus", "SPECIES", 114, 124], ["any new infection", "PROBLEM", 48, 65], ["the MERS virus", "PROBLEM", 110, 124], ["new", "OBSERVATION_MODIFIER", 52, 55], ["infection", "OBSERVATION", 56, 65]]], ["Among 186 infected patients, 39 died of MERS, equating the fatality rate of MERS in South Korea to 20:97%.", [["MERS", "DISEASE", 40, 44], ["MERS", "DISEASE", 76, 80], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["MERS", "PROBLEM", 40, 44]]], ["In this paper, we define a super-spreader as a laboratory-confirmed patient who infected the disease to more than five contacts.Background of MERS outbreak in South KoreaThe characteristics of the MERS outbreak in South Korea are that one index case who traveled to middle eastern countries introduced the disease to the population of South Korea, and the pattern of transmission is limited to inter-hospital or intrahospital infection, except one possible case of household transmission.", [["infection", "DISEASE", 426, 435], ["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["the disease", "PROBLEM", 89, 100], ["the disease", "PROBLEM", 302, 313], ["intrahospital infection", "PROBLEM", 412, 435], ["disease", "OBSERVATION", 93, 100], ["MERS", "OBSERVATION", 142, 146], ["disease", "OBSERVATION", 306, 313], ["infection", "OBSERVATION", 426, 435]]], ["The size of the outbreak is much smaller than the size of the whole population in South Korea.", [["size", "OBSERVATION_MODIFIER", 4, 8], ["outbreak", "OBSERVATION_MODIFIER", 16, 24], ["much", "OBSERVATION_MODIFIER", 28, 32], ["smaller", "OBSERVATION_MODIFIER", 33, 40], ["size", "OBSERVATION_MODIFIER", 50, 54], ["whole", "OBSERVATION_MODIFIER", 62, 67], ["population", "OBSERVATION_MODIFIER", 68, 78]]], ["It enables us to investigate the detailed transmission dynamics of the infectious disease.", [["infectious disease", "DISEASE", 71, 89], ["the infectious disease", "PROBLEM", 67, 89], ["infectious", "OBSERVATION", 71, 81]]], ["This paper is designed to make a situational assessment on the outbreak of MERS in South Korea based on the basic reproductive ratio and the probability of ultimate extinction.", [["MERS", "DISEASE", 75, 79], ["a situational assessment", "TEST", 31, 55], ["the basic reproductive ratio", "TEST", 104, 132], ["ultimate extinction", "PROBLEM", 156, 175], ["ultimate extinction", "OBSERVATION", 156, 175]]], ["Furthermore, spatio-temporal proximity of the occurrence between patients is investigated using an autocorrelation function.Background of MERS outbreak in South KoreaThe data were publicly available by the Ministry of Health and Welfare, the Korea Centers for Disease Control and Prevention, and other press releases in South Korea.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["an autocorrelation function", "TEST", 96, 123], ["Disease Control", "TREATMENT", 260, 275], ["temporal", "OBSERVATION_MODIFIER", 20, 28], ["MERS", "OBSERVATION", 138, 142]]], ["Each infected patient was numbered in chronological order based on the infection confirmation date.", [["infection", "DISEASE", 71, 80], ["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["infected", "OBSERVATION", 5, 13], ["infection", "OBSERVATION", 71, 80]]], ["In this study, we count the period of the infection starting from Day 1 which corresponds to May 20, 2015.", [["infection", "DISEASE", 42, 51], ["this study", "TEST", 3, 13], ["the infection", "PROBLEM", 38, 51], ["infection", "OBSERVATION", 42, 51]]], ["Since there is no change in epidemic status after Day 200, we use the outbreak period from Day 1 (May 20, 2015) to Day 200 (December 5, 2015) for figures in this paper.", [["no", "UNCERTAINTY", 15, 17], ["change", "OBSERVATION_MODIFIER", 18, 24], ["epidemic", "OBSERVATION_MODIFIER", 28, 36]]], ["Fig. 1 displays the cumulative number of patients and deaths.Background of MERS outbreak in South KoreaThe generation is determined by how closely a patient is linked to the index case, Patient 1.", [["deaths", "DISEASE", 54, 60], ["patients", "ORGANISM", 41, 49], ["patient", "ORGANISM", 149, 156], ["patients", "SPECIES", 41, 49], ["patient", "SPECIES", 149, 156], ["Patient", "SPECIES", 186, 193], ["MERS", "OBSERVATION", 75, 79]]], ["Gen 1 is a group of people who were directly infected from Patient 1, Gen 2 is infected from the members of Gen 1, and so on.", [["Gen 1", "GENE_OR_GENE_PRODUCT", 0, 5], ["people", "ORGANISM", 20, 26], ["Gen 2", "CELL", 70, 75], ["Gen 1", "GENE_OR_GENE_PRODUCT", 108, 113], ["people", "SPECIES", 20, 26], ["Patient", "SPECIES", 59, 66], ["infected", "OBSERVATION", 79, 87]]], ["The MERS outbreak in South Korea ended with four generations from Gen 0 to Gen 3 with a total of 186 MERS patients.", [["MERS", "DISEASE", 101, 105], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114]]], ["The outbreak started in Seoul, South Korea, the shaded region in Fig. 2 , and spread out to the neighbor provinces.", [["Fig.", "ANATOMY", 65, 69]]], ["There were 17 hospitals where these 186 patients were confirmed with MERS.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48]]], ["Table 1 provides the hospital identification and its corresponding location in latitude and longitude for geographic information, and it will be used for spatio-temporal analysis later in this paper.Background of MERS outbreak in South KoreaThe box plot on the left in Fig. 3 displays the distribution of age, where the box represents the middle 50% with the median in red.", [["temporal analysis", "TEST", 161, 178], ["The box plot", "TEST", 241, 253], ["MERS", "OBSERVATION", 213, 217], ["plot", "OBSERVATION_MODIFIER", 249, 253], ["left", "ANATOMY_MODIFIER", 261, 265], ["distribution", "OBSERVATION_MODIFIER", 289, 301], ["middle", "ANATOMY_MODIFIER", 339, 345], ["red", "OBSERVATION", 369, 372]]], ["The median age of the entire population of patients in this MERS outbreak is 55, which is ten percent higher than the world median age (50) of MERS patients reported by the Centers for Disease Control and Prevention.", [["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 148, 156], ["Disease Control", "TREATMENT", 185, 200], ["median", "OBSERVATION_MODIFIER", 4, 10], ["entire", "OBSERVATION_MODIFIER", 22, 28], ["population", "OBSERVATION_MODIFIER", 29, 39]]], ["The gender ratio of patients is 1.45:1, with 110 male and 76 female patients.", [["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 68, 76]]], ["The fatality rates are 23:64% for male and 15:79% for female, indicating male predominance with p-value \u00bc 0.0885 based on a one-sided test.", [["The fatality rates", "TEST", 0, 18], ["a one-sided test", "TEST", 122, 138]]], ["Gen 2 has the highest rate of fatality, shown on the right in Fig. 3 , with 29:73% for male and 18:00% for female.Reproductive ratio and probability of extinctionThe basic reproductive ratio is important since a disease outbreak is classified as a minor outbreak or a major outbreak depending on this number.", [["Gen 2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Reproductive ratio", "PROBLEM", 114, 132], ["extinction", "PROBLEM", 152, 162], ["The basic reproductive ratio", "TEST", 162, 190], ["a disease outbreak", "PROBLEM", 210, 228], ["a minor outbreak", "PROBLEM", 246, 262], ["a major outbreak", "PROBLEM", 266, 282], ["right", "ANATOMY_MODIFIER", 53, 58], ["extinction", "OBSERVATION", 152, 162], ["reproductive ratio", "OBSERVATION", 172, 190], ["major", "OBSERVATION_MODIFIER", 268, 273], ["outbreak", "OBSERVATION", 274, 282]]], ["A minor outbreak ultimately extinguishes itself with the probability of 1 when R 1, while a major outbreak defines itself by the boundless spread of the disease with a positive probability when R > 1.", [["A minor outbreak", "PROBLEM", 0, 16], ["the disease", "PROBLEM", 149, 160], ["minor", "OBSERVATION_MODIFIER", 2, 7], ["outbreak", "OBSERVATION_MODIFIER", 8, 16], ["disease", "OBSERVATION", 153, 160]]], ["We adopt the survival function method that is introduced in (Heesterbeek & Dietz, 1996) , known as the gold standard determination of R. In this approach, the reproductive ratio is defined asReproductive ratio and probability of extinctionwhere b\u00f0t\u00de is the average number of newly infected individuals whom one infectious patient will produce per unit time when infected for total time t, and F\u00f0t\u00de is the survival function, i.e., the probability that a newly infected individual remains infectious for at least time t.", [["patient", "ORGANISM", 322, 329], ["patient", "SPECIES", 322, 329], ["the reproductive ratio", "TEST", 155, 177], ["a newly infected individual remains infectious", "PROBLEM", 451, 497], ["newly", "OBSERVATION_MODIFIER", 453, 458], ["infected", "OBSERVATION", 459, 467], ["infectious", "OBSERVATION", 487, 497]]], ["The function b\u00f0t\u00deF\u00f0t\u00de is called the reproduction function.", [["b\u00f0t\u00deF\u00f0t\u00de", "GENE_OR_GENE_PRODUCT", 13, 21], ["b\u00f0t\u00deF\u00f0t\u00de", "PROTEIN", 13, 21]]], ["This approach allows us to use a time dependent b\u00f0t\u00de instead of a fixed constant rate b.", [["a time dependent b\u00f0t\u00de", "TREATMENT", 31, 52], ["a fixed constant rate b.", "TREATMENT", 64, 88]]], ["The stochastic branching process model is often used to describe the beginning stage of a disease outbreak when the number of infected patients remains significantly smaller than the entire population.", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["a disease outbreak", "PROBLEM", 88, 106], ["stochastic", "OBSERVATION", 4, 14], ["branching process", "OBSERVATION", 15, 32], ["disease", "OBSERVATION", 90, 97], ["infected", "OBSERVATION_MODIFIER", 126, 134], ["significantly", "OBSERVATION_MODIFIER", 152, 165], ["smaller", "OBSERVATION_MODIFIER", 166, 173]]], ["The network of individual contacts and transmission is more focused in this approach, and a network diagram of patients, consisting of two major objects: vertices and edges, is often used to visualize it.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119]]], ["Vertices represent infected patients in our study, and edges are contacts between the members that cause transmission of the disease.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["our study", "TEST", 40, 49], ["the disease", "PROBLEM", 121, 132], ["infected", "OBSERVATION_MODIFIER", 19, 27], ["disease", "OBSERVATION", 125, 132]]], ["We assume that every contact through each edge leads to an infection.", [["infection", "DISEASE", 59, 68], ["an infection", "PROBLEM", 56, 68], ["infection", "OBSERVATION", 59, 68]]], ["The degree of a vertex is the number of edges connected to the vertex in the network.", [["degree", "OBSERVATION_MODIFIER", 4, 10], ["vertex", "OBSERVATION_MODIFIER", 16, 22], ["number", "OBSERVATION_MODIFIER", 30, 36], ["edges", "OBSERVATION_MODIFIER", 40, 45], ["vertex", "ANATOMY_MODIFIER", 63, 69]]], ["For a random node with a vertex degree k, the excess degree of the vertex is defined as the number of contacts infected by the current vertex.", [["node", "ANATOMY", 13, 17], ["node", "MULTI-TISSUE_STRUCTURE", 13, 17], ["a random node", "TEST", 4, 17], ["a vertex degree k", "TEST", 23, 40], ["node", "OBSERVATION", 13, 17], ["excess", "OBSERVATION_MODIFIER", 46, 52], ["degree", "OBSERVATION_MODIFIER", 53, 59], ["vertex", "ANATOMY_MODIFIER", 67, 73], ["number", "OBSERVATION_MODIFIER", 92, 98], ["infected", "OBSERVATION", 111, 119], ["vertex", "ANATOMY_MODIFIER", 135, 141]]], ["Since the current vertex has the k connected neighbor vertices including the source node who infected the disease to the current node, and a patient cannot be infected again from its descendants as we assumed earlier, then the excess degree of the current node is \u00f0k \u00c0 1\u00de.", [["source node", "ANATOMY", 77, 88], ["node", "ANATOMY", 129, 133], ["node", "ANATOMY", 256, 260], ["node", "MULTI-TISSUE_STRUCTURE", 84, 88], ["node", "MULTI-TISSUE_STRUCTURE", 129, 133], ["patient", "ORGANISM", 141, 148], ["node", "MULTI-TISSUE_STRUCTURE", 256, 260], ["patient", "SPECIES", 141, 148], ["the disease", "PROBLEM", 102, 113], ["source node", "OBSERVATION", 77, 88], ["disease", "OBSERVATION", 106, 113], ["node", "OBSERVATION", 129, 133], ["infected", "OBSERVATION", 159, 167], ["degree", "OBSERVATION_MODIFIER", 234, 240], ["node", "OBSERVATION", 256, 260]]], ["The distribution of vertex degree is essential in the description of disease transmission since it determines how fast or slow the disease spreads or dies out.Reproductive ratio and probability of extinctionWe start with the probability generating function of the neighbor distribution in a power series representation:Reproductive ratio and probability of extinctionwhere Pr\u00f0X\u00de is the probability density function for a discrete random variable X. The power series (2) converges for 0 z 1 since this series is differentiable and P \u221e x\u00bc0 Pr\u00f0X \u00bc x\u00de \u00bc 1.", [["P", "CHEMICAL", 530, 531], ["disease transmission", "PROBLEM", 69, 89], ["slow the disease spreads", "PROBLEM", 122, 146], ["Reproductive ratio", "PROBLEM", 159, 177], ["Reproductive ratio", "PROBLEM", 319, 337], ["extinctionwhere Pr\u00f0X\u00de", "PROBLEM", 357, 378], ["this series", "TEST", 496, 507], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["vertex degree", "OBSERVATION_MODIFIER", 20, 33], ["disease", "OBSERVATION", 131, 138]]], ["The interval \u00bd0; 1 is taken as the domain for G\u00f0z\u00de since z represents probability.", [["G\u00f0z\u00de", "PROBLEM", 46, 50]]], ["Let q k\u00c01 be the probability that a vertex has excess degree \u00f0k \u00c0 1\u00de and consider the probability generating function of the descendent distribution in terms of q k :Reproductive ratio and probability of extinctionTo derive the probability of ultimate extinction, let z n be the probability that the infection will die out within n generations.", [["infection", "DISEASE", 300, 309], ["Let q k\u00c01", "GENE_OR_GENE_PRODUCT", 0, 9], ["Let q k\u00c01", "DNA", 0, 9], ["Reproductive ratio", "PROBLEM", 166, 184], ["extinction", "PROBLEM", 204, 214], ["ultimate extinction", "PROBLEM", 243, 262], ["the infection", "PROBLEM", 296, 309], ["extinction", "OBSERVATION", 204, 214], ["infection", "OBSERVATION", 300, 309]]], ["We assume that q 0 is positive, otherwise the infection will never die out, and that q j is non-negative for all j > 0.", [["infection", "DISEASE", 46, 55], ["the infection", "PROBLEM", 42, 55], ["infection", "OBSERVATION", 46, 55]]], ["For a random vertex with excess degree j, the probabilities z n and z n\u00c01 are compared and depicted in Fig. 6 .", [["n\u00c01", "DNA", 70, 73], ["excess degree j", "PROBLEM", 25, 40]]], ["The sequence fz n g is monotonically increasing since the probability that an infection dies out within n generations is generally larger than or equal to the probability that it dies out within \u00f0n \u00c0 1\u00de generations.", [["infection", "DISEASE", 78, 87], ["an infection", "PROBLEM", 75, 87], ["monotonically", "OBSERVATION_MODIFIER", 23, 36], ["increasing", "OBSERVATION_MODIFIER", 37, 47], ["infection", "OBSERVATION", 78, 87], ["larger", "OBSERVATION_MODIFIER", 131, 137]]], ["For a certain j, the probability of ultimate extinction of the infection within n generations is the product of q j and z j n\u00c01 .", [["infection", "DISEASE", 63, 72], ["n\u00c01", "PROTEIN", 124, 127], ["the infection", "PROBLEM", 59, 72], ["q j and z j n\u00c01", "TREATMENT", 112, 127], ["infection", "OBSERVATION", 63, 72]]], ["Thus the probability z n is the summation over all possible non-negative integers j2J, which is the expected value of z J n\u00c01 where J \u00bc N\u222af0g:Reproductive ratio and probability of extinctionSince z n is a Cauchy sequence, then it converges.", [["Cauchy sequence", "DNA", 205, 220], ["Reproductive ratio", "PROBLEM", 142, 160], ["a Cauchy sequence", "TEST", 203, 220], ["extinction", "OBSERVATION", 180, 190]]], ["By taking the limit to Equation (4), then we have:Reproductive ratio and probability of extinctionwhich is a fixed-point problem.", [["Reproductive ratio", "PROBLEM", 50, 68], ["a fixed-point problem", "PROBLEM", 107, 128]]], ["It is important to know where the zeros of Equation (5) are located since it provides the probability for equilibrium when the infection eventually dies out.", [["infection", "DISEASE", 127, 136], ["the infection", "PROBLEM", 123, 136], ["infection", "OBSERVATION", 127, 136]]], ["If z \u00c3 is 1, then the infection will certainly extinguish, otherwise it may manifest into a major outbreak.", [["infection", "DISEASE", 22, 31], ["the infection", "PROBLEM", 18, 31], ["infection", "OBSERVATION", 22, 31], ["major", "OBSERVATION_MODIFIER", 92, 97], ["outbreak", "OBSERVATION", 98, 106]]], ["The detailed calculation and derivation can be found in (Brauer & Castillo-Chavez, 2011 ).Spatio-temporal analysis: auto-correlationWhile the stochastic branching process model gathers the information of the individual transmission in each generation and predicts the probability of the ultimate extinction of the disease, it does not include both spatial and temporal information of the transmission.", [["Spatio", "TEST", 90, 96], ["the disease", "PROBLEM", 310, 321], ["stochastic", "OBSERVATION_MODIFIER", 142, 152], ["branching", "OBSERVATION_MODIFIER", 153, 162], ["disease", "OBSERVATION", 314, 321], ["temporal", "OBSERVATION_MODIFIER", 360, 368]]], ["Autocorrelation analysis is the most straightforward way to establish direct links between two series.", [["Autocorrelation analysis", "TEST", 0, 24]]], ["In this section, we adapt the autocorrelation function to analyze the spatio-temporal proximity of occurrence during a disease outbreak.Spatio-temporal analysis: auto-correlationWe modify the traditional definition of autocorrelation function (Reynolds & Madden, 1988 ) for our analysis.", [["a disease outbreak", "PROBLEM", 117, 135], ["Spatio", "TEST", 136, 142], ["our analysis", "TEST", 274, 286], ["disease", "OBSERVATION", 119, 126]]], ["Let a realization X i;j indicate occurrence of a disease where X i;j \u00bc 1 if a vertex v i infects the disease to another vertex v j , otherwise X i;j \u00bc 0.", [["a disease", "PROBLEM", 47, 56], ["the disease", "PROBLEM", 97, 108], ["disease", "OBSERVATION", 49, 56], ["disease", "OBSERVATION", 101, 108]]], ["Let I be the index set of vertices and N \u00f0i\u00de be the index set of vertices that are infected by a vertex v i in the neighborhood of vertex v i for i2I .Spatio-temporal analysis: auto-correlationWe define indicator functions, \u25b3 s in space and \u25b3 t in time, respectively, such that Fig. 6 .", [["Let I", "GENE_OR_GENE_PRODUCT", 0, 5], ["i2I", "PROTEIN", 146, 149], ["Spatio", "TEST", 151, 157], ["infected", "OBSERVATION", 83, 91]]], ["Probability that a disease dies out within n generations from a vertex with excess degree j.Spatio-temporal analysis: auto-correlationwhere d s \u00f0v i ; v j \u00de and d t \u00f0v i ; v j \u00de are the spatial distance and serial interval of occurrence between two vertices v i and v j , respectively.", [["a disease dies", "PROBLEM", 17, 31], ["the spatial distance", "PROBLEM", 182, 202], ["disease", "OBSERVATION", 19, 26]]], ["For all i2I and j2N \u00f0i\u00de, we define the spatio-temporal autocorrelation function of occurrence as:Spatio-temporal analysis: auto-correlationwhich describes how likely the distance and time difference between two connected vertices vary together when one vertex, v i , transmitted the disease to the neighbor vertices v j for j2N \u00f0i\u00de.", [["i2I", "PROTEIN", 8, 11], ["j2N \u00f0i\u00de", "PROTEIN", 16, 23], ["the spatio", "TEST", 35, 45], ["disease", "OBSERVATION", 283, 290]]], ["However, we use the full variable term instead of the fluctuation part since we are interested in the number of occurrences rather than the fluctuation of occurrence.Results and discussionThe network map for the transmission of MERS in South Korea during 2015 is shown in Fig. 7 .", [["MERS", "DISEASE", 228, 232]]], ["It starts from the index case (Gen 0), numbered as 1 in the map, who transmitted MERS to 29 people in the next generation, Gen 1, and so on.", [["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98]]], ["Since the sources of infection for Patients 43, 44, 51, 53, 166, 178, 183, 184 and 185 are unknown, we assume that their excess degree of vertex is 0.", [["infection", "DISEASE", 21, 30], ["Patients", "ORGANISM", 35, 43], ["Patients", "SPECIES", 35, 43], ["infection", "PROBLEM", 21, 30], ["infection", "OBSERVATION", 21, 30], ["vertex", "ANATOMY_MODIFIER", 138, 144]]], ["The source of infection for Patient 52 is also unknown but the excess degree of vertex is 1 as Patient 52 infected MERS to Patient 119.", [["infection", "DISEASE", 14, 23], ["Patient", "SPECIES", 28, 35], ["Patient", "SPECIES", 123, 130], ["infection", "PROBLEM", 14, 23], ["infection", "OBSERVATION", 14, 23]]], ["In Fig. 7 , there are a few super-spreaders, Patients 1, 14, 15, 16 and 76, who contributed to 83% of all active cases.Results and discussionTo calculate the reproductive rate for the MERS outbreak in South Korea, we use Equation (1) in a discrete form.", [["Patients", "ORGANISM", 45, 53], ["Patients", "SPECIES", 45, 53], ["few", "OBSERVATION_MODIFIER", 24, 27]]], ["The average number b\u00f0t\u00de of new patients from an infectious patient per unit time (one day) and the survival function F\u00f0t\u00de at time t are graphed in Fig. 8 .", [["patients", "ORGANISM", 31, 39], ["patient", "ORGANISM", 59, 66], ["patients", "SPECIES", 31, 39], ["patient", "SPECIES", 59, 66], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["new", "OBSERVATION_MODIFIER", 27, 30], ["infectious", "OBSERVATION", 48, 58]]], ["The calculated reproductive ratio based on these two functions is R \u00bc 3:7949 which is considerably larger than 1 and this outbreak is classified as a major outbreak.", [["The calculated reproductive ratio", "TEST", 0, 33], ["reproductive", "OBSERVATION_MODIFIER", 15, 27], ["considerably", "OBSERVATION_MODIFIER", 86, 98], ["larger", "OBSERVATION_MODIFIER", 99, 105], ["major", "OBSERVATION_MODIFIER", 150, 155], ["outbreak", "OBSERVATION", 156, 164]]], ["For the probability of ultimate extinction that is the root of Equation (5), we define h\u00f0z\u00de \u00bc G 1 \u00f0z\u00de \u00c0 z.", [["h\u00f0z\u00de", "TEST", 87, 91], ["extinction", "OBSERVATION", 32, 42]]], ["The graph on the left in Fig. 9 shows h\u00f0z\u00de and the probability of ultimate extinction for R > 1, i.e., the zero of the function h\u00f0z\u00de less than 1, is located at z \u00c3 \u00bc 0:4996.", [["The graph on the left in Fig.", "TEST", 0, 29], ["h\u00f0z\u00de", "PROBLEM", 38, 42], ["left", "ANATOMY_MODIFIER", 17, 21]]], ["The graph on the right shows the profile of the probability of ultimate extinction over the outbreak.", [["The graph on the right", "TEST", 0, 22], ["right", "ANATOMY_MODIFIER", 17, 22], ["ultimate", "OBSERVATION_MODIFIER", 63, 71], ["extinction", "OBSERVATION", 72, 82]]], ["The probability drops but immediately increases after the appearance of super-spreaders on Days 14e16, which indicates how important successful quarantine of super-spreaders is during an epidemic.Results and discussionThe demographical distribution of each generation over the 17 hospitals in Fig. 2 as well as in Table 1 is depicted in Fig. 10 .", [["The probability drops", "PROBLEM", 0, 21], ["probability", "OBSERVATION_MODIFIER", 4, 15], ["drops", "OBSERVATION", 16, 21]]], ["One may expect a strong association between the size (bed counts) of the hospital and the number of MERS cases.", [["strong", "OBSERVATION_MODIFIER", 17, 23], ["size", "OBSERVATION_MODIFIER", 48, 52]]], ["However, we found the association to be very weak with a coefficient of determination close to zero for this particular outbreak.", [["very weak", "PROBLEM", 40, 49], ["this particular outbreak", "PROBLEM", 104, 128], ["very", "OBSERVATION_MODIFIER", 40, 44], ["weak", "OBSERVATION", 45, 49]]], ["Our interest lies in the spatio-temporal proximity of occurrence between two patients where one patient infected MERS to the other, i.e. the two connected vertices in Fig. 7 .", [["patients", "ORGANISM", 77, 85], ["patient", "ORGANISM", 96, 103], ["patients", "SPECIES", 77, 85], ["patient", "SPECIES", 96, 103], ["temporal", "OBSERVATION_MODIFIER", 32, 40], ["infected", "OBSERVATION", 104, 112], ["Fig", "OBSERVATION_MODIFIER", 167, 170]]], ["For this purpose, we use the geographical distance and the difference of the confirmation dates (serial interval) between these paired patients.", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["the confirmation", "TEST", 73, 89]]], ["The distance is measured by the haversine formula between two hospitals in latitude and longitude in Table 1 .", [["the haversine formula", "TREATMENT", 28, 49], ["distance", "OBSERVATION_MODIFIER", 4, 12]]], ["While this Euclidean distance may not give the exact travel distance in a metropolis such as Seoul in South Korea, we assume that it is sufficient to characterize the geometrical distances between hospitals or the travel distances of patients.", [["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 234, 242]]], ["The distributions of the distance and the serial interval between all connected vertices in Fig. 7 are depicted in Fig. 11 .", [["all connected vertices in Fig.", "TREATMENT", 66, 96], ["distributions", "OBSERVATION_MODIFIER", 4, 17], ["distance", "OBSERVATION_MODIFIER", 25, 33]]], ["As we observe in the graph on the left in Fig. 11 , there are three major distances, approximately 0 km, 53 km and 81 km, that are well associated with the major distances in Fig. 10 , characterizing inter-hospital or intra-hospital transmission.", [["left", "ANATOMY_MODIFIER", 34, 38], ["inter-hospital", "OBSERVATION_MODIFIER", 200, 214], ["intra-hospital transmission", "OBSERVATION", 218, 245]]], ["Most of the patients in Gen 1 are located at Hospital K1 in Fig. 10 , where the index case in Gen 0 was also confirmed, contributing the highest probability at the distance of 0 km in the left graph of Fig. 11 .", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["left", "ANATOMY_MODIFIER", 188, 192]]], ["The major hospitals in Gen 2 are S2, K1-K3 and D1-D2.", [["K1-K3", "GENE_OR_GENE_PRODUCT", 37, 42], ["D1-D2", "GENE_OR_GENE_PRODUCT", 47, 52], ["K1", "PROTEIN", 37, 39], ["D1", "PROTEIN", 47, 49], ["D2", "PROTEIN", 50, 52], ["S2", "ANATOMY", 33, 35]]], ["Considering the three prominent distances in the graph on the left in Fig. 11 , we infer that the disease was transmitted intensely between S2 and K1-K3 (about 53 km apart), and between K1-K3 and D1-D2 (about 81 km apart), rather than transmitted directly between S2 and D1-D2 (about 133 km apart), unless otherwise intra-hospital (0 km apart) transmission in Gen 2.", [["K1-K3", "GENE_OR_GENE_PRODUCT", 147, 152], ["K1-K3", "GENE_OR_GENE_PRODUCT", 186, 191], ["D1-D2", "GENE_OR_GENE_PRODUCT", 196, 201], ["D1-D2", "GENE_OR_GENE_PRODUCT", 271, 276], ["K1", "PROTEIN", 147, 149], ["K3", "PROTEIN", 150, 152], ["K1", "PROTEIN", 186, 188], ["D1", "PROTEIN", 196, 198], ["D2", "PROTEIN", 199, 201], ["D1", "PROTEIN", 271, 273], ["D2", "PROTEIN", 274, 276], ["the disease", "PROBLEM", 94, 105], ["K1", "TEST", 186, 188], ["prominent", "OBSERVATION_MODIFIER", 22, 31], ["distances", "OBSERVATION_MODIFIER", 32, 41], ["left", "ANATOMY_MODIFIER", 62, 66], ["disease", "OBSERVATION", 98, 105]]], ["Lastly, the major hospitals in Gen 3 are located mostly within 25 km from each other in Seoul, and the total number of patients in Gen 3 is not as high as those in other generations.", [["patients", "ORGANISM", 119, 127], ["Gen 3", "GENE_OR_GENE_PRODUCT", 131, 136], ["patients", "SPECIES", 119, 127]]], ["The mean serial time interval is 9.8057 days with a 95% confidence interval of (9.1975, 10.414) in the graph on the right in Fig. 11 .", [["right", "ANATOMY_MODIFIER", 116, 121], ["Fig", "OBSERVATION", 125, 128]]], ["The function h\u00f0z\u00de \u00bc G 1 \u00f0z\u00de \u00c0 z on the left and the probability of ultimate extinction in terms of days on the right. the left and the corresponding contour plots in st -plane in the right.", [["left", "ANATOMY", 39, 43], ["left", "ANATOMY", 122, 126], ["G 1", "PROTEIN", 20, 23], ["The function", "TEST", 0, 12], ["h\u00f0z\u00de", "TEST", 13, 17], ["G", "TEST", 20, 21], ["left", "ANATOMY_MODIFIER", 39, 43], ["ultimate extinction", "OBSERVATION", 67, 86], ["right", "ANATOMY_MODIFIER", 111, 116], ["left", "ANATOMY_MODIFIER", 122, 126], ["contour", "OBSERVATION_MODIFIER", 149, 156], ["plots", "OBSERVATION_MODIFIER", 157, 162], ["st -", "ANATOMY_MODIFIER", 166, 170], ["plane", "ANATOMY_MODIFIER", 170, 175], ["right", "ANATOMY_MODIFIER", 183, 188]]], ["The second to the fourth rows in Fig. 12 are the autocorrelations for Gens 1, 2 and 3, respectively.", [["3", "GENE_OR_GENE_PRODUCT", 84, 85], ["Gens", "TEST", 70, 74], ["fourth", "OBSERVATION_MODIFIER", 18, 24], ["rows", "OBSERVATION_MODIFIER", 25, 29]]], ["The autocorrelation over the full domain has a few distinct spikes at certain sand t-lags.", [["a few distinct spikes", "PROBLEM", 45, 66], ["few", "OBSERVATION_MODIFIER", 47, 50], ["distinct", "OBSERVATION_MODIFIER", 51, 59], ["spikes", "OBSERVATION_MODIFIER", 60, 66]]], ["The peaks in the spatial and temporal lag domain explains that there are a few hospitals mainly involved in the transmission, that characterizes a typical pattern of inter-and intra-hospital transmission.", [["The peaks", "PROBLEM", 0, 9], ["inter-and intra-hospital transmission", "PROBLEM", 166, 203], ["peaks", "OBSERVATION_MODIFIER", 4, 9], ["spatial", "OBSERVATION_MODIFIER", 17, 24], ["temporal", "OBSERVATION_MODIFIER", 29, 37], ["lag", "OBSERVATION_MODIFIER", 38, 41], ["few", "OBSERVATION_MODIFIER", 75, 78], ["typical", "OBSERVATION_MODIFIER", 147, 154], ["intra-hospital transmission", "OBSERVATION", 176, 203]]], ["The transmissions in Gen 1 were mainly intrahospital as there is very little spatial distribution.", [["very", "OBSERVATION_MODIFIER", 65, 69], ["little", "OBSERVATION_MODIFIER", 70, 76], ["spatial", "OBSERVATION_MODIFIER", 77, 84], ["distribution", "OBSERVATION_MODIFIER", 85, 97]]], ["In Fig. 10 , we can infer that most of Gen 2 in Hospital S2 were infected by patients from Hospital K1 in Gen 1 that were located about 53 km apart.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85]]], ["This explains the peak in the autocorrelation in Gen 2.", [["Gen 2", "GENE_OR_GENE_PRODUCT", 49, 54], ["peak", "OBSERVATION_MODIFIER", 18, 22]]], ["The patients in Gen 3 were mostly infected from patients at the same hospital or nearby hospitals.", [["patients", "ORGANISM", 4, 12], ["Gen 3", "CELL", 16, 21], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 48, 56], ["infected", "OBSERVATION", 34, 42]]], ["To understand these graphs better, we note that the projections of the autocorrelation in the first row in Fig. 12 onto s-axis and t-axis have similar patterns with the left graph and the right graph in Fig. 11 , respectively.ConclusionIn this paper, we examine and assess the outbreak of MERS in South Korea based on the reproductive ratio and the probability of ultimate extinction as well as the spatio-temporal autocorrelation of occurrence.ConclusionThe basic reproductive ratio is the expected number of secondary infections arising from an infectious individual over the entire epidemic.", [["MERS", "DISEASE", 289, 293], ["infections", "DISEASE", 520, 530], ["the left graph", "TEST", 165, 179], ["the reproductive ratio", "TEST", 318, 340], ["ultimate extinction", "PROBLEM", 364, 383], ["the spatio", "TEST", 395, 405], ["The basic reproductive ratio", "TEST", 455, 483], ["secondary infections", "PROBLEM", 510, 530], ["an infectious individual", "PROBLEM", 544, 568], ["left", "ANATOMY_MODIFIER", 169, 173], ["right", "ANATOMY_MODIFIER", 188, 193], ["extinction", "OBSERVATION", 373, 383], ["number", "OBSERVATION_MODIFIER", 500, 506], ["secondary", "OBSERVATION_MODIFIER", 510, 519], ["infections", "OBSERVATION", 520, 530], ["infectious", "OBSERVATION_MODIFIER", 547, 557], ["entire", "OBSERVATION_MODIFIER", 578, 584], ["epidemic", "OBSERVATION_MODIFIER", 585, 593]]], ["Since the estimation of the reproductive ratio is based on sufficient data acquired from the fully-completed or well established epidemic, the prediction of further development of the epidemic is somewhat limited (Mills et al., 2004) .", [["the reproductive ratio", "TEST", 24, 46]]], ["Though there are different approaches for estimating the reproductive ratio (Hefferman, Smith, & Wahl, 2005) , we chose to use the survival function method that is widely applicable as there is no assumption of a constant transmission rate.", [["the survival function method", "TREATMENT", 127, 155], ["a constant transmission rate", "PROBLEM", 211, 239], ["no assumption of", "UNCERTAINTY", 194, 210]]], ["To calculate the reproductive ratio, the average contact rate b\u00f0t\u00de as a function of t is directly simulated from the data instead of using a constant rate in other works (Chang, 2017; Choi, Jung, Choi, Hur, & Ki, 2018) , and the survival function is also examined from the outbreak data.", [["the survival function", "TEST", 225, 246]]], ["The resulting reproductive ratio for the MERS outbreak in South Korea is R \u00bc 3:7949, and the MERS outbreak in South Korea is classified as a major outbreak.ConclusionThe stochastic branching process model fits well with this scenario of the MERS outbreak in South Korea since it involves a relatively small number of patients compared to the whole population of South Korea, allowing us to trace the individual contacts and gain the detailed dynamics of the transmission.", [["MERS", "DISEASE", 41, 45], ["patients", "ORGANISM", 317, 325], ["patients", "SPECIES", 317, 325], ["major", "OBSERVATION_MODIFIER", 141, 146], ["outbreak", "OBSERVATION", 147, 155], ["stochastic", "OBSERVATION", 170, 180], ["branching process", "OBSERVATION", 181, 198], ["relatively", "OBSERVATION_MODIFIER", 290, 300], ["small", "OBSERVATION_MODIFIER", 301, 306], ["number", "OBSERVATION_MODIFIER", 307, 313]]], ["Based on the transmission data, we estimate the probability of ultimate extinction by using the probability generating function and assuming the probability of extinction eventually reaches the equilibrium state.", [["the transmission data", "TEST", 9, 30], ["extinction", "PROBLEM", 160, 170], ["extinction", "OBSERVATION", 160, 170]]], ["The probability of ultimate extinction of the MERS outbreak in South Korea is calculated as 0.4996.ConclusionWhile the reproductive ratio and the probability of ultimate extinction are useful to classify the outbreak and predict the extinction of the disease in a long term, it fails to provide any spatial or spatio-temporal aspects of the transmission.", [["MERS", "DISEASE", 46, 50], ["the reproductive ratio", "TEST", 115, 137], ["ultimate extinction", "PROBLEM", 161, 180], ["the disease", "PROBLEM", 247, 258], ["ultimate extinction", "OBSERVATION", 19, 38], ["disease", "OBSERVATION", 251, 258], ["temporal", "OBSERVATION_MODIFIER", 317, 325]]], ["The spatial and temporal proximity of the transmission between occurrences is measured based on the autocorrelation function that describes how likely the spatial and temporal differences between patients vary together.", [["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["spatial", "OBSERVATION_MODIFIER", 4, 11], ["temporal", "OBSERVATION_MODIFIER", 16, 24], ["proximity", "OBSERVATION_MODIFIER", 25, 34], ["spatial", "OBSERVATION_MODIFIER", 155, 162], ["temporal", "OBSERVATION_MODIFIER", 167, 175]]], ["The autocorrelation profiles the entire transmission period, as well as over each generation period, and provides good insight in understanding and characterizing the patterns of inter-hospital or intra-hospital transmission of the MERS outbreak in South Korea.", [["MERS", "DISEASE", 232, 236]]], ["We observed a few distinct peaks of autocorrelation values in the spatial and temporal domain, clearly displaying the characteristics of the MERS outbreak in South Korea.ConclusionFinally, we observe that a few super-spreaders greatly contributed to the MERS epidemic in South Korea, infecting 83% of all active cases, and elevated the reproductive ratio.", [["MERS", "DISEASE", 254, 258], ["autocorrelation values", "TEST", 36, 58], ["a few super-spreaders", "PROBLEM", 205, 226], ["elevated the reproductive ratio", "PROBLEM", 323, 354], ["few", "OBSERVATION_MODIFIER", 14, 17], ["distinct", "OBSERVATION_MODIFIER", 18, 26], ["peaks", "OBSERVATION_MODIFIER", 27, 32], ["temporal domain", "ANATOMY", 78, 93], ["MERS", "OBSERVATION", 141, 145], ["active", "OBSERVATION_MODIFIER", 305, 311], ["cases", "OBSERVATION", 312, 317], ["elevated", "OBSERVATION_MODIFIER", 323, 331]]], ["To reduce the number of super-spreaders and consequently the reproductive ratio, more thorough quarantine can be ordered.", [["the reproductive ratio", "TEST", 57, 79], ["number", "OBSERVATION_MODIFIER", 14, 20]]], ["However, Lipsitch et al. (Lipsitch et al., 2003) also argued the tradeoff between reducing the reproductive ratio and stressing the population with excessive quarantine, suggesting that the reproductive ratio may not always be the best measure.", [["excessive quarantine", "TREATMENT", 148, 168], ["the reproductive ratio", "PROBLEM", 186, 208]]], ["As a future endeavor, modeling super-spreading events with nondiffusive terms in mathematical equations will be investigated and a better quarantine plan will be suggested.Sources of financial supportNone.Declarations of conflicts of interestNo conflict of interest.", [["modeling super-spreading events", "PROBLEM", 22, 53], ["financial supportNone", "TREATMENT", 183, 204]]]]}